{"title":"Bestselling Joint Injections","description":"","products":[{"product_id":"synvisc-mono-1-x-2-ml","title":"Synvisc Mono 1x 2.0 ml","description":"\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003eDescription for \u003ca href=\"https:\/\/stakonmed.de\/collections\/synvisc\" title=\"Synvisc | Joint injections | StakonMed\"\u003eSynvisc\u003c\/a\u003e Mono\u003cbr\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eHylan G-F 20 is available as\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003e, 2-ml pack.\u003cbr\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e, 6-ml pack.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cbr\u003eHylan G-F 20 is a sterile, pyrogen-free, elastoviscous fluid containing Hylan A and Hylan B polymers derived from a highly purified avian extract. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. The average molecular weight of Hylan A is approximately 6,000,000 Daltons, and Hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in a buffered physiological sodium chloride solution (pH 7.2 ± 0.3).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePROPERTIES\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHylan G-F 20 is biologically similar to hyaluronan. Hyaluronan is a component of synovial fluid and is responsible for its viscoelasticity. However, the mechanical (elasto-viscous) properties of Hylan G-F 20 exceed those of synovial fluid and hyaluronan solutions of comparable concentration. At a frequency of 2.5 Hertz, Hylan G-F 20 has an elasticity (G’: shock absorption factor) of 111 ± 13 Pascal (Pa) and a viscosity (G’’: shock dissipation factor) of 25 ± 2 Pa. At a frequency of 2.5 Hertz, the elasticity and viscosity of knee synovial fluid measured by a comparable method in 18- to 27-year-olds were G’ = 117 ± 13 Pa and G’’ = 45 ± 8 Pa. Hylans are broken down in the body in the same way as hyaluronan; the breakdown products are non-toxic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eINDICATIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHylan G-F 20\u003cbr\u003e• serves as a temporary replacement or supplement to synovial fluid. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• is indicated for patients at all stages of joint disease.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• shows the most effective results in patients who actively and regularly move the affected joints. \u003c\/span\u003e\u003cspan\u003emove regularly.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The therapeutic effect of Hylan G-F 20 is based on viscosupplementation, \u003c\/span\u003e\u003cspan\u003ea process in which the physiological and rheological conditions of the \u003c\/span\u003e\u003cspan\u003earthritic joint tissue to be restored.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eViscosupplementation with Hylan G-F 20 is a therapy to relieve pain and physical discomfort, enabling improved joint mobility. \u003c\/span\u003e\u003cspan\u003eIn vitro\u003c\/span\u003e\u003cspan\u003e-Studies have shown that Hylan G-F 20 protects cartilage cells from certain physical and chemical damage.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003eis intended only for intra-articular use by the physician to treat pain associated with degenerative joint disease of the knee, hip, ankle, or shoulder.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eis intended only for intra-articular use by a physician to treat pain associated with degenerative joint disease of the knee.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCONTRAINDICATIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• If venous or lymphatic congestion occurs in the affected limb, Hylan G-F 20 should not be injected into the joint.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F 20 must not be used in infected or severely inflamed joints or in patients with skin diseases or infections at the injection site. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F-20 must not be used in patients with known hypersensitivity (allergy) \u003c\/span\u003e\u003cspan\u003eused against hyaluronan (sodium hyaluronate).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not inject intravascularly.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not inject extra-articularly and not into the synovial tissue or capsule. \u003c\/span\u003e\u003cspan\u003eSide effects at the injection site may especially occur if the \u003c\/span\u003e\u003cspan\u003eInjection of \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003enot strictly intra-articular.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Disinfectants containing quaternary ammonium salts can cause precipitation \u003c\/span\u003e\u003cspan\u003epromote hyaluronan. Therefore, they should not be used simultaneously, for example, to prepare the skin for the procedure.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePRECAUTIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• If there is a large intra-articular effusion before injection, Hylan G-F 20 should not be used.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• As with any invasive procedure in the joint, patients are advised to avoid strenuous activities for a few days after the injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F 20 has not been tested in pregnant women and children under 18 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F 20 contains small amounts of bird protein and should be avoided in patients who \u003c\/span\u003e\u003cspan\u003eshould not be used in patients who react hypersensitively to this.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Side effects affecting the injected joint: After injection of Hylan G-F 20 into the joint, temporary pain and\/or swelling and\/or effusions may occur at the injection site. Cases of acute inflammation characterized by joint pain, swelling, effusion, and occasionally warmth or stiffness of the joint have been reported after intra-articular injection of \u003c\/span\u003e\u003cspan\u003eSynvisc or Synvisc-One \u003c\/span\u003e\u003cspan\u003eobserved. Examination of the synovial fluid shows an aseptic fluid without crystals. This reaction often responds within a few days to treatment with a nonsteroidal anti-inflammatory drug (NSAID), intra-articular steroids, and\/or arthrocentesis, whereby a clinical benefit of the treatment may still be present even after the reactions have occurred.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Joint infections did not occur in any clinical study with \u003c\/span\u003e\u003cspan\u003eSynvisc\/Synvisc-One \u003c\/span\u003e\u003cspan\u003eand were rarely used in therapeutic applications with \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003ereported.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hypersensitivity reactions including anaphylactic reaction, \u003c\/span\u003e\u003cspan\u003eanaphylactoid reaction, anaphylactic shock, and angioedema have also been \u003c\/span\u003e\u003cspan\u003eobserved.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Since market introduction, the following systemic events have been reported, which are rare \u003c\/span\u003e\u003cspan\u003eafter administration of \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003emay occur: rash, urticaria, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia (abnormal sensations such as tingling), peripheral edema, malaise, breathing difficulties, flushing, and facial swelling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Controlled clinical studies showed no statistically significant differences in the number or type of systemic side effects between the patient group that \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003ereceived, and the control group.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The controlled clinical study with \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a comparable number and type of side effects between the patient group that \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003ereceived, and the control group that received a placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDOSAGE AND ADMINISTRATION\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not use Hylan G-F 20 if the package is already opened or damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The contents of the syringe must be used immediately after opening the package. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Remove synovial fluid and effusions before injecting Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Inject at room temperature.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Avoid touching the plunger when removing the syringe from the blister (or \u003c\/span\u003e\u003cspan\u003efrom the tray) want to take. Only touch the syringe body.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Use strictly aseptic techniques during administration and proceed \u003c\/span\u003e\u003cspan\u003ebe especially careful when removing the protective cap.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Twist the protective cap before removing it. This minimizes \u003c\/span\u003e\u003cspan\u003eProduct leakage.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Use an appropriate needle size:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003e– 18 to 22 Gauge\u003cbr\u003eUse an appropriate needle length depending on the joint to be treated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003e– 18 to 20 Gauge\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• To achieve the best possible seal of the needle and thus prevent leakage during administration, hold the Luer-lock connection of the syringe vial firmly while screwing in the needle tightly.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Avoid excessive twisting or applying leverage when attaching the needle to the syringe or removing the needle shield, as this could cause the needle tip to break.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Inject strictly intra-articularly and, if necessary, perform under imaging guidance, especially for joints such as the hip and shoulder.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The contents of a syringe are intended for single use only. The recommended dosage corresponds to the injection of the entire contents (2 ml for \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003eand 6 ml for \u003c\/span\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003cspan\u003e) of a syringe. Unused \u003c\/span\u003e\u003cspan\u003eSynvisc\/Synvisc-One \u003c\/span\u003e\u003cspan\u003eis to be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Syringes and\/or needles must not be reused. Reusing syringes, needles, and\/or product residues from already used syringes leads to loss of sterility. This can result in product contamination and\/or incomplete treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• When using fluoroscopy, ionic and non-ionic contrast agents may be used. A maximum of 1 ml contrast agent may be used per 2 ml of Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not re-sterilize Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDOSAGE INSTRUCTIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe dosage of Hylan G-F 20 depends on the joint to be treated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOsteoarthritis of the knee joint:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe recommended treatment consists of 3 weekly intra-articular injections of 2 ml each. To achieve maximum effect, it is necessary to complete all 3 injections. The recommended maximum dosage is 6 injections within six months, with at least four weeks between treatment series.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe recommended treatment consists of a 6 ml intra-articular injection. The injection can be repeated six months after the first injection if the patient's symptoms justify it.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eOsteoarthritis of the hip joint\/upper ankle joint\/ \u003c\/span\u003e\u003cspan\u003eShoulder joint:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAn initial treatment with a single 2 ml injection is recommended. However, if adequate relief of symptoms is not achieved after this injection, administration of a second 2 ml injection is recommended. Clinical data have shown that patients benefit from a second injection if it is given within one to three months after the first injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDURATION OF EFFECT\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTreatment with Hylan G-F 20 acts only locally in the joint; it does not produce a general systemic effect.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt is reported that the effect in patients who respond to treatment generally lasts up to 26 weeks, although both shorter and longer durations of effect have been observed. Furthermore, prospective clinical data in patients with knee osteoarthritis have shown a treatment benefit lasting up to 52 weeks after a single treatment cycle with three \u003c\/span\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003cspan\u003e-injections were shown.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProspective clinical study data in patients with gonarthrosis after a single injection of \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003ea reduction in pain lasting up to 52 weeks, along with related improvements in mobility and function.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical data from a double-blind, randomized, controlled study in patients with gonarthrosis showed a statistically significant and clinically meaningful reduction in pain compared to placebo. A total of 253 patients were treated (124 received \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eand 129 received placebo). Over 26 weeks, patients under \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed an average percentage change in pain from baseline of 36%, while patients in the placebo group showed an average percentage change in pain from baseline of 29%.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdditional prospective clinical data from two multicenter, open-label studies in patients with gonarthrosis after a single injection of \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a statistically significant improvement in pain relief for up to 52 weeks compared to baseline.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the first study, 394 patients who \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a statistically significant change in the WOMAC A1 - walking pain subscore (-28 ± 19.89 mm on a 100 mm VAS, Visual Analog Scale) from baseline to week 26. Additionally, statistically significant changes from baseline were observed in WOMAC A1 and WOMAC A, B, and C scores across all six observation periods between week 1 and week 52, demonstrating improvements in walking pain and pain (WOMAC A1 -32.7 ± 19.95 mm; WOMAC A -29.18 ± 19.158 mm), mobility (WOMAC B -25.77 ± 22.047 mm), and function (WOMAC C -25.72 ± 19.449 mm) over 52 weeks.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the second study, 571 patients who \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a statistically significant improvement in pain over 26 weeks, measured by the Verbal Pain Questionnaire (VPQ). The average pain score improved from 3.20 at the start of treatment to 2.24 at the week 26 visit, with 64.6% of patients achieving pain relief. Secondary endpoints showed a statistically significant improvement in VPQ scores at all observation points from week 1 to week 52, with average VPQ scores decreasing from 3.20 at baseline to 2.26 at the week 52 visit, and 61.5% of patients achieving pain relief.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCONTENT PER ml \u003c\/span\u003e\u003cspan\u003e(Hylan G-F 20)\u003cbr\u003e1 ml contains: 8.0 mg Hylan, 8.5 mg sodium chloride, 0.16 mg disodium hydrogen phosphate, 0.04 mg sodium dihydrogen phosphate, water for injection q.s.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDOSAGE FORM\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe contents of the syringes are sterile and pyrogen-free. Store between +2 °C and +30 °C.\u003cbr\u003eDo not freeze.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003eis supplied in a 2.25 ml glass syringe vial containing 2 ml of Hylan G-F 20. \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eis supplied in a 10 ml glass syringe vial containing 6 ml of Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eINFORMATION FOR PATIENTS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInform the patient before the injection that Synvisc and Synvisc-One are made from highly purified avian-derived hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e","brand":"Sanofi-Aventis GmbH","offers":[{"title":"Default Title","offer_id":47355873526100,"sku":"144","price":64.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/synvisc-mono-sanofi-aventis-deutschland-gmbh-gelenkspritzen-stakonmed-847719.jpg?v=1772216091"},{"product_id":"synvisc-classic-3-x-2-ml","title":"Synvisc Classic 3x 2.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003eDescription for \u003ca href=\"https:\/\/stakonmed.de\/collections\/synvisc\" title=\"Synvisc | Joint Injections | StakonMed\"\u003eSynvisc\u003c\/a\u003e Classic\u003cbr\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eHylan G-F 20 is available as\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003e, 2-ml pack.\u003cbr\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e, 6-ml pack.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cbr\u003eHylan G-F 20 is a sterile, pyrogen-free, elastoviscous fluid containing Hylan A and Hylan B polymers derived from a highly purified avian extract. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. The average molecular weight of Hylan A is approximately 6,000,000 Daltons, and Hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in a buffered physiological sodium chloride solution (pH 7.2 ± 0.3).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePROPERTIES\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHylan G-F 20 is biologically similar to hyaluronan. Hyaluronan is a component of synovial fluid and is responsible for its viscoelasticity. However, the mechanical (elasto-viscous) properties of Hylan G-F 20 exceed those of synovial fluid and hyaluronan solutions of comparable concentration. At a frequency of 2.5 Hertz, Hylan G-F 20 has an elasticity (G’: shock absorption factor) of 111 ± 13 Pascal (Pa) and a viscosity (G’’: shock dissipation factor) of 25 ± 2 Pa. At a frequency of 2.5 Hertz, the elasticity and viscosity of knee synovial fluid measured by a comparable method in 18- to 27-year-olds were G’ = 117 ± 13 Pa and G’’ = 45 ± 8 Pa. Hylans are broken down in the body in the same way as hyaluronan; the breakdown products are non-toxic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eINDICATIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHylan G-F 20\u003cbr\u003e• serves as a temporary replacement or supplement to synovial fluid. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• is indicated for patients at all stages of joint disease.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• shows the most effective results in patients who actively and regularly move the affected joints. \u003c\/span\u003e\u003cspan\u003emove regularly.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The therapeutic effect of Hylan G-F 20 is based on viscosupplementation, \u003c\/span\u003e\u003cspan\u003ea process in which the physiological and rheological conditions of the \u003c\/span\u003e\u003cspan\u003earthritic joint tissue to be restored.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eViscosupplementation with Hylan G-F 20 is a therapy to relieve pain and physical discomfort, enabling improved joint mobility. \u003c\/span\u003e\u003cspan\u003eIn vitro\u003c\/span\u003e\u003cspan\u003e-Studies have shown that Hylan G-F 20 protects cartilage cells from certain physical and chemical damage.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003eis intended only for intra-articular use by the physician to treat pain associated with degenerative joint disease of the knee, hip, ankle, or shoulder.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eis intended only for intra-articular use by a physician to treat pain associated with degenerative joint disease of the knee.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCONTRAINDICATIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• If venous or lymphatic congestion occurs in the affected limb, Hylan G-F 20 should not be injected into the joint.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F 20 must not be used in infected or severely inflamed joints or in patients with skin diseases or infections in the injection area. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F-20 must not be used in patients with known hypersensitivity (allergy) \u003c\/span\u003e\u003cspan\u003eused against hyaluronan (sodium hyaluronate).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not inject intravascularly.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not inject extra-articularly and not into the synovial tissue or capsule. \u003c\/span\u003e\u003cspan\u003eSide effects at the injection site may especially occur if the \u003c\/span\u003e\u003cspan\u003eInjection of \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003enot strictly intra-articular.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Disinfectants containing quaternary ammonium salts can cause precipitation \u003c\/span\u003e\u003cspan\u003efavor hyaluronan. Therefore, they should not be used simultaneously, for example, to prepare the skin for the procedure.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePRECAUTIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• If there is a large intra-articular effusion before injection, Hylan G-F 20 should not be used.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• As with any invasive procedure in the joint, patients are advised to avoid strenuous activities for a few days after the injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F 20 has not been tested in pregnant women and children under 18 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F 20 contains small amounts of bird protein and should be used with caution in patients who \u003c\/span\u003e\u003cspan\u003eshould not be used in patients who react hypersensitively to this.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Side effects affecting the joint injected: After injection of Hylan G-F 20 into the joint, temporary pain and\/or swelling and\/or effusions in the injection area may occur. Cases of acute inflammation characterized by joint pain, swelling, effusion, and occasionally warming or stiffness of the joint have been reported after intra-articular injection of \u003c\/span\u003e\u003cspan\u003eSynvisc or Synvisc-One \u003c\/span\u003e\u003cspan\u003eobserved. Examination of the synovial fluid shows an aseptic fluid without crystals. This reaction often responds within a few days to treatment with a nonsteroidal anti-inflammatory drug (NSAID), intra-articular steroids, and\/or arthrocentesis, whereby a clinical benefit of the treatment may still be present even after the reactions have occurred.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Joint infections did not occur in any clinical study with \u003c\/span\u003e\u003cspan\u003eSynvisc\/Synvisc-One \u003c\/span\u003e\u003cspan\u003eand were rarely used in therapeutic applications with \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003ereported.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hypersensitivity reactions including anaphylactic reaction, \u003c\/span\u003e\u003cspan\u003eanaphylactoid reaction, anaphylactic shock, and angioedema have also been \u003c\/span\u003e\u003cspan\u003eobserved.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Since market introduction, the following systemic events have been reported, which are rare \u003c\/span\u003e\u003cspan\u003eafter administration of \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003emay occur: rash, urticaria, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia (abnormal sensations such as tingling), peripheral edema, malaise, breathing difficulties, flushing, and facial swelling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Controlled clinical studies showed no statistically significant differences in the number or type of systemic side effects between the patient group that \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003ereceived, and the control group.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The controlled clinical study with \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a comparable number and type of side effects between the patient group that \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003ereceived, and the control group that received a placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDOSAGE AND ADMINISTRATION\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not use Hylan G-F 20 if the package has already been opened or damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The contents of the syringe must be used immediately after opening the package. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Remove synovial fluid and effusions before injecting Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Inject at room temperature.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Avoid touching the plunger when removing the syringe from the blister (or \u003c\/span\u003e\u003cspan\u003efrom the tray) want to take. Only touch the syringe body.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Use strictly aseptic techniques during administration and proceed \u003c\/span\u003e\u003cspan\u003ebe especially careful when removing the protective cap.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Twist the protective cap before removing it. This minimizes \u003c\/span\u003e\u003cspan\u003eProduct leakage.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Use an appropriate needle size:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003e– 18 to 22 Gauge\u003cbr\u003eUse an appropriate needle length according to the joint to be treated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003e– 18 to 20 Gauge\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• To achieve the best possible seal of the needle and thus prevent leakage during administration, hold the Luer-lock connection of the syringe vial firmly while screwing in the needle tightly.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Avoid excessive twisting or applying leverage when attaching the needle to the syringe or removing the needle shield, as this could cause the needle tip to break.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Inject strictly intra-articularly and, if necessary, perform under imaging guidance, especially for joints such as the hip and shoulder.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The contents of one syringe are intended for single use only. The recommended dosage corresponds to the injection of the entire contents (2 ml for \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003eand 6 ml for \u003c\/span\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003cspan\u003e) of a syringe. Unused \u003c\/span\u003e\u003cspan\u003eSynvisc\/Synvisc-One \u003c\/span\u003e\u003cspan\u003eis to be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Syringes and\/or needles must not be reused. Reusing syringes, needles, and\/or product residues from already used syringes results in loss of sterility. This can lead to product contamination and\/or incomplete treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• When using fluoroscopy, ionic and non-ionic contrast agents may be used. A maximum of 1 ml contrast agent may be used per 2 ml of Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not re-sterilize Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDOSAGE INSTRUCTIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe dosage of Hylan G-F 20 depends on the joint to be treated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOsteoarthritis of the knee joint:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe recommended treatment consists of 3 weekly intra-articular injections of 2 ml each. To achieve maximum effect, it is necessary to complete all 3 injections. The recommended maximum dosage is 6 injections within six months, with at least four weeks between treatment series.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe recommended treatment consists of a 6 ml intra-articular injection. The injection can be repeated six months after the first injection if the patient's symptoms justify it.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eOsteoarthritis of the hip joint\/upper ankle joint\/ \u003c\/span\u003e\u003cspan\u003eShoulder joint:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAn initial treatment with a single 2 ml injection is recommended. However, if adequate relief of symptoms is not achieved after this injection, administration of a second 2 ml injection is recommended. Clinical data have shown that patients benefit from a second injection if it is given within one to three months after the first injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDURATION OF EFFECT\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTreatment with Hylan G-F 20 acts only locally in the joint; it does not produce a general systemic effect.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt is reported that the effect in patients who respond to treatment generally lasts up to 26 weeks, although both shorter and longer durations of effect have been observed. Furthermore, prospective clinical data in patients with knee osteoarthritis have shown a treatment benefit lasting up to 52 weeks after a single treatment cycle with three \u003c\/span\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003cspan\u003e-injections were shown.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProspective clinical study data in patients with gonarthrosis after a single injection of \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003ea reduction in pain lasting up to 52 weeks, along with related improvements in mobility and function.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical data from a double-blind, randomized, controlled study in patients with gonarthrosis showed a statistically significant and clinically meaningful reduction in pain compared to placebo. A total of 253 patients were treated (124 received \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eand 129 received placebo). Over 26 weeks, patients under \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed an average percentage change in pain from baseline of 36%, while patients in the placebo group showed an average percentage change in pain from baseline of 29%.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdditional prospective clinical data from two multicenter, open-label studies in patients with gonarthrosis after a single injection of \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a statistically significant improvement in pain relief for up to 52 weeks compared to baseline.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the first study, 394 patients who \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003ereceived a statistically significant change in the WOMAC A1 - walking pain subscore (-28 ± 19.89 mm on a 100 mm VAS, Visual Analog Scale) from baseline to week 26. Additionally, statistically significant changes from baseline were observed in WOMAC A1 and WOMAC A, B, and C scores across all six observation periods between week 1 and week 52, demonstrating improvements in walking pain and pain (WOMAC A1 -32.7 ± 19.95 mm; WOMAC A -29.18 ± 19.158 mm), mobility (WOMAC B -25.77 ± 22.047 mm), and function (WOMAC C -25.72 ± 19.449 mm) over 52 weeks.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the second study, 571 patients who \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003ereceived a statistically significant improvement in pain over 26 weeks, measured by the Verbal Pain Questionnaire (VPQ). The average pain score improved from 3.20 at the start of treatment to 2.24 at the week 26 visit, with 64.6% of patients achieving pain relief. Secondary endpoints showed a statistically significant improvement in VPQ scores at all observation points from week 1 to week 52, with average VPQ scores decreasing from 3.20 at baseline to 2.26 at the week 52 visit, and 61.5% of patients achieving pain relief.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCONTENT PER ml \u003c\/span\u003e\u003cspan\u003e(Hylan G-F 20)\u003cbr\u003e1 ml contains: 8.0 mg Hylan, 8.5 mg sodium chloride, 0.16 mg disodium hydrogen phosphate, 0.04 mg sodium dihydrogen phosphate, water for injection q.s.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDOSAGE FORM\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe contents of the syringes are sterile and pyrogen-free. Store between +2 °C and +30 °C.\u003cbr\u003eDo not freeze.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003eis supplied in a 2.25 ml glass syringe vial containing 2 ml of Hylan G-F 20. \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eis supplied in a 10 ml glass syringe vial containing 6 ml of Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eINFORMATION FOR PATIENTS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInform the patient before the injection that Synvisc and Synvisc-One are made from highly purified avian-derived hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Sanofi-Aventis GmbH","offers":[{"title":"Default Title","offer_id":47355873591636,"sku":"145","price":174.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/synvisc-classic-sanofi-aventis-deutschland-gmbh-gelenkspritzen-stakonmed-109547.jpg?v=1772216066"},{"product_id":"synvisc-one-1-x-6-ml","title":"Synvisc One 1x 6.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003eDescription for \u003ca href=\"https:\/\/stakonmed.de\/collections\/synvisc\" title=\"Synvisc | Joint injections | StakonMed\"\u003eSynvisc\u003c\/a\u003e One\u003cbr\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eHylan G-F 20 is available as\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003e, 2-ml pack.\u003cbr\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e, 6-ml pack.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cbr\u003eHylan G-F 20 is a sterile, pyrogen-free, elastoviscous fluid containing Hylan A and Hylan B polymers derived from a highly purified avian extract. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. The average molecular weight of Hylan A is approximately 6,000,000 Daltons, and Hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in a buffered physiological sodium chloride solution (pH 7.2 ± 0.3).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePROPERTIES\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHylan G-F 20 is biologically similar to hyaluronan. Hyaluronan is a component of synovial fluid and is responsible for its viscoelasticity. However, the mechanical (elasto-viscous) properties of Hylan G-F 20 exceed those of synovial fluid and hyaluronan solutions of comparable concentration. At a frequency of 2.5 Hertz, Hylan G-F 20 has an elasticity (G’: shock absorption factor) of 111 ± 13 Pascal (Pa) and a viscosity (G’’: shock dissipation factor) of 25 ± 2 Pa. At a frequency of 2.5 Hertz, the elasticity and viscosity of knee synovial fluid measured by a comparable method in 18- to 27-year-olds were G’ = 117 ± 13 Pa and G’’ = 45 ± 8 Pa. Hylans are broken down in the body in the same way as hyaluronan; the breakdown products are non-toxic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eINDICATIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHylan G-F 20\u003cbr\u003e• serves as a temporary replacement or supplement to synovial fluid. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• is indicated for patients at all stages of joint disease.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• shows the most effective results in patients who actively and regularly move the affected joints. \u003c\/span\u003e\u003cspan\u003emove regularly.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The therapeutic effect of Hylan G-F 20 is based on viscosupplementation, \u003c\/span\u003e\u003cspan\u003ea process in which the physiological and rheological conditions of the \u003c\/span\u003e\u003cspan\u003earthritic joint tissue to be restored.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eViscosupplementation with Hylan G-F 20 is a therapy to relieve pain and physical discomfort, enabling improved joint mobility. \u003c\/span\u003e\u003cspan\u003eIn vitro\u003c\/span\u003e\u003cspan\u003e-Studies have shown that Hylan G-F 20 protects cartilage cells from certain physical and chemical damage.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003eis intended only for intra-articular use by the physician to treat pain associated with degenerative joint disease of the knee, hip, ankle, or shoulder.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eis intended only for intra-articular use by a physician to treat pain associated with degenerative joint disease of the knee.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCONTRAINDICATIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• If venous or lymphatic congestion occurs in the affected limb, Hylan G-F 20 should not be injected into the joint.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F 20 must not be used in infected or severely inflamed joints or in patients with skin diseases or infections in the injection area. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F-20 must not be used in patients with known hypersensitivity (allergy) \u003c\/span\u003e\u003cspan\u003eused against hyaluronan (sodium hyaluronate).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not inject intravascularly.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not inject extra-articularly and not into the synovial tissue or capsule. \u003c\/span\u003e\u003cspan\u003eSide effects at the injection site may especially occur if the \u003c\/span\u003e\u003cspan\u003eInjection of \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003enot strictly intra-articular.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Disinfectants containing quaternary ammonium salts can cause flocculation \u003c\/span\u003e\u003cspan\u003efavor hyaluronan. Therefore, they should not be used simultaneously, for example, to prepare the skin for the procedure.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePRECAUTIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• If there is a large intra-articular effusion before injection, Hylan G-F 20 should not be used.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• As with any invasive procedure in the joint, patients are advised to avoid strenuous activities for a few days after the injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F 20 has not been tested in pregnant women and children under 18 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hylan G-F 20 contains small amounts of bird protein and should be avoided in patients who \u003c\/span\u003e\u003cspan\u003eshould not be used in patients who react hypersensitively to this.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Side effects affecting the joint injected: After injection of Hylan G-F 20 into the joint, temporary pain and\/or swelling and\/or effusions in the injection area may occur. Cases of acute inflammation characterized by joint pain, swelling, effusion, and occasionally warming or stiffness of the joint have been reported after intra-articular injection of \u003c\/span\u003e\u003cspan\u003eSynvisc or Synvisc-One \u003c\/span\u003e\u003cspan\u003eobserved. Examination of the synovial fluid shows an aseptic fluid without crystals. This reaction often responds within a few days to treatment with a nonsteroidal anti-inflammatory drug (NSAID), intra-articular steroids, and\/or arthrocentesis, whereby a clinical benefit of the treatment may still be present even after the reactions have occurred.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Joint infections did not occur in any clinical study with \u003c\/span\u003e\u003cspan\u003eSynvisc\/Synvisc-One \u003c\/span\u003e\u003cspan\u003eand were rarely used in therapeutic applications with \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003ereported.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Hypersensitivity reactions including anaphylactic reaction, \u003c\/span\u003e\u003cspan\u003eanaphylactoid reaction, anaphylactic shock, and angioedema have also been \u003c\/span\u003e\u003cspan\u003eobserved.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Since market introduction, the following systemic events have been reported, which are rare \u003c\/span\u003e\u003cspan\u003eafter administration of \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003emay occur: rash, urticaria, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia (abnormal sensations such as tingling), peripheral edema, malaise, breathing difficulties, flushing, and facial swelling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Controlled clinical studies showed no statistically significant differences in the number or type of systemic side effects between the patient group that \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003ereceived, and the control group.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The controlled clinical study with \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a comparable number and type of side effects between the patient group that \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003ereceived, and the control group that received a placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDOSAGE AND ADMINISTRATION\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not use Hylan G-F 20 if the package has already been opened or damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The contents of the syringe must be used immediately after opening the package. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Remove synovial fluid and effusions before injecting Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Inject at room temperature.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Avoid touching the plunger when removing the syringe from the blister (or \u003c\/span\u003e\u003cspan\u003efrom the tray) want to take. Only touch the syringe body.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Use strictly aseptic techniques during administration and \u003c\/span\u003e\u003cspan\u003ebe especially careful when removing the protective cap.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Twist the protective cap before removing it. This minimizes \u003c\/span\u003e\u003cspan\u003eProduct leakage.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Use an appropriate needle size:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003e– 18 to 22 Gauge\u003cbr\u003eUse an appropriate needle length according to the joint to be treated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003e– 18 to 20 Gauge\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• To achieve the best possible seal of the needle and thus prevent leakage during administration, hold the Luer-lock connection of the syringe vial firmly while screwing in the needle tightly.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Avoid excessive twisting or applying leverage when attaching the needle to the syringe or removing the needle shield, as this could cause the needle tip to break.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Inject strictly intra-articularly and, if necessary, perform under imaging guidance, especially for joints such as the hip and shoulder.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The contents of a syringe are intended for single use only. The recommended dosage corresponds to the injection of the full contents (2 ml for \u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003eand 6 ml for \u003c\/span\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003cspan\u003e) of a syringe. Unused \u003c\/span\u003e\u003cspan\u003eSynvisc\/Synvisc-One \u003c\/span\u003e\u003cspan\u003eis to be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Syringes and\/or needles must not be reused. Reuse of syringes, needles, and\/or product residues from already used syringes leads to loss of sterility. This can result in product contamination and\/or incomplete treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• When using fluoroscopy, ionic and non-ionic contrast agents may be used. A maximum of 1 ml contrast agent may be used per 2 ml of Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Do not re-sterilize Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDOSAGE INSTRUCTIONS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe dosage of Hylan G-F 20 depends on the joint to be treated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOsteoarthritis of the knee joint:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe recommended treatment consists of 3 weekly intra-articular injections of 2 ml each. To achieve maximum effect, it is necessary to complete all 3 injections. The recommended maximum dosage is 6 injections within six months, with at least four weeks between treatment series.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe recommended treatment consists of a 6 ml intra-articular injection. The injection can be repeated six months after the first injection if the patient's symptoms justify it.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eOsteoarthritis of the hip joint\/upper ankle joint\/ \u003c\/span\u003e\u003cspan\u003eShoulder joint:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAn initial treatment with a single 2 ml injection is recommended. However, if adequate relief of symptoms is not achieved after this injection, administration of a second 2 ml injection is recommended. Clinical data have shown that patients benefit from a second injection if it is given within one to three months after the first injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDURATION OF EFFECT\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTreatment with Hylan G-F 20 acts only locally in the joint; it does not produce a general systemic effect.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt is reported that the effect in patients who respond to treatment generally lasts up to 26 weeks, but both shorter and longer durations of effect have been observed. Furthermore, prospective clinical data in patients with knee osteoarthritis have shown a treatment benefit of up to 52 weeks after a single treatment cycle with three \u003c\/span\u003e\u003cspan\u003eSynvisc\u003c\/span\u003e\u003cspan\u003e-injections were shown.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynvisc-One\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProspective clinical study data in patients with gonarthrosis after a single injection of \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003ea reduction in pain for up to 52 weeks as well as associated improvements in mobility and function.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical data from a double-blind, randomized, controlled study in patients with gonarthrosis showed a statistically significant and clinically meaningful reduction in pain compared to placebo. A total of 253 patients were treated (124 received \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eand 129 received placebo). Over 26 weeks, patients under \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed an average percentage change in pain from baseline of 36%, while patients in the placebo group showed an average percentage change in pain from baseline of 29%.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdditional prospective clinical data from two multicenter, open-label studies in patients with gonarthrosis after a single injection of \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a statistically significant improvement in pain relief for up to 52 weeks compared to baseline.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the first study, 394 patients who \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a statistically significant change in the WOMAC A1 - walking pain subscore (-28 ± 19.89 mm on a 100 mm VAS, Visual Analog Scale) from baseline to week 26. Additionally, statistically significant changes from baseline were observed in WOMAC A1 and WOMAC A, B, and C scores across all six observation periods between week 1 and week 52, demonstrating improvements in walking pain and pain (WOMAC A1 -32.7 ± 19.95 mm; WOMAC A -29.18 ± 19.158 mm), mobility (WOMAC B -25.77 ± 22.047 mm), and function (WOMAC C -25.72 ± 19.449 mm) over 52 weeks.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the second study, 571 patients who \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eshowed a statistically significant improvement in pain over 26 weeks, measured by the Verbal Pain Questionnaire (VPQ). The average pain score improved from 3.20 at the start of treatment to 2.24 at the week 26 visit, with 64.6% of patients achieving pain relief. Secondary endpoints showed a statistically significant improvement in VPQ scores at all observation points from week 1 to week 52, with average VPQ scores decreasing from 3.20 at baseline to 2.26 at the week 52 visit, and 61.5% of patients achieving pain relief.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCONTENT PER ml \u003c\/span\u003e\u003cspan\u003e(Hylan G-F 20)\u003cbr\u003e1 ml contains: 8.0 mg Hylan, 8.5 mg sodium chloride, 0.16 mg disodium hydrogen phosphate, 0.04 mg sodium dihydrogen phosphate, water for injection q.s.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDOSAGE FORM\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe contents of the syringes are sterile and pyrogen-free. Store between +2 °C and +30 °C.\u003cbr\u003eDo not freeze.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSynvisc \u003c\/span\u003e\u003cspan\u003eis supplied in a 2.25 ml glass syringe vial containing 2 ml of Hylan G-F 20. \u003c\/span\u003e\u003cspan\u003eSynvisc-One \u003c\/span\u003e\u003cspan\u003eis supplied in a 10 ml glass syringe vial containing 6 ml of Hylan G-F 20.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eINFORMATION FOR PATIENTS\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInform the patient before the injection that Synvisc and Synvisc-One are made from highly purified avian-derived hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e","brand":"Sanofi-Aventis GmbH","offers":[{"title":"Default Title","offer_id":47355873657172,"sku":"146","price":189.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/synvisc-one-sanofi-aventis-deutschland-gmbh-gelenkspritzen-stakonmed-927488.jpg?v=1772216110"},{"product_id":"albomed-mini-1-x-1-ml","title":"Albomed mini 1x 1.0 ml","description":"\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/albomed\" title=\"Albomed | Gelenkspritzen | StakonMed\"\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/albomed\" title=\"Albomed | Gelenkspritzen | StakonMed\"\u003eGel\u003c\/a\u003e\u003cbr\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eUltra One Gel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made of highly purified sodium hyaluronate obtained by bacterial fermentation without \u003c\/span\u003e\u003cspan\u003esodium hyaluronate obtained from genetic modifications with high molecular weight, which is used to improve \u003c\/span\u003e\u003cspan\u003eserves the viscosity in the intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDepending on the product variant and concentration, 1 ml of aqueous, physiological phosphate buffer solution contains 10 mg, \u003c\/span\u003e\u003cspan\u003e16 mg, 22 mg, 25 mg or 30 mg sodium hyaluronate. The sodium hyaluronate hydrogel is in a weak, sterile, isotonic, and apyrogenic phosphate-buffered saline solution with a pH value \u003c\/span\u003e\u003cspan\u003efrom 7.2 (6.8 – 7.4) in sufficient volume for injection. Fill volumes vary depending on the variant from 1 to 4.8 ml. The translation of the chemical components is listed in the table in English (weight per volume as \u003c\/span\u003e\u003cspan\u003emg substance per 1 ml hydrogel):\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e(a) Sodium hyaluronate, (b) Sodium chloride, (c) Disodium hydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO,\u003cbr\u003e(d) Sodium dihydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO, (e) Water for injection purposes\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eAn essential component of healthy synovial fluid is the widespread glycosaminoglycan hyaluronic acid. \u003c\/span\u003e\u003cspan\u003eThis natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003eThe contained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eContraindications\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used in patients\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- with known hypersensitivity to any of the components\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia or under use\u003c\/span\u003e\u003cspan\u003euse of anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered directly into the joint cavity; injections into blood vessels and surrounding tissue must be avoided. Do not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single treatment session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. In the treated\u003c\/span\u003e\u003cspan\u003e- affected joint, local symptoms such as pain, redness, warmth, and swelling may occur. \u003c\/span\u003e\u003cspan\u003eThese symptoms can be reduced if the treated area is cooled with an ice pack for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. In cases of intense \u003c\/span\u003e\u003cspan\u003eIf pain or inflammation occurs, treatment should be discontinued. Treatment of adverse reactions should only be carried out under the supervision of the attending physician. Immediately after the injection, strenuous physical activity should be avoided and other instructions from the doctor should be followed. Medical personnel should inform the patient\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must report any adverse event or complication to a doctor. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds. \u003c\/span\u003e\u003cspan\u003esuch as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products that contain these, or with \u003c\/span\u003e\u003cspan\u003eSolutions containing quaternary ammonium compounds as biocidal preservatives. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe prefilled syringe is to be removed from its packaging. The protective cap is to be removed from the Luer-Lock thread. A suitable sterile injection needle is to be screwed onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended that solutions containing quaternary ammonium compounds as biocidal preservatives be rinsed before injection. \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003einitially reduce the effusion by aspiration and examine it for bacterial etiology. The hydrogel can be injected 1 to 5 times at intervals determined by the physician. \u003c\/span\u003e\u003cspan\u003eInjected intra-articularly at intervals. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eDepending on the fill volume, several joints of a patient can be treated simultaneously. Unused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eA box with one prefilled syringe of 1 ml - 4.8 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDurability\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the \u003c\/span\u003e\u003cspan\u003eSyringe blister and printed on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, warning symbols on the packaging must be observed.\u003cbr\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003cbr\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging.\u003cbr\u003eSyringe content is non-toxic and non-flammable.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing with other \u003c\/span\u003e\u003cspan\u003epatients or the same patient at a different time are the intended properties and the \u003c\/span\u003e\u003cspan\u003eSterility is not guaranteed. Otherwise, possible transmission of material contamination and pathogens \u003c\/span\u003e\u003cspan\u003efrom the environment, the clinical area, or (other) patients could lead to health complications \u003c\/span\u003e\u003cspan\u003elead to. Resealing or resterilization does not constitute an allowed or guaranteed restoration of \u003c\/span\u003e\u003cspan\u003eusable condition.\u003cbr\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste, and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStatus of information 05\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ALBOMED GmbH","offers":[{"title":"Default Title","offer_id":47355873689940,"sku":"101","price":25.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/albomed-mini-albomed-gmbh-gelenkspritzen-stakonmed-795107.jpg?v=1772213474"},{"product_id":"albomed-standard-1-x-2ml","title":"Albomed Standard 1x 2.0 ml","description":"\u003cp\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003eGel\u003c\/a\u003e\u003cbr\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eUltra One Gel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made of highly purified sodium hyaluronate obtained by bacterial fermentation without \u003c\/span\u003e\u003cspan\u003esodium hyaluronate obtained from genetic modifications with high molecular weight, which is used to improve \u003c\/span\u003e\u003cspan\u003eserves the viscosity in the intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDepending on the product variant and concentration, 1 ml of aqueous, physiological phosphate buffer solution contains 10 mg, \u003c\/span\u003e\u003cspan\u003e16 mg, 22 mg, 25 mg or 30 mg sodium hyaluronate. The sodium hyaluronate hydrogel is in a weak, sterile, isotonic, and apyrogenic phosphate-buffered saline solution with a pH value \u003c\/span\u003e\u003cspan\u003efrom 7.2 (6.8 – 7.4) in sufficient volume for injection. Fill volumes vary depending on the variant from 1 to 4.8 ml. The translation of the chemical components is listed in the table in English (weight per volume as \u003c\/span\u003e\u003cspan\u003emg substance per 1 ml hydrogel):\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e(a) Sodium hyaluronate, (b) Sodium chloride, (c) Disodium hydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO,\u003cbr\u003e(d) Sodium dihydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO, (e) Water for injection purposes\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eAn essential component of healthy synovial fluid is the widespread glycosaminoglycan hyaluronic acid. \u003c\/span\u003e\u003cspan\u003eThis natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003eThe contained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eContraindications\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used in patients\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- with known hypersensitivity to any of the components\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia or under use\u003c\/span\u003e\u003cspan\u003euse of anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered directly into the joint cavity; injections into blood vessels and surrounding tissue must be avoided. Do not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single treatment session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. In the treated\u003c\/span\u003e\u003cspan\u003e- affected joint, local symptoms such as pain, redness, warmth, and swelling may occur. \u003c\/span\u003e\u003cspan\u003eThese symptoms can be reduced if the treated area is cooled with an ice pack for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. In cases of intense \u003c\/span\u003e\u003cspan\u003eIf pain or inflammation occurs, treatment should be discontinued. Treatment of adverse reactions should only be carried out under the supervision of the attending physician. Immediately after the injection, strenuous physical activity should be avoided and other instructions from the doctor should be followed. Medical personnel should inform the patient\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must report any adverse event or complication to a doctor. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds. \u003c\/span\u003e\u003cspan\u003esuch as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products that contain these, or with \u003c\/span\u003e\u003cspan\u003eSolutions containing quaternary ammonium compounds as biocidal preservatives. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe prefilled syringe is to be removed from its packaging. The protective cap is to be removed from the Luer-Lock thread. A suitable sterile injection needle is to be screwed onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended that solutions containing quaternary ammonium compounds as biocidal preservatives be rinsed before injection. \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003einitially reduce the effusion by aspiration and examine it for bacterial etiology. The hydrogel can be injected 1 to 5 times at intervals determined by the physician. \u003c\/span\u003e\u003cspan\u003eInjected intra-articularly at intervals. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eDepending on the fill volume, several joints of a patient can be treated simultaneously. Unused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eA box with one prefilled syringe of 1 ml - 4.8 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDurability\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the \u003c\/span\u003e\u003cspan\u003eSyringe blister and printed on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, warning symbols on the packaging must be observed.\u003cbr\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003cbr\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging.\u003cbr\u003eSyringe content is non-toxic and non-flammable.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing with other \u003c\/span\u003e\u003cspan\u003epatients or the same patient at a different time are the intended properties and the \u003c\/span\u003e\u003cspan\u003eSterility is not guaranteed. Otherwise, possible transmission of material contamination and pathogens \u003c\/span\u003e\u003cspan\u003efrom the environment, the clinical area, or (other) patients could lead to health complications \u003c\/span\u003e\u003cspan\u003elead to. Resealing or resterilization does not constitute an allowed or guaranteed restoration of \u003c\/span\u003e\u003cspan\u003eusable condition.\u003cbr\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste, and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStatus of information 05\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ALBOMED GmbH","offers":[{"title":"Default Title","offer_id":47355873722708,"sku":"102","price":29.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/albomed-standard-albomed-gmbh-gelenkspritzen-stakonmed-488852.jpg?v=1772213626"},{"product_id":"albomed-standard-50-x-2-ml","title":"Albomed Standard 50x 2.0 ml","description":"\u003cp\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003eGel\u003c\/a\u003e\u003cbr\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eUltra One Gel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made of highly purified sodium hyaluronate obtained by bacterial fermentation without \u003c\/span\u003e\u003cspan\u003esodium hyaluronate obtained from genetic modifications with high molecular weight, which is used to improve \u003c\/span\u003e\u003cspan\u003eserves the viscosity in the intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDepending on the product variant and concentration, 1 ml of aqueous, physiological phosphate buffer solution contains 10 mg, \u003c\/span\u003e\u003cspan\u003e16 mg, 22 mg, 25 mg or 30 mg sodium hyaluronate. The sodium hyaluronate hydrogel is in a weak, sterile, isotonic, and apyrogenic phosphate-buffered saline solution with a pH value \u003c\/span\u003e\u003cspan\u003efrom 7.2 (6.8 – 7.4) in sufficient volume for injection. Fill volumes vary depending on the variant from 1 to 4.8 ml. The translation of the chemical components is listed in the table in English (weight per volume as \u003c\/span\u003e\u003cspan\u003emg substance per 1 ml hydrogel):\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e(a) Sodium hyaluronate, (b) Sodium chloride, (c) Disodium hydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO,\u003cbr\u003e(d) Sodium dihydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO, (e) Water for injection purposes\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eAn essential component of healthy synovial fluid is the widespread glycosaminoglycan hyaluronic acid. \u003c\/span\u003e\u003cspan\u003eThis natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003eThe contained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eContraindications\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used in patients\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- with known hypersensitivity to any of the components\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia or under use\u003c\/span\u003e\u003cspan\u003euse of anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered directly into the joint cavity; injections into blood vessels and surrounding tissue must be avoided. Do not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single treatment session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. In the treated\u003c\/span\u003e\u003cspan\u003e- affected joint, local symptoms such as pain, redness, warmth, and swelling may occur. \u003c\/span\u003e\u003cspan\u003eThese symptoms can be reduced if the treated area is cooled with an ice pack for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. In cases of intense \u003c\/span\u003e\u003cspan\u003eIf pain or inflammation occurs, treatment should be discontinued. Treatment of adverse reactions should only be carried out under the supervision of the attending physician. Immediately after the injection, strenuous physical activity should be avoided and other instructions from the doctor should be followed. Medical personnel should inform the patient\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must report any adverse event or complication to a doctor. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds. \u003c\/span\u003e\u003cspan\u003esuch as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products that contain these, or with \u003c\/span\u003e\u003cspan\u003eSolutions containing quaternary ammonium compounds as biocidal preservatives. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe prefilled syringe is to be removed from its packaging. The protective cap is to be removed from the Luer-Lock thread. A suitable sterile injection needle is to be screwed onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended that solutions containing quaternary ammonium compounds as biocidal preservatives be rinsed before injection. \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003einitially reduce the effusion by aspiration and examine it for bacterial etiology. The hydrogel can be injected 1 to 5 times at intervals determined by the physician. \u003c\/span\u003e\u003cspan\u003eInjected intra-articularly at intervals. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eDepending on the fill volume, several joints of a patient can be treated simultaneously. Unused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eA box with one prefilled syringe of 1 ml - 4.8 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDurability\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the \u003c\/span\u003e\u003cspan\u003eSyringe blister and printed on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, warning symbols on the packaging must be observed.\u003cbr\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003cbr\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging.\u003cbr\u003eSyringe content is non-toxic and non-flammable.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing with other \u003c\/span\u003e\u003cspan\u003epatients or the same patient at a different time are the intended properties and the \u003c\/span\u003e\u003cspan\u003eSterility is not guaranteed. Otherwise, possible transmission of material contamination and pathogens \u003c\/span\u003e\u003cspan\u003efrom the environment, the clinical area, or (other) patients could lead to health complications \u003c\/span\u003e\u003cspan\u003elead to. Resealing or resterilization does not constitute an allowed or guaranteed restoration of \u003c\/span\u003e\u003cspan\u003eusable condition.\u003cbr\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste, and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStatus of information 05\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ALBOMED GmbH","offers":[{"title":"Default Title","offer_id":47355873755476,"sku":"103","price":1247.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/albomed-standard-50x-20-ml-albomed-gmbh-gelenkspritzen-stakonmed-9575618.jpg?v=1772274020"},{"product_id":"albomed-forte-plus-1-x-2-ml","title":"Albomed Forte Plus 1x 2.0 ml","description":"\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003eGel\u003c\/a\u003e\u003cbr\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eUltra One Gel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made of highly purified sodium hyaluronate obtained by bacterial fermentation without \u003c\/span\u003e\u003cspan\u003esodium hyaluronate obtained from genetic modifications with high molecular weight, which is used to improve \u003c\/span\u003e\u003cspan\u003eserves the viscosity in the intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDepending on the product variant and concentration, 1 ml of aqueous, physiological phosphate buffer solution contains 10 mg, \u003c\/span\u003e\u003cspan\u003e16 mg, 22 mg, 25 mg or 30 mg sodium hyaluronate. The sodium hyaluronate hydrogel is in a weak, sterile, isotonic, and apyrogenic phosphate-buffered saline solution with a pH value \u003c\/span\u003e\u003cspan\u003efrom 7.2 (6.8 – 7.4) in sufficient volume for injection. Fill volumes vary depending on the variant from 1 to 4.8 ml. The translation of the chemical components is listed in the table in English (weight per volume as \u003c\/span\u003e\u003cspan\u003emg substance per 1 ml hydrogel):\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e(a) Sodium hyaluronate, (b) Sodium chloride, (c) Disodium hydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO,\u003cbr\u003e(d) Sodium dihydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO, (e) Water for injection purposes\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eAn essential component of healthy synovial fluid is the widespread glycosaminoglycan hyaluronic acid. \u003c\/span\u003e\u003cspan\u003eThis natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003eThe contained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eContraindications\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used in patients\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- with known hypersensitivity to any of the components\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia or under use\u003c\/span\u003e\u003cspan\u003euse of anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered directly into the joint cavity; injections into blood vessels and surrounding tissue must be avoided. Do not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single treatment session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. In the treated\u003c\/span\u003e\u003cspan\u003e- affected joint, local symptoms such as pain, redness, warmth, and swelling may occur. \u003c\/span\u003e\u003cspan\u003eThese symptoms can be reduced if the treated area is cooled with an ice pack for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. In cases of intense \u003c\/span\u003e\u003cspan\u003eIf pain or inflammation occurs, treatment should be discontinued. Treatment of adverse reactions should only be carried out under the supervision of the attending physician. Immediately after the injection, strenuous physical activity should be avoided and other instructions from the doctor should be followed. Medical personnel should inform the patient\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must report any adverse event or complication to a doctor. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds. \u003c\/span\u003e\u003cspan\u003esuch as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products that contain these, or with \u003c\/span\u003e\u003cspan\u003eSolutions containing quaternary ammonium compounds as biocidal preservatives. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe prefilled syringe is to be removed from its packaging. The protective cap is to be removed from the Luer-Lock thread. A suitable sterile injection needle is to be screwed onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended that solutions containing quaternary ammonium compounds as biocidal preservatives be rinsed before injection. \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003einitially reduce the effusion by aspiration and examine it for bacterial etiology. The hydrogel can be injected 1 to 5 times at intervals determined by the physician. \u003c\/span\u003e\u003cspan\u003eInjected intra-articularly at intervals. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eDepending on the fill volume, several joints of a patient can be treated simultaneously. Unused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eA box with one prefilled syringe of 1 ml - 4.8 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDurability\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the \u003c\/span\u003e\u003cspan\u003eSyringe blister and printed on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, warning symbols on the packaging must be observed.\u003cbr\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003cbr\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging.\u003cbr\u003eSyringe content is non-toxic and non-flammable.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing with other \u003c\/span\u003e\u003cspan\u003epatients or the same patient at a different time are the intended properties and the \u003c\/span\u003e\u003cspan\u003eSterility is not guaranteed. Otherwise, possible transmission of material contamination and pathogens \u003c\/span\u003e\u003cspan\u003efrom the environment, the clinical area, or (other) patients could lead to health complications \u003c\/span\u003e\u003cspan\u003elead to. Resealing or resterilization does not constitute an allowed or guaranteed restoration of \u003c\/span\u003e\u003cspan\u003eusable condition.\u003cbr\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste, and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStatus of information 05\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ALBOMED GmbH","offers":[{"title":"Default Title","offer_id":47355879031124,"sku":"104","price":71.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/albomed-forte-plus-albomed-gmbh-gelenkspritzen-stakonmed-555514.jpg?v=1772213811"},{"product_id":"albomed-one-1-x-3-ml","title":"Albomed One 1x 3.0 ml","description":"\u003cp\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003eGel\u003c\/a\u003e\u003cbr\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eUltra One Gel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made of highly purified sodium hyaluronate obtained by bacterial fermentation without \u003c\/span\u003e\u003cspan\u003esodium hyaluronate obtained from genetic modifications with high molecular weight, which is used to improve \u003c\/span\u003e\u003cspan\u003eserves the viscosity in the intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDepending on the product variant and concentration, 1 ml of aqueous, physiological phosphate buffer solution contains 10 mg, \u003c\/span\u003e\u003cspan\u003e16 mg, 22 mg, 25 mg or 30 mg sodium hyaluronate. The sodium hyaluronate hydrogel is in a weak, sterile, isotonic, and apyrogenic phosphate-buffered saline solution with a pH value \u003c\/span\u003e\u003cspan\u003efrom 7.2 (6.8 – 7.4) in sufficient volume for injection. Fill volumes vary depending on the variant from 1 to 4.8 ml. The translation of the chemical components is listed in the table in English (weight per volume as \u003c\/span\u003e\u003cspan\u003emg substance per 1 ml hydrogel):\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e(a) Sodium hyaluronate, (b) Sodium chloride, (c) Disodium hydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO,\u003cbr\u003e(d) Sodium dihydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO, (e) Water for injection purposes\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eAn essential component of healthy synovial fluid is the widespread glycosaminoglycan hyaluronic acid. \u003c\/span\u003e\u003cspan\u003eThis natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003eThe contained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eContraindications\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used in patients\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- with known hypersensitivity to any of the components\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia or under use\u003c\/span\u003e\u003cspan\u003euse of anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered directly into the joint cavity; injections into blood vessels and surrounding tissue must be avoided. Do not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single treatment session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. In the treated\u003c\/span\u003e\u003cspan\u003e- affected joint, local symptoms such as pain, redness, warmth, and swelling may occur. \u003c\/span\u003e\u003cspan\u003eThese symptoms can be reduced if the treated area is cooled with an ice pack for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. In cases of intense \u003c\/span\u003e\u003cspan\u003eIf pain or inflammation occurs, treatment should be discontinued. Treatment of adverse reactions should only be carried out under the supervision of the attending physician. Immediately after the injection, strenuous physical activity should be avoided and other instructions from the doctor should be followed. Medical personnel should inform the patient\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must report any adverse event or complication to a doctor. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds. \u003c\/span\u003e\u003cspan\u003esuch as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products that contain these, or with \u003c\/span\u003e\u003cspan\u003eSolutions containing quaternary ammonium compounds as biocidal preservatives. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe prefilled syringe is to be removed from its packaging. The protective cap is to be removed from the Luer-Lock thread. A suitable sterile injection needle is to be screwed onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended that solutions containing quaternary ammonium compounds as biocidal preservatives be rinsed before injection. \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003einitially reduce the effusion by aspiration and examine it for bacterial etiology. The hydrogel can be injected 1 to 5 times at intervals determined by the physician. \u003c\/span\u003e\u003cspan\u003eInjected intra-articularly at intervals. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eDepending on the fill volume, several joints of a patient can be treated simultaneously. Unused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eA box with one prefilled syringe of 1 ml - 4.8 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDurability\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the \u003c\/span\u003e\u003cspan\u003eSyringe blister and printed on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, warning symbols on the packaging must be observed.\u003cbr\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003cbr\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging.\u003cbr\u003eSyringe content is non-toxic and non-flammable.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing with other \u003c\/span\u003e\u003cspan\u003epatients or the same patient at a different time are the intended properties and the \u003c\/span\u003e\u003cspan\u003eSterility is not guaranteed. Otherwise, possible transmission of material contamination and pathogens \u003c\/span\u003e\u003cspan\u003efrom the environment, the clinical area, or (other) patients could lead to health complications \u003c\/span\u003e\u003cspan\u003elead to. Resealing or resterilization does not constitute an allowed or guaranteed restoration of \u003c\/span\u003e\u003cspan\u003eusable condition.\u003cbr\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste, and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStatus of information 05\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ALBOMED GmbH","offers":[{"title":"Default Title","offer_id":47355879063892,"sku":"105","price":134.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/albomed-one-albomed-gmbh-gelenkspritzen-stakonmed-351413.jpg?v=1772213495"},{"product_id":"albomed-ultra-one-1-x-4-8-ml","title":"Albomed Ultra One 1x 4.8 ml","description":"\u003cp\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003eGel\u003c\/a\u003e\u003cbr\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eUltra One Gel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made of highly purified sodium hyaluronate obtained by bacterial fermentation without \u003c\/span\u003e\u003cspan\u003esodium hyaluronate obtained from genetic modifications with high molecular weight, which is used to improve \u003c\/span\u003e\u003cspan\u003eserves the viscosity in the intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDepending on the product variant and concentration, 1 ml of aqueous, physiological phosphate buffer solution contains 10 mg, \u003c\/span\u003e\u003cspan\u003e16 mg, 22 mg, 25 mg or 30 mg sodium hyaluronate. The sodium hyaluronate hydrogel is in a weak, sterile, isotonic, and apyrogenic phosphate-buffered saline solution with a pH value \u003c\/span\u003e\u003cspan\u003efrom 7.2 (6.8 – 7.4) in sufficient volume for injection. Fill volumes vary depending on the variant from 1 to 4.8 ml. The translation of the chemical components is listed in the table in English (weight per volume as \u003c\/span\u003e\u003cspan\u003emg substance per 1 ml hydrogel):\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e(a) Sodium hyaluronate, (b) Sodium chloride, (c) Disodium hydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO,\u003cbr\u003e(d) Sodium dihydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO, (e) Water for injection purposes\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eAn essential component of healthy synovial fluid is the widespread glycosaminoglycan hyaluronic acid. \u003c\/span\u003e\u003cspan\u003eThis natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003eThe contained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eContraindications\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used in patients\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- with known hypersensitivity to any of the components\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia or under use\u003c\/span\u003e\u003cspan\u003euse of anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered directly into the joint cavity; injections into blood vessels and surrounding tissue must be avoided. Do not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single treatment session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. In the treated\u003c\/span\u003e\u003cspan\u003e- affected joint, local symptoms such as pain, redness, warmth, and swelling may occur. \u003c\/span\u003e\u003cspan\u003eThese symptoms can be reduced if the treated area is cooled with an ice pack for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. In cases of intense \u003c\/span\u003e\u003cspan\u003eIf pain or inflammation occurs, treatment should be discontinued. Treatment of adverse reactions should only be carried out under the supervision of the attending physician. Immediately after the injection, strenuous physical activity should be avoided and other instructions from the doctor should be followed. Medical personnel should inform the patient\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must report any adverse event or complication to a doctor. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds. \u003c\/span\u003e\u003cspan\u003esuch as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products that contain these, or with \u003c\/span\u003e\u003cspan\u003eSolutions containing quaternary ammonium compounds as biocidal preservatives. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe prefilled syringe is to be removed from its packaging. The protective cap is to be removed from the Luer-Lock thread. A suitable sterile injection needle is to be screwed onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended that solutions containing quaternary ammonium compounds as biocidal preservatives be rinsed before injection. \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003einitially reduce the effusion by aspiration and examine it for bacterial etiology. The hydrogel can be injected 1 to 5 times at intervals determined by the physician. \u003c\/span\u003e\u003cspan\u003eInjected intra-articularly at intervals. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eDepending on the fill volume, several joints of a patient can be treated simultaneously. Unused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eA box with one prefilled syringe of 1 ml - 4.8 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDurability\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the \u003c\/span\u003e\u003cspan\u003eSyringe blister and printed on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, warning symbols on the packaging must be observed.\u003cbr\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003cbr\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging.\u003cbr\u003eSyringe content is non-toxic and non-flammable.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing with other \u003c\/span\u003e\u003cspan\u003epatients or the same patient at a different time are the intended properties and the \u003c\/span\u003e\u003cspan\u003eSterility is not guaranteed. Otherwise, possible transmission of material contamination and pathogens \u003c\/span\u003e\u003cspan\u003efrom the environment, the clinical area, or (other) patients could lead to health complications \u003c\/span\u003e\u003cspan\u003elead to. Resealing or resterilization does not constitute an allowed or guaranteed restoration of \u003c\/span\u003e\u003cspan\u003eusable condition.\u003cbr\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste, and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStatus of information 05\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ALBOMED GmbH","offers":[{"title":"Default Title","offer_id":47355879326036,"sku":"106","price":149.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/albomed-ultra-one-albomed-gmbh-gelenkspritzen-stakonmed-374730.jpg?v=1772213914"},{"product_id":"albomed-innoryos-1-x-2-ml","title":"Albomed Innoryos 1x 2.0 ml","description":"\u003cp\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e\u003ca title=\"Albomed | Gelenkspritzen | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/albomed\"\u003eGel\u003c\/a\u003e\u003cbr\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eUltra One Gel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made of highly purified sodium hyaluronate obtained by bacterial fermentation without \u003c\/span\u003e\u003cspan\u003esodium hyaluronate obtained from genetic modifications with high molecular weight, which is used to improve \u003c\/span\u003e\u003cspan\u003eserves the viscosity in the intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDepending on the product variant and concentration, 1 ml of aqueous, physiological phosphate buffer solution contains 10 mg, \u003c\/span\u003e\u003cspan\u003e16 mg, 22 mg, 25 mg or 30 mg sodium hyaluronate. The sodium hyaluronate hydrogel is in a weak, sterile, isotonic, and apyrogenic phosphate-buffered saline solution with a pH value \u003c\/span\u003e\u003cspan\u003efrom 7.2 (6.8 – 7.4) in sufficient volume for injection. Fill volumes vary depending on the variant from 1 to 4.8 ml. The translation of the chemical components is listed in the table in English (weight per volume as \u003c\/span\u003e\u003cspan\u003emg substance per 1 ml hydrogel):\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e(a) Sodium hyaluronate, (b) Sodium chloride, (c) Disodium hydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO,\u003cbr\u003e(d) Sodium dihydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO, (e) Water for injection purposes\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eAn essential component of healthy synovial fluid is the widespread glycosaminoglycan hyaluronic acid. \u003c\/span\u003e\u003cspan\u003eThis natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003eThe contained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eContraindications\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used in patients\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- with known hypersensitivity to any of the components\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia or under use\u003c\/span\u003e\u003cspan\u003euse of anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered directly into the joint cavity; injections into blood vessels and surrounding tissue must be avoided. Do not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single treatment session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. In the treated\u003c\/span\u003e\u003cspan\u003e- affected joint, local symptoms such as pain, redness, warmth, and swelling may occur. \u003c\/span\u003e\u003cspan\u003eThese symptoms can be reduced if the treated area is cooled with an ice pack for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. In cases of intense \u003c\/span\u003e\u003cspan\u003eIf pain or inflammation occurs, treatment should be discontinued. Treatment of adverse reactions should only be carried out under the supervision of the attending physician. Immediately after the injection, strenuous physical activity should be avoided and other instructions from the doctor should be followed. Medical personnel should inform the patient\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must report any adverse event or complication to a doctor. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds. \u003c\/span\u003e\u003cspan\u003esuch as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products that contain these, or with \u003c\/span\u003e\u003cspan\u003eSolutions containing quaternary ammonium compounds as biocidal preservatives. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe prefilled syringe is to be removed from its packaging. The protective cap is to be removed from the Luer-Lock thread. A suitable sterile injection needle is to be screwed onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended that solutions containing quaternary ammonium compounds as biocidal preservatives be rinsed before injection. \u003c\/span\u003e\u003cspan\u003eKD Intra-Articular\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eGel \u003c\/span\u003e\u003cspan\u003einitially reduce the effusion by aspiration and examine it for bacterial etiology. The hydrogel can be injected 1 to 5 times at intervals determined by the physician. \u003c\/span\u003e\u003cspan\u003eInjected intra-articularly at intervals. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eDepending on the fill volume, several joints of a patient can be treated simultaneously. Unused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eA box with one prefilled syringe of 1 ml - 4.8 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDurability\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the \u003c\/span\u003e\u003cspan\u003eSyringe blister and printed on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, warning symbols on the packaging must be observed.\u003cbr\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003cbr\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging.\u003cbr\u003eSyringe content is non-toxic and non-flammable.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing with other \u003c\/span\u003e\u003cspan\u003epatients or the same patient at a different time are the intended properties and the \u003c\/span\u003e\u003cspan\u003eSterility is not guaranteed. Otherwise, possible transmission of material contamination and pathogens \u003c\/span\u003e\u003cspan\u003efrom the environment, the clinical area, or (other) patients could lead to health complications \u003c\/span\u003e\u003cspan\u003elead to. Resealing or resterilization does not constitute an allowed or guaranteed restoration of \u003c\/span\u003e\u003cspan\u003eusable condition.\u003cbr\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste, and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStatus of information 05\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ALBOMED GmbH","offers":[{"title":"Default Title","offer_id":47355879358804,"sku":"107","price":74.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/albomed-innoryos-albomed-gmbh-gelenkspritzen-stakonmed-473622.jpg?v=1772213397"},{"product_id":"durolane-1-x-3-ml","title":"Durolane 1x 3.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eComposition\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003e1 ml contains:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStabilized hyaluronic acid 20 mg \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIsotonic saline solution, pH 7 q.s.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/durolane\" title=\"Durolane | Joint injections | StakonMed\"\u003eDUROLANE\u003c\/a\u003e* is intended for intra-articular injection for the symptomatic treatment of mild to moderate knee and hip osteoarthritis. Additionally, DUROLANE is intended for intra-articular injection for the symptomatic treatment of mild to moderate osteoarthritis of indicated synovial joints as well as pain following arthroscopic procedures. It must be injected by a licensed physician or according to local regulations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eDUROLANE contains 20 mg\/ml stabilized non-animal hyaluronic acid in buffered isotonic saline solution with a pH of 7. DUROLANE is a sterile, transparent viscoelastic gel supplied in a 3-ml glass syringe. The product is intended for single use only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHyaluronic acid is identical in all living organisms. It is a natural polysaccharide found in all body tissues, with particularly high \u003c\/span\u003e\u003cspan\u003eConcentrations in synovial fluid and skin. DUROLANE \u003c\/span\u003e\u003cspan\u003econsists of biosynthetically produced hyaluronic acid that has been purified and stabilized. DUROLANE is broken down in the body by the same metabolic processes as endogenous hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe body's hyaluronic acid is a natural component of synovial fluid and serves in the joints both as a lubricant for cartilage and tendons and as a shock absorber. Hyaluronic acid injections into the joint to restore viscosity and elasticity can simultaneously relieve pain and improve joint mobility.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eDUROLANE is a \u003c\/span\u003e\u003cspan\u003eSingle-dose preparation in a single-use syringe \u003c\/span\u003e\u003cspan\u003eand may only be injected once per treatment series. The recommended dose is 3 ml per knee, hip, or shoulder joint. The recommended dose is 1–2 ml for compound joints (e.g., elbow or ankle) and about 1 ml for small synovial joints (e.g., thumb).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSymptomatic treatment of mild to moderate knee and hip osteoarthritis. DUROLANE is also approved for the symptomatic treatment of mild to moderate osteoarthritis pain in ankle, shoulder, elbow, hand, finger, and toe joints. DUROLANE is also indicated for the treatment of pain following arthroscopic procedures on the joint in the presence of osteoarthritis within three months after the procedure.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNone known.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWarnings\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE must not be used in infected or severely inflamed \u003c\/span\u003e\u003cspan\u003eSynovial joint must not be injected.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE must not be injected in case of active skin disease or infection at or near the injection site.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE must not be injected intravascularly or extra-articularly \u003c\/span\u003e\u003cspan\u003eor injected into the synovial tissue or joint capsule \u003c\/span\u003e\u003cspan\u003ewill be.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE must not be re-sterilized, as the product may be damaged. \u003c\/span\u003e\u003cspan\u003eThe product may be damaged as a result.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE should be used with special caution in patients with venous or lymphatic congestion in the leg.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The use of DUROLANE in pregnant or breastfeeding women or in children has not yet been studied.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• A separate DUROLANE syringe must be used for each joint to be treated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• As with all invasive joint treatments, there is a small risk of infection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE must not be used in patients with known hypersensitivity to the product. \u003c\/span\u003e\u003cspan\u003ePatients must not be injected with products based on hyaluronic acid if they have known hypersensitivity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Local anesthetics must not be used in patients with known allergy or hypersensitivity to local anesthetics.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Injections under fluoroscopic guidance and under \u003c\/span\u003e\u003cspan\u003eUse of a contrast agent is not allowed in known \u003c\/span\u003e\u003cspan\u003eAllergy or hypersensitivity of the patient to \u003c\/span\u003e\u003cspan\u003eshould not be performed with the contrast agent.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Repeat injections into the knee at intervals shorter than 6 months after the initial injection have not yet been studied in clinical trials.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Increasing injection pressure may indicate that the needle is incorrectly positioned outside the joint or that the joint is overfilled.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The efficacy of DUROLANE after arthroscopic procedures performed solely for diagnostic or investigative purposes or in the absence of joint osteoarthritis has not been established.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE should be used with caution in patients with existing chondrocalcinosis, as the injection may trigger an acute attack.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdverse events\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMost adverse events reported in clinical studies for the treatment of osteoarthritis of the knee and hip joints were described as temporary pain, swelling, and\/or stiffness of the joint. These adverse events were of mild or moderate intensity and required treatment with painkillers or nonsteroidal anti-inflammatory drugs (NSAIDs) in only a few cases.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe use of hyaluronic acid preparations for the treatment of other joints did not lead to any additional specific adverse events.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNone of the other reported adverse events were interpreted as acute joint inflammation or allergic reaction. They did not require any medical interventions such as surgical procedures or administration of systemic or intra-articular steroids or antibiotics.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdverse events must be reported to the regional Bioventus representative.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe safety and efficacy of DUROLANE in combination with other intra-articular injection agents have not yet been studied.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eApplication\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGeneral information on use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE may only be injected by a licensed physician (or according to applicable local regulations) familiar with the intra-articular injection technique for the synovial joint being treated, and only in facilities specially equipped for intra-articular injections.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE must be injected under strictly aseptic conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• DUROLANE must only be injected into the joint space. • For intra-articular injection into certain synovial joints, image guidance is required to ensure correct positioning and to avoid damage to adjacent \u003c\/span\u003e\u003cspan\u003eto avoid damage to vital structures.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• With or without image guidance, the injection path for the \u003c\/span\u003e\u003cspan\u003ethe intra-articular injection should be chosen to avoid damage to adjacent vital structures.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Before injection, clean the injection site with alcohol or another suitable antiseptic solution. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Any existing joint effusion should be removed before injecting DUROLANE. For removing the effusion and injecting DUROLANE, \u003c\/span\u003e\u003cspan\u003euse the same needle.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The recommended needle gauge is 18 to 22 G; the needle \u003c\/span\u003e\u003cspan\u003eshould be chosen sufficiently long.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Using smaller needles reduces the pressure needed for \u003c\/span\u003e\u003cspan\u003ethe pressure required to introduce the product increases. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdditional information on treatment of synovial joints with image guidance\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003e• Intra-articular injection into hip joints should be performed under \u003c\/span\u003e\u003cspan\u003efluoroscopic control (preferably using \u003c\/span\u003e\u003cspan\u003emay be administered with contrast medium or under ultrasound guidance to ensure correct needle placement in the joint space.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The decision to treat other synovial joints is made by the treating physician.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Pain from the injection can be minimized by using topical freezing agents or subcutaneously administered local anesthesia.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Image-guided injections should only be performed by physicians experienced with such procedures.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdditional information on treatment after arthroscopic procedures\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e• After the arthroscopic procedure, the intra-articular \u003c\/span\u003e\u003cspan\u003eto perform the injection outside the sterile field because \u003c\/span\u003e\u003cspan\u003ethe outside of the syringe is not sterile.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Joints frequently undergoing arthroscopic procedures\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe joints commonly treated are the knee, hip, shoulder, elbow, ankle, and wrist.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePlease inform the patient of the following:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• As with all invasive joint treatments, strenuous activities should be avoided for the first two days after the injection (e.g., tennis, jogging, or long walks).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• In the first week after the DUROLANE injection, temporary reactions such as pain and\/or swelling\/stiffness may occur. They are of mild to moderate intensity. If symptoms persist for more than one week, a doctor should be consulted.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eEffect\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Clinical studies on DUROLANE in osteoarthritis of the knee and hip show significant moderate benefits 6 months after treatment \u003c\/span\u003e\u003cspan\u003esignificant moderate improvement compared to baseline \u003c\/span\u003e\u003cspan\u003eBenefits such as improvement in pain and mobility of the knee and hip.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Studies investigating repeated treatments of the knee 6 months after the first injection showed no increase in adverse events.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Controlled studies of DUROLANE in osteoarthritis \u003c\/span\u003e\u003cspan\u003eof the knee joint showed a significant benefit in \u003c\/span\u003e\u003cspan\u003eresponsive patients compared to saline solution and no worse results compared to a corticosteroid in a targeted patient population.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Clinical studies of other hyaluronic acid products comparable to DUROLANE for the treatment of osteoarthritis as well as after arthroscopic procedures on joints other than the knee and hip showed a moderate benefit compared to baseline. Certain studies also showed improvements in the hyaluronic acid-treated group compared to control therapies such as saline solution and corticosteroids. Improvements in pain and mobility were observed up to 6 months after treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• The half-life of DUROLANE in the human knee is approximately 4 weeks.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eScope of delivery\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDUROLANE is supplied in a 3 ml glass syringe with a Luer-Lock connection, packaged in a blister pack. The contents of the syringe are sterile. The outside of the syringe is not sterile.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDUROLANE is intended for single use only and must not be re-sterilized. The product must be used immediately after removing the syringe from its packaging. Opened or damaged blister packs or syringes must not be used.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe syringe and unused material must be disposed of immediately after treatment and must not be reused due to the risk of contamination for unused material and the associated other risks, such as infection risk. When disposing, recognized medical procedures as well as applicable national or local regulations and the guidelines of the respective institution must be observed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eShelf life and storage\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDUROLANE must be stored in its original packaging at temperatures below 30°C. The expiration date is indicated on the packaging. Do not use the product after this date. Protect from frost.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Bioventus Coöperatief U.A.","offers":[{"title":"Default Title","offer_id":47355879391572,"sku":"110","price":118.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/durolane-1x-30-ml-bioventus-cooperatief-ua-gelenkspritzen-stakonmed-7595272.jpg?v=1772274016"},{"product_id":"go-on-1-x-2-5-ml","title":"Go-On 1x 2.5 ml","description":"\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003eDESCRIPTION:\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"Go-On | Joint Injections | StakonMed\" href=\"https:\/\/stakonmed.de\/collections\/go-on\" data-mce-href=\"https:\/\/stakonmed.de\/collections\/go-on\"\u003eGO-ON\u003c\/a\u003e® is a sterile, pyrogen-free sodium hyaluronate solution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eCOMPOSITION: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 GO-ON® prefilled syringe contains 2.5 ml of a 1% sodium hyaluronate solution as well as sodium chloride, sodium monohydrogen phosphate, sodium dihydrogen phosphate, and water for injection purposes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003ePROPERTIES: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate is a natural, high-molecular-weight polysaccharide composed of a linear chain of disaccharide units made up of sodium glucuronate and N-acetylglucosamine. Sodium hyaluronate is present in many tissues of the human body and is the main component of synovial fluid, where it occurs in high concentrations. It plays an important role as a joint lubricant in coordinating the physical and mechanical interactions between adjacent tissues. As a viscoelastic support material, it also maintains the spacing between tissues. Sodium hyaluronate preparations can have different molecular weights but share the same chemical structure. GO-ON® is a 1% sodium hyaluronate solution obtained from Streptococcus equi through fermentation processes and subsequent purification.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eINDICATIONS: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGO-ON is indicated as a viscoelastic supplementation of the synovial fluid in the knee. Viscosupplementation is recommended for patients with normal weight or moderate overweight with symptomatic mild to moderate knee OA whose condition cannot be sufficiently improved by non-pharmacological treatment and analgesics\/NSAIDs or who cannot take analgesics\/NSAIDs. The product acts as a lubricant and mechanical support and is suitable for treating symptoms\u003cbr\u003eof osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eCONTRAINDICATIONS: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGO-ON® must not be used in patients with a history of hypersensitivity to any of the product's components or in inflammatory joint diseases such as rheumatoid arthritis or ankylosing spondylitis. Since the safety of this product has not been established in children, pregnant, or breastfeeding women, it must not be used in these patients. Recognized contraindications for intra-articular hyaluronic acid injection include active joint infections, bacteremia, and diseases of the overlying skin. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWARNINGS AND PRECAUTIONS: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis product may only be used by doctors. In particular, the doctor should have training as an orthopedist, rheumatologist, or physiatrist. | \u003c\/span\u003e\u003cspan\u003eRecommendations regarding injection techniques: - Ensure that the joint shows no clinical signs of acute inflammation (heat, redness, swelling) before injection of GO-ON®; \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003e- If necessary, removal of excess synovial fluid (due to joint effusion) before injection; \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003e- Use of aseptic technique to avoid contamination and infection at the injection site. Do not use if the blister packaging has been opened and\/or damaged. The product must not be used after the expiration date indicated on the box. The product should be kept out of reach of children. In patients with osteoarthritis, this preparation may worsen an existing local inflammation. Therefore, it is advisable to administer the product only after the local symptom has been alleviated.\u003cbr\u003eIn rare cases, local pain may occur after administration of the product.\u003cbr\u003eTo avoid pain after the injection, instructions should be given,\u003cbr\u003ekeeping the site as still as possible for 2-6 hours after the injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product must be injected strictly into the intra-articular area, as otherwise it may cause pain. Avoid injections into blood vessels or surrounding tissue! The preparation should be administered with caution to patients who have frequently shown hypersensitivity to medications, and the patient should remain under clinical observation for at least 1 hour after the injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSIDE EFFECTS: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn rare cases, some patients develop a skin rash, such as urticaria and pruritus. In such cases, administration should be discontinued and the patient treated accordingly. Pain (mainly transient pain after administration), swelling and effusions, as well as infections at the injection site, have been reported only rarely. Patients rarely complain of redness, warmth, and a feeling of heaviness at the injection site. Shock has been reported only in rare cases. Anaphylactic reactions may occur. In this case, administration should be stopped, the patient closely monitored, and appropriate treatment carried out. Other reported incidents include reactive arthritis, necrosis of the M. vastus medialis and skin, pulmonary embolism, lesions, torn meninges with injections into facet joints, skin rash, deep vein inflammation, general fatigue, high blood pressure, cardiac arrhythmias, knee inflammations, knee cysts, allergic reactions, and surgical interventions. After injection of GO-ON®, local side effects may occur in the treated joint, such as pain, warmth, redness, and\/or swelling and effusion. These side effects can be alleviated by applying an ice pack to the treated joint for \u003c\/span\u003e\u003cspan\u003ecan be reduced by 5 to 10 minutes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eINTERACTIONS WITH OTHER MEDICATIONS: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThere is a known incompatibility between sodium hyaluronate and quaternary ammonium salts, such as benzalkonium chloride, which can be used as skin disinfectants. Therefore, GO-ON® must never come into contact with such products or with medical or surgical devices treated with these types of products, as hyaluronic acid may precipitate in their presence. No incompatibilities (interactions) with other solutions for intra-articular administration have been observed with GO-ON® so far. During the first days of treatment, the simultaneous administration of oral analgesics or anti-inflammatory drugs may prove beneficial.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDOSAGE AND ADMINISTRATION: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGO-ON should be injected into the affected joint a total of 5 times at weekly intervals. Depending on the severity of the joint disease, the effect of a course of five treatments can last up to 6 months.\u003cbr\u003eTreatment cycles can be repeated if necessary. In the case of effusion in a joint, it is recommended to puncture it, immobilize the joint, apply an ice pack, and\/or administer corticosteroids by intra-articular injection. Treatment with GO-ON® can be repeated 2-3 days later. Remove the syringe from the blister, take off the rubber stopper, attach a suitable sterilized needle (e.g., 19 or 21 G), and secure it with a slight twist. When attaching the needle and removing the needle cover, be careful not to tighten it too much or lever it excessively. Before injection, press out excess air from the syringe. GO-ON should be administered separately and not mixed with other substances before injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eFEATURES AND MODE OF ACTION: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe viscoelastic synovial fluid, due to its hyaluronic acid content, is found in all synovial joints, especially \u003c\/span\u003e\u003cspan style=\"font-size: 0.875rem;\" data-mce-style=\"font-size: 0.875rem;\"\u003ein the large joints, which are subjected to considerable stress due to body weight. Here, synovial fluid serves as joint lubricant and shock absorber, ensuring normal, pain-free joint movements. Furthermore, synovial fluid supplies nutrients to the joint cartilage. Degenerative joint diseases such as osteoarthritis are associated with a significant reduction in the viscosity of synovial fluid, which impairs its lubricating and shock-absorbing function. As a result, mechanical joint stress and the loss of joint cartilage tissue increase so significantly \u003c\/span\u003e\u003cspan style=\"font-size: 0.875rem;\" data-mce-style=\"font-size: 0.875rem;\"\u003ethat pain and functional limitations occur in the affected joints \u003c\/span\u003e\u003cspan style=\"font-size: 0.875rem;\" data-mce-style=\"font-size: 0.875rem;\"\u003eIt has been proven that the quality improvement of synovial fluid caused by intra-articular injection of sodium hyaluronate preparations also improves its viscoelastic properties. This promotes its function as a lubricant and shock absorber, which reduces mechanical joint stress. This leads to pain relief and improved joint mobility. This effect can last more than six months after a treatment cycle of five intra-articular injections.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePACKAGING: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGO-ON® is supplied as a prefilled syringe with 2.5 ml (25 mg) sodium hyaluronate solution. The product was sterilized by steam inside the blister. One package contains\u003cbr\u003e1 syringe.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSHELF LIFE: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e3 years\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSTORAGE: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore at 2°C to 25°C.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eSYMBOLS ON THE PACKAGING: \u003c\/span\u003e\u003cspan\u003e1: \u003c\/span\u003e\u003cspan\u003eBatch number | \u003c\/span\u003e\u003cspan\u003e2: \u003c\/span\u003e\u003cspan\u003eUse by |\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e3: \u003c\/span\u003e\u003cspan\u003eSingle use only | \u003c\/span\u003e\u003cspan\u003e4: \u003c\/span\u003e\u003cspan\u003eObserve instructions for use. | \u003c\/span\u003e\u003cspan\u003e5: \u003c\/span\u003e\u003cspan\u003eSterile by moist heat | \u003c\/span\u003e\u003cspan\u003e6: \u003c\/span\u003e\u003cspan\u003eStorage temperature 2-25°C | \u003c\/span\u003e\u003cspan\u003e7: \u003c\/span\u003e\u003cspan\u003eManufacturer | \u003c\/span\u003e\u003cspan\u003e8: \u003c\/span\u003e\u003cspan\u003eDo not use if the packaging is damaged! | \u003c\/span\u003e\u003cspan\u003e9: \u003c\/span\u003e\u003cspan\u003eKeep dry | \u003c\/span\u003e\u003cspan\u003e10: \u003c\/span\u003e\u003cspan\u003eDo not re-sterilize\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eUSE OF GO-ON®: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e❶ \u003c\/span\u003e\u003cspan\u003eRemove the syringe from the container. If the product is stored in the refrigerator (see storage conditions), take it out twenty or thirty minutes before use. | \u003c\/span\u003e\u003cspan\u003e❷ \u003c\/span\u003e\u003cspan\u003eTurn and remove the rubber stopper. | \u003c\/span\u003e\u003cspan\u003e❸ \u003c\/span\u003e\u003cspan\u003eAttach a 19- or 21-gauge injection needle. When attaching the needle and removing the needle cap, be careful not to tighten too much or lever too hard, as this could break the syringe tip. | \u003c\/span\u003e\u003cspan\u003e❹ \u003c\/span\u003e\u003cspan\u003eThe syringe is ready for use. *Before administration, thoroughly disinfect the injection site. Do not use a disinfectant containing quaternary ammonium salts at the same time.\u003cbr\u003eReusing single-use products carries a potential infection risk for patients or users. Contamination of the unit can lead to injury, illness, or death of the patient.\u003cbr\u003ePlease dispose of GO-ON® according to local regulations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eNOTE: \u003c\/span\u003e\u003cspan\u003eThe GO-ON® implant is considered safe in the magnetic resonance (MR) environment. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMANUFACTURER ACCORDING TO MEDICAL DEVICE REGULATIONS:\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eRottapharm Ltd.\u003c\/span\u003e\u003cspan\u003e, Damastown Industrial Park, Mulhuddart-Dublin 15, Ireland;\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e+353 1 8852 700\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eDISTRIBUTION FOR BELGIUM: \u003c\/span\u003e\u003cspan\u003eSee folding box\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003eDISTRIBUTION FOR GERMANY: \u003c\/span\u003e\u003cspan\u003eSee folding box \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDISTRIBUTION FOR AUSTRIA\u003c\/span\u003e\u003cspan\u003eSee folding box\u003cbr\u003eThis instruction manual was last revised in 03\/2021 M1161A\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Viatris Healthcare GmbH","offers":[{"title":"Default Title","offer_id":47355879424340,"sku":"111","price":22.1,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/go-on-viatris-healthcare-gmbh-gelenkspritzen-stakonmed-987449.jpg?v=1772214420"},{"product_id":"go-on-matrix-1-x-2-ml","title":"Go-On Matrix 1x 2.0 ml","description":"","brand":"Viatris Healthcare GmbH","offers":[{"title":"Default Title","offer_id":47355879457108,"sku":"112","price":66.95,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/products\/go-on-matrix-viatris-healthcare-gmbh-gelenkspritzen-stakonmed-877406.jpg?v=1709318606"},{"product_id":"hialurom-forte-1-x-2-ml","title":"Hialurom Forte 1x 2.0 ml","description":"\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/hialurom\" title=\"Hialurom | Gelenkspritzen | StakonMed\"\u003eHIALUROM\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003eSodium hyaluronate 30 mg 2 ml, sterile solution for injection in a prefilled syringe\u003c\/p\u003e\n\u003cp\u003eFor intraarticular injection\u003c\/p\u003e\n\u003cp\u003eDESCRIPTION:\u003c\/p\u003e\n\u003cp\u003eHialurom is a sterile, viscoelastic solution of sodium hyaluronate. Hialurom contains 30 mg in 2 ml of sterile sodium hyaluronate with a molecular weight of 1.5 - 2.4 million Daltons, dissolved in physiological saline with an average osmolarity of 335 milliosmols, in a prefilled syringe. The sodium hyaluronate is obtained by bacterial fermentation of a Streptococcus strain and subsequently purified.\u003c\/p\u003e\n\u003cp\u003eEach milliliter of Hialurom contains 15 mg sodium hyaluronate, sodium chloride, and water for injection.\u003c\/p\u003e\n\u003cp\u003eSterile by moist heat.\u003c\/p\u003e\n\u003cp\u003eINDICATIONS:\u003c\/p\u003e\n\u003cp\u003eHialurom is indicated as a viscoelastic supplement or replacement of synovial fluid in the human knee joint.\u003c\/p\u003e\n\u003cp\u003eHialurom is indicated for the symptomatic treatment of knee osteoarthritis. Hialurom acts as a lubricant and mechanical support.\u003c\/p\u003e\n\u003cp\u003eCONTRAINDICATIONS:\u003c\/p\u003e\n\u003cp\u003eThe following pre-existing conditions may represent relative or absolute contraindications for the use of Hialurom:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eallergies (hypersensitivity) to any of the components of Hialurom,\u003c\/li\u003e\n\u003cli\u003eexisting skin infections at the injection site,\u003c\/li\u003e\n\u003cli\u003eknown infection in the index finger joint,\u003c\/li\u003e\n\u003cli\u003eknown systemic bleeding disorders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eHialurom may contain traces of proteins from gram-positive bacteria and is contraindicated for patients with known allergies of this type.\u003c\/p\u003e\n\u003cp\u003ePOSSIBLE SIDE EFFECTS:\u003c\/p\u003e\n\u003cp\u003eSodium hyaluronate is a natural component of human tissue. Since sodium hyaluronate is classified as non-inflammatory, all inflammatory reactions are attributed to the injection procedure itself. Occasionally, mild to moderate temporary swelling and discomfort have been observed after intraarticular injection of sodium hyaluronate preparations. There are minimal risks associated with the injection procedure, primarily infections and bleeding.\u003c\/p\u003e\n\u003cp\u003eADMINISTRATION AND DOSAGE:\u003c\/p\u003e\n\u003cp\u003eHialurom may only be administered by medical professionals trained in intraarticular injection techniques.\u003c\/p\u003e\n\u003cp\u003eHialurom may only be administered intraarticularly.\u003c\/p\u003e\n\u003cp\u003eIt must not be administered intravenously.\u003c\/p\u003e\n\u003cp\u003eStrict aseptic administration techniques must be followed.\u003c\/p\u003e\n\u003cp\u003eThe injection site must be properly disinfected (70% alcohol or another disinfectant). Disinfectants containing quaternary ammonium salts should not be used for skin disinfection, as this may cause a failure reaction of the hyaluronic acid. Hialurom is administered once weekly into the affected joint over three consecutive weeks. For bilateral treatment, a separate syringe should be used for each knee. Each joint may only undergo one treatment cycle within a 6-month period.\u003c\/p\u003e\n\u003cp\u003eAny joint effusion must be removed by joint aspiration before injecting Hialurom. The joint space must not be overfilled. Hialurom is available as a prefilled syringe and must not be diluted. The contents of the Hialurom prefilled syringe are sterile and must be used immediately once the package is opened. Hialurom must be slowly injected into the joint space using a standard intra-articular injection technique.\u003c\/p\u003e\n\u003cp\u003eRemove the prefilled syringe from the packaging. Break the visible seal before use and remove the cap from the prefilled syringe. Attach the hypodermic needle of a suitable size (gauge) and length (inch) and ensure it is properly secured by gently twisting. Prime the syringe before injection.\u003c\/p\u003e\n\u003cp\u003eCommon needle sizes for injections into the knee are between 18 and 21 G (1.2-0.8 mm).\u003c\/p\u003e\n\u003cp\u003eThe final choice of needle for each treatment is made by the doctor,\u003c\/p\u003e\n\u003cp\u003ePRECAUTIONS:\u003c\/p\u003e\n\u003cp\u003eGeneral precautions for intraarticular injections must be observed. Hialurom must only be injected into the joint space by trained medical personnel. If pain increases during the injection, the injection must be stopped and the needle withdrawn.\u003c\/p\u003e\n\u003cp\u003ePatients must be carefully examined for signs of acute inflammation before administration, and the doctor must decide whether treatment with Hialurom should be started in such cases.\u003c\/p\u003e\n\u003cp\u003eAs with any invasive joint procedure, it is recommended not to overload the joint immediately after the intraarticular injection.\u003c\/p\u003e\n\u003cp\u003ePatients who experience abnormal follow-up complications after administration of Hialurom must see a doctor immediately. There is insufficient data to recommend use in children and adolescents, pregnant and breastfeeding women. Hialurom must not be administered simultaneously or mixed intraarticularly with other products.\u003c\/p\u003e\n\u003cp\u003eWARNINGS:\u003c\/p\u003e\n\u003cp\u003eThe product Hialurom is intended for single use!\u003c\/p\u003e\n\u003cp\u003eDo not reuse.\u003c\/p\u003e\n\u003cp\u003eEach Hialurom prefilled syringe is intended for use on a single patient only.\u003c\/p\u003e\n\u003cp\u003eDo not use the syringe if the seal is opened or damaged.\u003c\/p\u003e\n\u003cp\u003eThe product must not be re-sterilized as this may damage or alter the product.\u003c\/p\u003e\n\u003cp\u003eThe product should only be used if the solution is clear.\u003c\/p\u003e\n\u003cp\u003eUsed needles and syringes must be disposed of after each injection and must not be kept for other administrations.\u003c\/p\u003e\n\u003cp\u003eReusing already used needles and syringes can lead to the transmission of infectious agents (including HIV and hepatitis).\u003c\/p\u003e\n\u003cp\u003eHialurom should be brought to room temperature before use by storing it, if necessary, for about 20-45 minutes at appropriate temperatures before administration.\u003c\/p\u003e\n\u003cp\u003eKeep out of reach of children.\u003c\/p\u003e\n\u003cp\u003eDo not use after the expiration date on the label.\u003c\/p\u003e\n\u003cp\u003ePROPERTIES AND MODE OF ACTION:\u003c\/p\u003e\n\u003cp\u003eThe sodium hyaluronate in Hialurom is a polysaccharide consisting of sodium glucuronate and N-acetylglucosamine.\u003c\/p\u003e\n\u003cp\u003eSodium hyaluronate is ubiquitous in human tissue and is found in high concentrations in certain tissues such as the vitreous body, synovial fluid, umbilical cord, and dermis. In synovial joints, sodium hyaluronate acts as a lubricant and shock absorber, enabling normal movements without joint pain. In degenerative joint diseases (osteoarthritis), the viscoelasticity of synovial fluid is impaired, which greatly increases mechanical stress on the joint and destruction of joint cartilage, leading to restricted and painful joint movement.\u003c\/p\u003e\n\u003cp\u003eThe lubricating and shock-absorbing properties of sodium hyaluronate reduce pain and improve joint mobility when administered intra-articularly.\u003c\/p\u003e\n\u003cp\u003eThis effect can last for 6 months after a treatment cycle of 1-3 intra-articular injections.\u003c\/p\u003e\n\u003cp\u003eViscosupplementation with hyaluronic acid is an effective and well-tolerated therapy for knee osteoarthritis. Viscosupplementation is also a well-tolerated therapy for osteoarthritis of other joints, but a consensus on the effectiveness of viscosupplementation with hyaluronic acid for other joint osteoarthritis has not yet been reached worldwide.\u003c\/p\u003e\n\u003cp\u003eCOMPOSITION:\u003c\/p\u003e\n\u003cp\u003eEach milliliter of Hialurom contains 15 mg sodium hyaluronate, 9 mg sodium chloride, and water for injection. Each syringe contains 2 ml of sterile, viscoelastic solution of 30 mg sodium hyaluronate. Hialurom is available in a carton box with the following contents:\u003c\/p\u003e\n\u003cp\u003e- one blister with a disposable prefilled syringe and instructions for use,\u003c\/p\u003e\n\u003cp\u003e- three blisters with disposable prefilled syringes and instructions for use.\u003c\/p\u003e\n\u003cp\u003eSTORAGE:\u003c\/p\u003e\n\u003cp\u003eThe product should be stored in its original packaging. The storage temperature should not exceed 25°C. Do not freeze.\u003c\/p\u003e\n\u003cp\u003eInformation status: February 2019\u003c\/p\u003e","brand":"actrevo GmbH","offers":[{"title":"Default Title","offer_id":47355879489876,"sku":"113","price":29.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hialurom-forte-actrevo-gmbh-gelenkspritzen-stakonmed-243872.jpg?v=1772214439"},{"product_id":"hialurom-hondro-1-x-3-ml","title":"Hialurom Hondro 1x 3.0 ml","description":"\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/hialurom\" title=\"Hialurom | Joint injections | StakonMed\"\u003eHIALUROM\u003c\/a\u003e HONDRO\u003c\/p\u003e\n\u003cp\u003eSodium hyaluronate 60 mg\/3 ml and chondroitin sodium sulfate 90 mg\/3 ml, solution for injection in a prefilled syringe.\u003c\/p\u003e\n\u003cp\u003eFor intra-articular injection\u003c\/p\u003e\n\u003cp\u003eDESCRIPTION:\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro is a sterile, viscoelastic solution containing two highly purified cross-linked biological polymers, sodium hyaluronate and chondroitin sodium sulfate. Hialurom Hondro consists of sodium hyaluronate derived from bacterial fermentation of a Streptococcus strain and chondroitin sodium sulfate derived from bovine cartilage.\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro is a sterile, viscoelastic solution obtained using aseptic processing techniques and supplied in a single-use glass syringe containing 3 ml of solution.\u003c\/p\u003e\n\u003cp\u003eCOMPOSITION:\u003c\/p\u003e\n\u003cp\u003eEach prefilled syringe contains 60 mg sodium hyaluronate, 90 mg chondroitin sodium sulfate, sodium chloride, sodium dihydrogen phosphate monohydrate, disodium phosphate dodecahydrate, sodium hydroxide and\/or hydrochloric acid (for pH adjustment), and water for injection.\u003c\/p\u003e\n\u003cp\u003eINDICATIONS:\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro is indicated as a viscoelastic supplement or replacement for synovial fluid in the human knee joint.\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro is indicated for the symptomatic treatment of mild to severe knee osteoarthritis. Hialurom Hondro acts as a lubricant and mechanical support.\u003c\/p\u003e\n\u003cp\u003eCONTRAINDICATIONS:\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro must not be used in:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eknown allergies (hypersensitivity) to\u003cbr\u003esodium hyaluronate, chondroitin sulfate, or any other component of Hialurom\u003c\/li\u003e\n\u003cli\u003eHondro,\u003c\/li\u003e\n\u003cli\u003epre-existing skin infections at the injection site,\u003c\/li\u003e\n\u003cli\u003eknown infection in the index finger joint,\u003c\/li\u003e\n\u003cli\u003eknown systemic bleeding disorders, bleeding, or tendency to bleed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eHialurom Hondro may contain traces of proteins from gram-positive bacteria and is contraindicated for patients with known allergies of this type.\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro should not be used in patients with known hypersensitivity to bovine materials.\u003c\/p\u003e\n\u003cp\u003ePOSSIBLE SIDE EFFECTS:\u003c\/p\u003e\n\u003cp\u003eAfter intra-articular injection of Hialurom Hondro, swelling and temporary pain may occur. These reactions generally subside within 72 hours.\u003c\/p\u003e\n\u003cp\u003eReported product-related side effects\u003c\/p\u003e\n\u003cp\u003eThe most frequently reported side effects after marketing related to the use of Hialurom Hondro were\u003c\/p\u003e\n\u003cp\u003eJoint pain, joint stiffness, joint effusion, joint swelling, joint warming, and gait disturbance.\u003c\/p\u003e\n\u003cp\u003eCases of fever and malaise have also been reported. These side effects improved within a few days after treatment, such as applying ice to the injection site, treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), or antipyretics.\u003c\/p\u003e\n\u003cp\u003eDOSAGE AND METHOD OF ADMINISTRATION:\u003c\/p\u003e\n\u003cp\u003eNot for intravenous injection.\u003c\/p\u003e\n\u003cp\u003eThis product is for intra-articular use only. It must not be injected extra-articularly.\u003c\/p\u003e\n\u003cp\u003eStrict aseptic administration techniques must be followed.\u003c\/p\u003e\n\u003cp\u003eThe injection site must be properly disinfected (70% alcohol or another disinfectant).\u003c\/p\u003e\n\u003cp\u003eDisinfectants containing quaternary ammonium salts should not be used for skin disinfection, as this may cause a reaction with the hyaluronic acid.\u003c\/p\u003e\n\u003cp\u003eIf present, remove joint effusions before injecting Hialurom Hondro. Joint puncture (arthrocentesis) before injection is recommended. Remove the prefilled syringe from the packaging. Break the visible seal before administration and remove the cap from the prefilled syringe. Attach the hypodermic needle of an appropriate gauge and length and ensure it is properly secured by gently twisting. Common needle sizes for knee injections range between 18 and 21 G (1.2–0.8 mm).\u003c\/p\u003e\n\u003cp\u003eThe final choice of needle for each intra-articular treatment is made by the physician.\u003c\/p\u003e\n\u003cp\u003eInjection of subcutaneous lidocaine or another anesthetic before the injection with Hialurom Hondro may be advisable.\u003c\/p\u003e\n\u003cp\u003eAs with any invasive joint procedure, it is recommended that the patient avoid any strenuous activity and prolonged (e.g., over one hour) physical exertion, such as tennis or jogging, for 48 hours after the injection.\u003c\/p\u003e\n\u003cp\u003ePRECAUTIONS FOR USE:\u003c\/p\u003e\n\u003cp\u003eAlthough sodium hyaluronate and chondroitin sodium sulfate are highly purified biological polymers, the physician must be aware of the risks of allergies inherently associated with the use of biological materials.\u003c\/p\u003e\n\u003cp\u003eGeneral precautions for intra-articular injections must be observed.\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro may only be injected by medical professionals trained in intra-articular administration techniques.\u003c\/p\u003e\n\u003cp\u003eIf the pain increases during the injection, the injection must be stopped and the needle withdrawn.\u003c\/p\u003e\n\u003cp\u003ePatients must be carefully examined for signs of acute inflammation before injection, and the doctor must decide whether treatment with Hialurom Hondro should be started in such cases.\u003c\/p\u003e\n\u003cp\u003ePatients who experience abnormal subsequent complications after administration of Hialurom Hondro must immediately consult a doctor.\u003c\/p\u003e\n\u003cp\u003eThe safety and effectiveness of Hialurom Hondro have not been established in children and adolescents, as well as in pregnant and breastfeeding women.\u003c\/p\u003e\n\u003cp\u003eSince there is no clinical evidence for the use of sodium hyaluronate and chondroitin sodium sulfate in patients with concomitant inflammatory arthropathy (such as rheumatoid arthritis, gouty arthritis), recent orthopedic surgery, or trauma to the index finger joint, treatment with Hialurom Hondro is not recommended for these patients.\u003c\/p\u003e\n\u003cp\u003eThere have been some case reports of increased INR (International Normalized Ratio) in patients who simultaneously received warfarin and dietary supplements containing glucosamine and chondroitin. Due to limited information, caution is advised when treating patients with Hialurom Hondro who are also taking anticoagulants or platelet aggregation inhibitors.\u003c\/p\u003e\n\u003cp\u003eWARNINGS:\u003c\/p\u003e\n\u003cp\u003eCheck the expiration date and the condition of the packaging before use.\u003c\/p\u003e\n\u003cp\u003eDo not use Hialurom Hondro after the expiration date printed on the packaging.\u003c\/p\u003e\n\u003cp\u003eDo not use the syringe if the seal is opened or damaged.\u003c\/p\u003e\n\u003cp\u003eUse the product only if the solution is clear.\u003c\/p\u003e\n\u003cp\u003eAfter opening, the contents of the syringe must be used immediately.\u003c\/p\u003e\n\u003cp\u003eThe product Hialurom Hondro is intended for single use only! Do not reuse. Each prefilled syringe of Hialurom Hondro is intended for a single application in one patient only.\u003c\/p\u003e\n\u003cp\u003eUsed needles and syringes must be disposed of after injection and must not be kept for other injections. Reusing already used needles and syringes can lead to the transmission of infectious agents (including HIV and hepatitis).\u003c\/p\u003e\n\u003cp\u003eDo not re-sterilize as this may damage or alter the product.\u003c\/p\u003e\n\u003cp\u003eFEATURES AND MODE OF ACTION:\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro is a product for viscosupplementation, which is a safe, effective, and well-established treatment for osteoarthritis, where a solution based on hyaluronic acid is injected into the affected synovial joint.\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro acts as a temporary supplement and replacement for synovial fluid.\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro relieves joint pain, improves joint mobility, and protects cartilage.\u003c\/p\u003e\n\u003cp\u003eHyaluronic acid is a main component of synovial fluid and cartilage and is responsible for lubrication and cushioning of the joints thanks to its viscoelastic and rheological properties. It reduces friction between joint surfaces and protects soft tissue from injury by acting as a shock absorber.\u003c\/p\u003e\n\u003cp\u003eThe amount and quality of hyaluronic acid in synovial fluid is reduced in patients with osteoarthritis because its synthesis by joint and cartilage cells is impaired. Therefore, the protection of joint surfaces is greatly reduced, cartilage becomes vulnerable due to friction and pressure, and is subject to structural degradation.\u003c\/p\u003e\n\u003cp\u003eChondroitin sulfate, a sulfated glycosaminoglycan, is an important structural component of the extracellular cartilage matrix. Due to specific interactions, chondroitin sulfate optimizes the flow properties of hyaluronic acid.\u003c\/p\u003e\n\u003cp\u003eFurthermore, in vitro studies have shown that chondroitin sulfate inhibits enzymes mainly involved in the destruction of the cartilage matrix: metalloproteinases and aggrecanases. Chondroitin sulfate also inhibits the secretion of pro-inflammatory factors.\u003c\/p\u003e\n\u003cp\u003eThese data support the observed clinical\u003c\/p\u003e\n\u003cp\u003eActivity of chondroitin sulfate as a symptomatic, slow-acting substance in osteoarthritis with pain relief and reinforcement function.\u003c\/p\u003e\n\u003cp\u003eA single injection of Hialurom Hondro restores joint protection through good lubrication and shock absorption and leads to a significant improvement in symptoms.\u003c\/p\u003e\n\u003cp\u003eViscosupplementation with hyaluronic acid is an effective and well-tolerated therapy for knee osteoarthritis.\u003c\/p\u003e\n\u003cp\u003eViscosupplementation is also a well-tolerated therapy for osteoarthritis of other joints, but a global consensus on the effectiveness of viscosupplementation with hyaluronic acid for other joint osteoarthritis has not yet been reached.\u003c\/p\u003e\n\u003cp\u003eCOMPOSITION:\u003c\/p\u003e\n\u003cp\u003eEach Hialurom Hondro prefilled syringe contains 3 ml of sterile, viscoelastic solution of sodium hyaluronate (60 mg) and chondroitin sodium sulfate (90 mg).\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro is available in a secondary packaging containing: one blister with a single-use prefilled syringe and instructions for use.\u003c\/p\u003e\n\u003cp\u003eHialurom Hondro is a medical device. It may only be used under the supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003eSHELF LIFE AND STORAGE:\u003c\/p\u003e\n\u003cp\u003eThe product should be stored in its original packaging. The storage temperature should not exceed 25°C. Do not freeze.\u003c\/p\u003e\n\u003cp\u003eInformation status: February 2019\u003c\/p\u003e","brand":"actrevo GmbH","offers":[{"title":"Default Title","offer_id":47355879522644,"sku":"114","price":121.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hialurom-hondro-actrevo-gmbh-gelenkspritzen-stakonmed-981485.jpg?v=1772214526"},{"product_id":"hialurom-tendon-1-x-2-ml","title":"Hialurom Tendon 1x 2.0 ml","description":"\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/hialurom\" title=\"Hialurom | Joint injections | StakonMed\"\u003eHIALUROM\u003c\/a\u003e Tendon\u003c\/p\u003e\n\u003cp\u003eSodium hyaluronate 40 mg\/2 ml, sterile solution for injection in a prefilled syringe\u003c\/p\u003e\n\u003cp\u003eFor peritendinous injection or injection into the tendon sheath.\u003c\/p\u003e\n\u003cp\u003eHialurom Tendon is a viscoelastic, isotonic solution containing 40 mg\/2 ml sodium hyaluronate in a physiological buffer solution. It also contains sodium chloride and mannitol (pH 7-8). Sodium hyaluronate is obtained by bacterial fermentation of a Streptococcus strain and subsequently purified.\u003c\/p\u003e\n\u003cp\u003eSterile by moist heat.\u003c\/p\u003e\n\u003cp\u003eIndications:\u003c\/p\u003e\n\u003cp\u003eFor pain relief and limited mobility in tendon disorders.\u003c\/p\u003e\n\u003cp\u003eContraindications:\u003c\/p\u003e\n\u003cp\u003eHialurom Tendon must not be used in:\u003c\/p\u003e\n\u003cp\u003e- known hypersensitivity to any of the components of Hialurom Tendon, known allergies (hypersensitivity) to proteins from gram-positive bacteria, existing infections at the injection site if other medications have already been injected at or around the injection site.\u003c\/p\u003e\n\u003cp\u003ePossible side effects:\u003c\/p\u003e\n\u003cp\u003eLocal side effects such as pain, warmth, bruising, redness, and swelling may occur after treatment with Hialurom Tendon.\u003c\/p\u003e\n\u003cp\u003eDosage and method of application:\u003c\/p\u003e\n\u003cp\u003eHialurom Tendon should only be administered by medical professionals trained in the specific injection techniques of peritendinous injection or injection into the tendon sheath.\u003c\/p\u003e\n\u003cp\u003eInjection into the tendon sheath:\u003c\/p\u003e\n\u003cp\u003eFor tendons with a tendon sheath, Hialurom Tendon is injected directly into the tendon sheath in the affected area.\u003c\/p\u003e\n\u003cp\u003ePeritendinous injection:\u003c\/p\u003e\n\u003cp\u003eFor tendons without a tendon sheath, the product is applied along the affected tendon but not into the tendon itself.\u003c\/p\u003e\n\u003cp\u003eInject Hialurom Tendon a total of 2 times at weekly intervals around the affected tendon or into the affected tendon sheath. Multiple tendons can be treated simultaneously. Repeat treatments are possible if needed.\u003c\/p\u003e\n\u003cp\u003eThe contents of the Hialurom Tendon prefilled syringe are sterile.\u003c\/p\u003e\n\u003cp\u003eThe prefilled syringe is taken out of the sterile packaging, the cap is removed, a suitable needle (e.g., 25 to 27G) is attached and secured with a slight twist.\u003c\/p\u003e\n\u003cp\u003eNeedle selection is the responsibility of the physician. Various factors influence the choice of the correct needle length and thickness, such as the anatomy of the treatment site, the distance of the tendon to be treated from the skin, and patient-specific factors like weight and age. Ultrasound monitoring of the treatment is recommended.\u003c\/p\u003e\n\u003cp\u003eRemove any air bubbles before use.\u003c\/p\u003e\n\u003cp\u003eInteractions:\u003c\/p\u003e\n\u003cp\u003eNo information is currently available on interactions of Hialurom Tendon with other drugs.\u003c\/p\u003e\n\u003cp\u003ePrecautions:\u003c\/p\u003e\n\u003cp\u003eCaution in patients with known hypersensitivity to medications.\u003c\/p\u003e\n\u003cp\u003eGeneral precautions for peritendinous injections or injections into the tendon sheath must be observed.\u003c\/p\u003e\n\u003cp\u003eHialurom Tendon must be correctly injected into the tendon sheath or correctly applied around the affected tendon, if necessary under ultrasound guidance.\u003c\/p\u003e\n\u003cp\u003eAvoid nerve injuries and injections into blood vessels.\u003c\/p\u003e\n\u003cp\u003eThe product should not be used in patients with known systemic bleeding disorders or a history of vasovagal reactions or syncope.\u003c\/p\u003e\n\u003cp\u003eThere is insufficient data to recommend the use of sodium hyaluronate in children, adolescents, pregnant or breastfeeding women. Treatment with Hialurom Tendon is not recommended in these cases.\u003c\/p\u003e\n\u003cp\u003ePatients who develop complications in the days following the injection must see a doctor immediately.\u003c\/p\u003e\n\u003cp\u003eWarnings:\u003c\/p\u003e\n\u003cp\u003eSingle-use product! The product Hialurom Tendon 40 mg\/2 ml is intended for single use for one patient only.\u003c\/p\u003e\n\u003cp\u003eDo not use the prefilled syringe if the seal or blister is damaged. Solution not used immediately after opening must be discarded and must not be used otherwise. After the first injection, the sterility of the solution can no longer be guaranteed.\u003c\/p\u003e\n\u003cp\u003eUsed needles and syringes must be disposed of after each injection and must not be kept for other administrations.\u003c\/p\u003e\n\u003cp\u003eDo not reuse! Reusing used needles and syringes can lead to the transmission of infectious agents (including HIV and hepatitis).\u003c\/p\u003e\n\u003cp\u003eThe product must not be re-sterilized, as this can damage or alter the product.\u003c\/p\u003e\n\u003cp\u003eGeneral aseptic precautions must be observed to protect the patient from infections.\u003c\/p\u003e\n\u003cp\u003eThe injection site must be properly disinfected (70% alcohol or another disinfectant). Disinfectants containing quaternary ammonium salts should not be used for skin disinfection, as this can cause a breakdown reaction of the hyaluronic acid.\u003c\/p\u003e\n\u003cp\u003eUse the product only if the liquid is clear and shows no cloudiness or discoloration.\u003c\/p\u003e\n\u003cp\u003eKeep out of reach of children.\u003c\/p\u003e\n\u003cp\u003eHialurom Tendon is a medical device. To be used only by a doctor.\u003c\/p\u003e\n\u003cp\u003eProperties and mode of action:\u003c\/p\u003e\n\u003cp\u003eA tendon is a robust structure made of fibrous connective tissue, designed to transmit forces from muscles to bones to withstand tension during muscle contraction. Tendons can be surrounded by different structures: e.g., fibrous bands, synovial sheaths, tendon sheaths, bursae.\u003c\/p\u003e\n\u003cp\u003eOveruse or incorrect loading can cause inflammation and\/or degenerative changes of the tendon, leading to pain and loss of function. Lubricating the tendon could reduce pain, improve tendon function, and decrease the possibility of adhesions.\u003c\/p\u003e\n\u003cp\u003eDue to its lubricating and viscoelastic properties, Hialurom Tendon supports the gliding ability of tendons as well as the physiological regeneration process. Additionally, Hialurom Tendon reduces the free passage of inflammation-promoting cells and molecules through the tendon sheath due to its macromolecular structure.\u003c\/p\u003e\n\u003cp\u003eHialurom Tendon is a clear solution of natural, highly pure sodium hyaluronate, obtained by fermentation and therefore free of animal proteins.\u003c\/p\u003e\n\u003cp\u003eHialurom Tendon is also stabilized by the addition of mannitol, a radical scavenger. In biocompatibility studies, Hialurom Tendon has proven to be particularly well tolerated.\u003c\/p\u003e\n\u003cp\u003ePackage of pitze Hialurom Tendon with 40 mg\/2 ml in sterile packaging.\u003c\/p\u003e\n\u003cp\u003eStorage:\u003c\/p\u003e\n\u003cp\u003eDo not store in the refrigerator. The product should be stored in its original packaging. Storage temperature should not exceed 25°C.\u003c\/p\u003e\n\u003cp\u003eInformation status: June 2016\u003c\/p\u003e","brand":"actrevo GmbH","offers":[{"title":"Default Title","offer_id":47355879555412,"sku":"115","price":52.89,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hialurom-tendon-actrevo-gmbh-gelenkspritzen-stakonmed-867519.jpg?v=1772214491"},{"product_id":"hya-ject-mini-1-x-1-ml","title":"Hya Ject mini 1x 1.0 ml","description":"\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eINFORMATION FOR USE \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/hya-ject\" title=\"Hya-Ject | Joint Injections | StakonMed\"\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate from fermentation 1.0%. Viscoelastic solution for injection into small joints. Sterile by moist heat.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComposition:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 ml isotonic solution contains 10.0 mg sodium hyaluronate as well as sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, and water for injection purposes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePain and restricted mobility in degenerative and traumatic changes of small synovial joints, such as the facet joints of the lumbar spine, the thumb saddle joint, the interphalangeal joints of fingers and toes, the big toe metatarsophalangeal joint, and the temporomandibular joint. For the treatment of large joints such as knee, hip, or shoulder joints, HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003epre-filled syringes with 20 mg\/2.0 ml should be used.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDo not use HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI in case of known hypersensitivity to any of the ingredients.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNo incompatibility (intolerance) of HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI with other intra-articularly applicable solutions has been reported so far. Concurrent use of orally administered analgesic and anti-inflammatory drugs during the first treatment days may be helpful for the patient.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSide effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDuring or after injection of HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI, very rare local and general accompanying symptoms such as pain, sensation of heat, redness, swelling\/joint effusion, and palpitations may occur.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage instructions and method of administration:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInject HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI a total of 1–3 times at weekly intervals into the affected joint. Multiple joints can be treated simultaneously. Depending on the severity of the joint disease, the effect of one treatment can last more than six months. Repeated treatment cycles are possible if needed. In case of joint effusion, puncture of the effusion, immobilization of the joint, and application of an ice pack and\/or intra-articular administration of corticosteroids are recommended. Treatment with HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI is started two to three days later. As long as the sterile packaging is unopened, the content and surface of the pre-filled syringe remain sterile. Remove the pre-filled syringe from the sterile packaging, unscrew the cap from the Luer-Lock connection, attach a suitable cannula (e.g., 19 to 25 G), and lock it with a slight twist. Before injection, remove any air bubble present in the syringe.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUse caution when applying HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI in patients with known hypersensitivity to drugs. As with all invasive joint treatments, infection can occur in very rare cases. Therefore, general precautions for intra-articular injections should be observed, including measures to prevent joint infection. HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI should be correctly injected into the joint space, if necessary under fluoroscopic control. Avoid injections into blood vessels and surrounding tissue! Since there is insufficient experience with the use of hyaluronic acid in children, pregnant and breastfeeding women, or patients with inflammatory joint diseases such as rheumatoid arthritis and ankylosing spondylitis, the use of HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI is not recommended in these cases. Do not use if the pre-filled syringe or sterile packaging is damaged. Any solution not used immediately after opening must be discarded. Otherwise, sterility is no longer guaranteed, which can lead to an infection risk. Store between 2 °C and 25 °C! Observe expiration date. Keep out of reach of children!\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 2\" class=\"page\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eJoint lubricant, which behaves viscoelastically due to its hyaluronic acid content, is present in all synovial joints, where it ensures normal, pain-free movement due to its lubricating and shock-absorbing properties. It is also responsible for supplying nutrients to the joint cartilage. In degenerative joint diseases, \u003c\/span\u003e\u003cspan\u003esuch as osteoarthritis, the viscoelasticity of the joint lubricant is significantly impaired, reducing its lubricating and shock-absorbing effect. This increases the mechanical load on the joint and the breakdown of joint cartilage to such an extent that pain and restricted mobility occur in the affected joint. A qualitative improvement of the joint lubricant by intra-articular administration of highly pure hyaluronic acid can improve the viscoelastic properties of the joint lubricant. This enhances its lubricating and shock-absorbing effect and reduces mechanical overload of the joint. The result is usually a reduction in pain and an improvement in joint mobility, which can last several months after one treatment cycle.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI is a clear solution of natural, highly pure sodium hyaluronate obtained by fermentation and therefore free of animal proteins. In biocompatibility studies, HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI has proven to be particularly well tolerated.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePackage size:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOne pre-filled syringe HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI with 10 mg\/1.0 ml in sterile packaging.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eFor use by a physician only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInformation status: 2017-07\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ORMED GmbH","offers":[{"title":"Default Title","offer_id":47355879588180,"sku":"116","price":16.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hya-ject-mini-ormed-gmbh-gelenkspritzen-stakonmed-907088.jpg?v=1772214557"},{"product_id":"hya-ject-1-x-2-ml","title":"Hya Ject 1x 2.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/hya-ject\" title=\"Hya-Ject  | Joint Injections | StakonMed\"\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e®\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate 1.0%. Viscous-elastic solution for injection into the joint space to improve mobility and relieve pain in osteoarthritis. Transparent solution made from natural, highly purified sodium hyaluronate obtained by fermentation. Free of animal proteins. Sterilized with moist heat. The contents and the outer surface of the HYA-JECT\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e prefilled syringe are sterile as long as the sterile barrier is intact. For single use only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComposition:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 ml isotonic solution (pH 7) contains 10.0 mg sodium hyaluronate, sodium chloride, disodium phosphate, sodium dihydrogen phosphate, and water for injection purposes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePain and restricted mobility of the knee and other large synovial joints such as hip and shoulder.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003emust not be administered to patients with known hypersensitivity to any of the components of the product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTreatment with HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eis not recommended for children, pregnant or breastfeeding women, or in inflammatory joint diseases such as rheumatoid arthritis or ankylosing spondylitis. If a joint effusion is present, it should be reduced first. National guidelines for intra-articular injections must be followed, including thorough disinfection of the injection site and other measures to prevent joint infections. HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eshould be injected precisely into the joint space, if necessary under imaging guidance. Avoid injections into blood vessels or surrounding tissue. Do not use if the prefilled syringe or sterile packaging is damaged. Any solution not used immediately after opening must be discarded. Otherwise, sterility cannot be guaranteed, which may pose an infection risk. Do not re-sterilize as this may damage the product. There is currently no information on impairment of diagnostic procedures such as magnetic resonance imaging, clinical assessments, or therapeutic treatments by HYA-JECT\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThere is currently no information on incompatibility of HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ewith other medical devices and drugs for intra-articular use or with oral analgesics or anti-inflammatory drugs.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSide effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn very rare cases (less than 1 in 10,000 patients), local reactions such as pain, warmth, redness, swelling\/joint effusion, itching, and other local intolerance reactions may occur during or after injection of HYA-JECT\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e. As with all invasive joint treatments, infection may occur in very rare cases. It cannot be completely excluded that in very rare cases the intra-articular injection itself causes systemic side effects such as tachycardia, hypotension, hypertension, palpitations, nausea, and shortness of breath. These reactions may occur independently of the solution administered. Patients should be informed about contraindications and side effects before injection of HYA-JECT\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eReporting of side effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAny serious incident related to the medical device must be reported to the manufacturer TRB CHEMEDICA AG and the responsible local authority of the user.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage and administration:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInject HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003e3–5 times at weekly intervals into the affected joint. Multiple joints can be treated simultaneously. Depending on the severity of the joint disease, the positive effect of a treatment cycle of five intra-articular injections can last at least six months. Sodium hyaluronate itself is broken down within a few days. If necessary, the treatment cycle can be repeated. Remove the prefilled syringe from the sterile packaging, remove the Luer Lock cap from the syringe, attach a suitable needle with Luer connection (e.g., 18 to 25 G) and lock it by slight rotation. Remove any air bubbles from the syringe before injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"page\" title=\"Page 2\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDisposal:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDispose of the syringe immediately after use in an appropriate safety container. Do not throw the HYA-JECT\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e prefilled syringe into household waste. Follow local regulations for proper disposal of the safety container.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynovial fluid, which behaves viscoelastically due to the presence of hyaluronic acid, is found in all synovial joints, where it ensures normal, pain-free movement because of its lubricating and cushioning properties. In degenerative joint diseases such as osteoarthritis, the viscoelasticity of synovial fluid is significantly reduced, impairing its lubricating and cushioning properties. This increases mechanical stress on the joint and cartilage destruction, ultimately leading to pain and restricted mobility of the affected joint. Supplementing this synovial fluid by intra-articular injections with highly purified hyaluronic acid can improve the viscoelastic properties of the synovial fluid. Lubricating and cushioning properties are enhanced, and mechanical overload of the joint is reduced. Clinical studies have shown pain relief and improved joint mobility for up to six months.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStorage:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore in a dry, light-protected place at 2°C to 25°C! Do not use after the expiration date indicated on the packaging. Keep out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1, 3, 5 prefilled syringes of 20 mg\/2.0 ml, each syringe individually sterile packed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs long as the EUDAMED database is not fully operational, the report on safety and clinical performance (SSCP) is available to the public on the company website www.trbchemedica.de.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eis a medical device. It may only be used by a physician experienced and trained in intra-articular injections.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDate of last revision: 2022-05\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ORMED GmbH","offers":[{"title":"Default Title","offer_id":47355879620948,"sku":"117","price":19.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hya-ject-ormed-gmbh-gelenkspritzen-stakonmed-740229.jpg?v=1772214594"},{"product_id":"hya-ject-plus-1-x-2-ml","title":"Hya Ject Plus 1x 2.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/hya-ject\" title=\"Hya-Ject | Joint Injections | StakonMed\"\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate 2.0%. Viscous-elastic solution for injection into the joint space to improve mobility and for \u003c\/span\u003e\u003cspan\u003epain relief in osteoarthritis. Transparent solution made from natural, highly purified, fermentation-derived \u003c\/span\u003e\u003cspan\u003esodium hyaluronate. Free from animal proteins. Sterilized with moist heat. The contents and the outer surface of the HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS prefilled syringe are sterile as long as the sterile barrier is intact. For single use only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComposition:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 ml isotonic solution (pH 7) contains 20.0 mg sodium hyaluronate, sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol, and water for injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePain and restricted mobility of the knee and other large synovial joints such as hip and shoulder.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS must not be administered to patients with known hypersensitivity to any of the components of the product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTreatment with HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS is not recommended for children, pregnant or breastfeeding women, or in inflammatory joint diseases such as rheumatoid arthritis or ankylosing spondylitis. If a joint effusion is present, it should be reduced first. National guidelines for intra-articular injections must be observed, including thorough disinfection of the injection site and other measures to prevent joint infections. HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS should be injected precisely into the joint space, if necessary under imaging guidance. Avoid injections into blood vessels or surrounding tissue. Do not use if the prefilled syringe or sterile packaging is damaged. Any solution not used immediately after opening must be discarded. Otherwise, sterility cannot be guaranteed, which may pose an infection risk. Do not re-sterilize as this may damage the product. There is currently no information on interference with diagnostic procedures such as magnetic resonance imaging, clinical assessments, or therapeutic treatments by HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThere is currently no information on incompatibility of HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS with other medical devices and drugs for intra-articular use or with oral analgesics or anti-inflammatory drugs.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSide effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn very rare cases (less than 1 in 10,000 patients), local side effects such as pain, warmth, redness, swelling\/joint effusion, itching, and other local intolerance reactions may occur during or after injection of HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS. As with all invasive joint treatments, infection may occur in very rare cases. It cannot be completely excluded that in very rare cases the intra-articular injection itself causes systemic side effects such as tachycardia, hypotension, hypertension, palpitations, nausea, and shortness of breath. These reactions may occur independently of the applied solution. Patients should be informed about contraindications and side effects before injection of HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eReporting side effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAny serious incident related to the medical device must be reported to the manufacturer TRB CHEMEDICA AG and the responsible local authority of the user.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage and administration:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInject HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS a total of 1–3 times at weekly intervals into the affected joint. Multiple joints can be treated simultaneously. Depending on the severity of the joint disease, the positive effect can last at least six months. Sodium hyaluronate itself is broken down within a few days. If necessary, the treatment cycle can be repeated. Remove the prefilled syringe from the sterile packaging, remove the Luer Lock cap from the syringe, attach a suitable needle with Luer connection (e.g., 18 to 25 G) and lock it by slight rotation. Remove any air bubbles from the syringe before injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 2\" class=\"page\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDisposal:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDispose of the syringe immediately after use in an appropriate safety container. Do not throw the HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS prefilled syringe into household waste. Follow local regulations for proper disposal of the safety container.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynovial fluid, which behaves viscoelastically due to the presence of hyaluronic acid, is found in all synovial joints, where it ensures normal, pain-free movement because of its lubricating and cushioning properties. In degenerative joint diseases such as osteoarthritis, the viscoelasticity of synovial fluid is significantly reduced, impairing its lubricating and cushioning properties. This increases mechanical stress on the joint and cartilage destruction, ultimately leading to pain and restricted mobility of the affected joint. Supplementing this synovial fluid by intra-articular injections with highly purified hyaluronic acid can improve the viscoelastic properties of the synovial fluid. Lubricating and cushioning properties are enhanced, and mechanical overload of the joint is reduced. Clinical studies have shown pain relief and improved joint mobility for up to six months.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS additionally contains mannitol, a radical scavenger that helps stabilize the sodium hyaluronate chains.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStorage:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore in a dry, light-protected place at 2°C to 25°C! Do not use after the expiration date indicated on the packaging. Keep out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 prefilled syringe containing 40 mg\/2.0 ml, HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS in sterile packaging.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs long as the EUDAMED database is not fully operational, the Safety and Clinical Performance Report (SSCP) is available to the public on the company website www.trbchemedica.de.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS is a medical device. It may only be used by a physician experienced and trained in intra-articular injections.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDate of last revision: 2022-05\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"page\" title=\"Page 2\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDisposal:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDispose of the syringe immediately after use in an appropriate safety container. Do not throw the HYA-JECT\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e prefilled syringe into household waste. Follow local regulations for proper disposal of the safety container.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynovial fluid, which behaves viscoelastically due to the presence of hyaluronic acid, is found in all synovial joints, where it ensures normal, pain-free movement because of its lubricating and cushioning properties. In degenerative joint diseases such as osteoarthritis, the viscoelasticity of synovial fluid is significantly reduced, impairing its lubricating and cushioning properties. This increases mechanical stress on the joint and cartilage destruction, ultimately leading to pain and restricted mobility of the affected joint. Supplementing this synovial fluid by intra-articular injections with highly purified hyaluronic acid can improve the viscoelastic properties of the synovial fluid. Lubricating and cushioning properties are enhanced, and mechanical overload of the joint is reduced. Clinical studies have shown pain relief and improved joint mobility for up to six months.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStorage:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore in a dry, light-protected place at 2°C to 25°C! Do not use after the expiration date indicated on the packaging. Keep out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1, 3, 5 prefilled syringes containing 20 mg\/2.0 ml each, each syringe individually sterile packed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs long as the EUDAMED database is not fully operational, the Safety and Clinical Performance Report (SSCP) is available to the public on the company website www.trbchemedica.de.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eis a medical device. It may only be used by a physician experienced and trained in intra-articular injections.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDate of last revision: 2022-05\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ORMED GmbH","offers":[{"title":"Default Title","offer_id":47355879653716,"sku":"118","price":57.85,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hya-ject-plus-ormed-gmbh-gelenkspritzen-stakonmed-716557.jpg?v=1772214625"},{"product_id":"hya-ject-tendon-1-x-2-ml","title":"Hya Ject Tendon 1x 2.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eINSTRUCTIONS FOR USE\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/hya-ject\" title=\"Hya-Ject | Gelenkspritzen | StakonMed\"\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate from fermentation 2.0%. Viscoelastic solution for injection into the tendon or tendon sheath. Sterile by moist heat.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComposition:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 ml isotonic solution contains 20.0 mg sodium hyaluronate as well as sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, mannitol, and water for injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor the treatment of pain and restricted mobility in tendon disorders.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eDo not use TENDON if there is a known hypersensitivity to any of the ingredients.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAn incompatibility (intolerance) of HYA­JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON incompatibility with other agents used on the tendon has not been reported so far.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSide effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAfter using HYA­JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON local side effects such as pain, warmth, bruising, redness, and swelling may occur at the treated tendon.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage instructions and method of application:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON inject a total of 2 times at weekly intervals around the diseased tendon or into the diseased \u003c\/span\u003e\u003cspan\u003eInject into the tendon sheath. Several tendons can be treated simultaneously. Repeat treatments are possible if needed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs long as the sterile packaging is not opened, the contents and surface of the HYA­JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON prefilled syringe sterile. The prefilled syringe is taken from the sterile packaging, the cap is removed from the Luer-Lock connection, a suitable cannula (e.g., 25 to 27 G) is attached and locked by a slight twist. Before injection, any air bubble present is removed from the syringe.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCaution when using HYA­JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON in patients with known hypersensitivity to drugs. As with all invasive treatments, infection can occur in very rare cases. Therefore, general precautions for peritendinous injections or injections into the tendon sheath should be observed. HYA­JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON must be correctly injected into the tendon sheath or correctly injected around the affected tendon, if necessary under fluoroscopic control. Avoid nerve injuries and injections into blood vessels! Since there is insufficient experience \u003c\/span\u003e\u003cspan\u003efor the use of HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON in children, pregnant and breastfeeding women, as well as in acute trauma, \u003c\/span\u003e\u003cspan\u003ethe use of HYA-JECT is\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON is not recommended in these cases. Do not use if the prefilled syringe or sterile packaging is damaged. Any solution not used immediately after opening must be discarded. Otherwise, sterility can no longer be guaranteed, which may lead to an infection risk. Store between 2 °C and 25 °C! Observe expiration date! Keep out of reach of children!\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA tendon is a robust structure made of fibrous connective tissue, designed to transfer forces from muscles to bones and withstand tension during muscle contraction. Tendons can be surrounded by different structures: e.g., fibrous ligaments, synovial sheaths, tendon sheaths, bursae. Overuse or incorrect loading can cause inflammation and\/or degenerative changes in the tendon, leading to pain and loss of function. Improving tendon gliding could reduce pain, improve tendon function, and decrease the likelihood of adhesions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 2\" class=\"page\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDue to its lubricating and viscoelastic properties, HYA-JECT supports\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON improves the gliding ability of the tendons as well as the physiological regeneration process. Additionally, HYA-JECT reduces\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON, due to its macromolecular structure, allows free passage of inflammation-promoting cells and molecules through the tendon sheath.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON is a clear solution of natural, highly pure sodium hyaluronate, obtained by fermentation and therefore free of animal proteins. HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON is also stabilized by the addition of mannitol, a free radical scavenger. In biocompatibility studies, HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON has proven to be particularly well tolerated.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePackage sizes:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA prefilled syringe HYA-JECT\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eTENDON at 40 mg\/2.0 ml in sterile packaging.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eTo be used only by a doctor.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInformation status: 2017-07\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"ORMED GmbH","offers":[{"title":"Default Title","offer_id":47355879686484,"sku":"119","price":59.95,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hya-ject-tendon-ormed-gmbh-gelenkspritzen-stakonmed-495361.jpg?v=1772214649"},{"product_id":"hyalubrix-1-x-2-ml","title":"Hyalubrix 1x 2.0 ml","description":"\u003ch2\u003eSolution with the sodium salt of hyaluronic acid for intraarticular use\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePre-filled syringe\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eProduct description\u003c\/h3\u003e\n\u003cp\u003eHYALUBRIX is a sterile, viscoelastic solution containing the sodium salt of hyaluronic acid, obtained by bacterial fermentation from a high molecular weight fraction.\u003c\/p\u003e\n\n\u003cp\u003eHyaluronic acid is an endogenous polysaccharide of the glycosaminoglycan family found in cartilage and joint fluid. It is continuously released into the joint and is one of the main components of joint fluid, giving it its characteristic viscosity and elasticity. These properties are crucial for the lubricating and shock-absorbing function of the fluid in healthy joints to protect cartilage and soft tissues from mechanical injury.\u003c\/p\u003e\n\n\u003cp\u003eTraumatic and degenerative joint changes lead to a deficiency of hyaluronic acid and a loss of viscosity in the joint fluid, which in turn impairs joint function and causes painful symptoms. Numerous data in the literature show that intraarticular injection of hyaluronic acid can restore the viscoelastic properties of the joint fluid.\u003c\/p\u003e\n\n\u003cp\u003eHYALUBRIX serves as a temporary replacement of joint fluid in patients with degenerative or mechanical joint disease that causes changes in the functional properties of the joint fluid. Weekly intraarticular injections of HYALUBRIX provide pain relief and improvement of joint function for up to six months in patients with degenerative or mechanical joint changes.\u003c\/p\u003e\n\n\u003ch3\u003eComposition\u003c\/h3\u003e\n\u003cp\u003eMain ingredient: sodium salt of hyaluronic acid 1.5%\u003c\/p\u003e\n\n\u003cp\u003eOther ingredients: sodium chloride, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, water for injection.\u003c\/p\u003e\n\n\u003ch3\u003eAreas of application\u003c\/h3\u003e\n\u003cp\u003eHYALUBRIX is indicated for the treatment of pain and improvement of joint function in patients with degenerative or mechanical joint changes of the knee, hip, shoulder, ankle, and thumb saddle joint.\u003c\/p\u003e\n\n\u003cp\u003eThe product is indicated for the treatment of persistent pain after initial failure of analgesics or failure or intolerance of nonsteroidal anti-inflammatory drugs.\u003c\/p\u003e\n\n\u003ch3\u003eIntended use\u003c\/h3\u003e\n\u003cp\u003eHYALUBRIX is a temporary joint fluid substitute and must be injected intraarticularly.\u003c\/p\u003e\n\n\u003ch3\u003eDosage and method of administration\u003c\/h3\u003e\n\u003cp\u003eHYALUBRIX is intended exclusively for intra-articular injection.\u003c\/p\u003e\n\n\u003cp\u003eThe product may only be used by licensed physicians (e.g., orthopedists, rheumatologists, specialists in physical and rehabilitative medicine, radiologists, sports medicine doctors, etc.).\u003c\/p\u003e\n\n\u003cp\u003eThe injection must be strictly intra-articular. The intra-articular injection must be performed according to the usual standard technique, taking anatomical conditions into account. For the hip, shoulder, and other less accessible joints, sonographic or fluoroscopic guidance is recommended.\u003c\/p\u003e\n\n\u003cp\u003eInject HYALUBRIX into the affected joint at weekly intervals over three weeks using a suitable sterile needle (e.g., 18 or 20 G).\u003c\/p\u003e\n\n\u003cp\u003eIf necessary, treatment can be repeated. However, no systematically collected data are available for this.\u003c\/p\u003e\n\n\u003cp\u003eClinical data demonstrate the efficacy of HYALUBRIX for up to six months. If clinically necessary, treatment can be repeated from three months after the first treatment cycle.\u003c\/p\u003e\n\n\u003cp\u003eAll rules of aseptic technique and injection procedure must be observed.\u003c\/p\u003e\n\n\u003cp\u003eAny joint effusion must be removed before use.\u003c\/p\u003e\n\n\u003ch3\u003eContraindications\u003c\/h3\u003e\n\u003cp\u003eDo not administer to patients with known hypersensitivity to any of the product components.\u003c\/p\u003e\n\n\u003cp\u003eDo not administer if infections or skin diseases are present at the injection site.\u003c\/p\u003e\n\n\u003cp\u003eDo not administer to patients with active synovitis.\u003c\/p\u003e\n\n\u003ch3\u003eUse in certain patient groups\u003c\/h3\u003e\n\u003cp\u003eThe safety and efficacy of HYALUBRIX in pregnant or breastfeeding women or patients under 18 years of age have not been studied. Therefore, use in these patient groups is contraindicated.\u003c\/p\u003e\n\n\u003ch3\u003eWarnings and precautions\u003c\/h3\u003e\n\u003cp\u003eDo not use if the packaging is damaged.\u003c\/p\u003e\n\n\u003cp\u003eDo not use the product after the expiration date indicated on the packaging. The expiration date applies to the product stored in the original packaging at a temperature not exceeding 25 °C.\u003c\/p\u003e\n\n\u003cp\u003eThe syringe is intended for single use only, i.e., for one injection in one patient. Inject the syringe contents into only one joint.\u003c\/p\u003e\n\n\u003cp\u003eIn the first 24 hours after the injection, patients can carry out all daily activities. However, it is recommended not to overload the treated joint.\u003c\/p\u003e\n\n\u003cp\u003eThe prepared syringe must be disposed of immediately after each use, regardless of whether the entire solution has been administered.\u003c\/p\u003e\n\n\u003cp\u003eWhen reprocessing and\/or reusing this product, Fidia Farmaceutici can no longer guarantee the effectiveness, functionality, material structure, purity, or sterility of the product. Reuse may lead to illness, infection, and\/or serious injury to the patient or user.\u003c\/p\u003e\n\n\u003cp\u003eAfter use, dispose of the product according to national regulations.\u003c\/p\u003e\n\n\u003cp\u003eKeep out of reach of children.\u003c\/p\u003e\n\n\u003ch3\u003eSide effects\u003c\/h3\u003e\n\u003cp\u003eAt the injection site, local pain, swelling, a feeling of warmth, and redness may occasionally occur. Such symptoms are generally mild and subside. After the intra-articular injection, applying an ice pack to the treated joint for five to ten minutes may reduce the frequency of these symptoms.\u003c\/p\u003e\n\n\u003cp\u003eIn people with hypersensitivity to the product components, local or systemic allergic reactions may occur.\u003c\/p\u003e\n\n\u003cp\u003eOccasionally, stronger inflammatory reactions (sometimes with sodium pyrophosphate crystals) have been reported in connection with intra-articular injections of hyaluronate.\u003c\/p\u003e\n\n\u003cp\u003eAs with any intra-articular treatment, septic arthritis may rarely occur if general precautions for injections are not observed or if the injection site is not sterile.\u003c\/p\u003e\n\n\u003ch3\u003eInteractions\u003c\/h3\u003e\n\u003cp\u003eThe product must not be used together with disinfectants containing quaternary ammonium salts, as hyaluronic acid may precipitate in their presence.\u003c\/p\u003e\n\n\u003cp\u003eTo avoid possible interactions, the simultaneous use of HYALUBRIX with other products administered intra-articularly should be avoided.\u003c\/p\u003e\n\n\u003ch3\u003eStorage\u003c\/h3\u003e\n\u003cp\u003eStore at a temperature not exceeding 25 °C.\u003c\/p\u003e\n\n\u003ch3\u003eDosage forms\u003c\/h3\u003e\n\u003cp\u003eBox with one prefilled syringe containing a solution of 30 mg\/2 ml sodium salt of hyaluronic acid.\u003c\/p\u003e\n\n\u003cp\u003eThe heat-sterilized syringe has a protective device and is airtight packed in a blister pack.\u003c\/p\u003e\n\n\u003cp\u003eAvailable package sizes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eBox with one prefilled syringe in a blister pack\u003c\/li\u003e\n  \u003cli\u003eBox with three prefilled syringes, each in a blister pack.\u003c\/li\u003e\n  \u003cli\u003eBox with 50 prefilled syringes (for healthcare facilities only)\u003c\/li\u003e\n  \u003cli\u003eBox with 100 prefilled syringes (for healthcare facilities only)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe package does not contain needles.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturer\u003c\/h3\u003e\n\u003cp\u003eFIDIA Farmaceutici S.p.A.\u003cbr\u003e\nVia Ponte della Fabbrica 3\/A\u003cbr\u003e\n35031 Abano Terme (PD), Italy\u003c\/p\u003e\n\n\u003ch3\u003eStatus of the information in the instructions for use:\u003c\/h3\u003e\n\u003cp\u003eMarch 2021\u003c\/p\u003e","brand":"Fidia Pharma GmbH","offers":[{"title":"Default Title","offer_id":47355879719252,"sku":"120","price":21.8,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hyalubrix-1x-20-ml-fidia-pharma-gmbh-gelenkspritzen-stakonmed-2067480.jpg?v=1777230013"},{"product_id":"hymovis-2-x-3-ml","title":"Hymovis 2x 3.0 ml","description":"\u003ch2\u003eHYADD® 4 for intra-articular injection\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePre-filled syringe\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eProduct description\u003c\/h3\u003e\n\u003cp\u003eHYMOVIS is a sterile, pyrogen-free hydrogel made with Hyadd4 (highly pure, naturally derived hexadecylamine sodium hyaluronate obtained by bacterial fermentation) in an isotonic buffered solution. Thanks to the high viscosity and elasticity of hexadecylamine sodium hyaluronate, HYMOVIS improves the lubricating function and shock absorption of synovial fluid and protects joint cartilage and soft tissues from mechanical injuries. Due to these properties, combined with an extended residence time in the joint, HYMOVIS relieves pain and simultaneously improves joint function within a short treatment regimen.\u003c\/p\u003e\n\n\u003ch3\u003eComposition\u003c\/h3\u003e\n\u003cp\u003eMain ingredient: Hyadd4 (sodium hyaluronate-hexadecylamide), 24 mg\/3 ml.\u003c\/p\u003e\n\n\u003cp\u003eOther ingredients: sodium chloride, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, water for injection.\u003c\/p\u003e\n\n\u003ch3\u003eIndications\u003c\/h3\u003e\n\u003cp\u003eHYMOVIS is indicated for the treatment of pain in osteoarthritis and for the conservative treatment of meniscus injuries of the knee, as well as to improve joint mobility by increasing the viscoelasticity of the synovial fluid.\u003c\/p\u003e\n\n\u003ch3\u003eMethod of administration\u003c\/h3\u003e\n\u003cp\u003eHYMOVIS is intended for intra-articular injection only.\u003c\/p\u003e\n\n\u003cp\u003eThe product must only be administered by a physician.\u003c\/p\u003e\n\n\u003cp\u003eSince the syringe is also sterile on the outside, it may be used for intra-articular injection in the operating room.\u003c\/p\u003e\n\n\u003cp\u003eDue to its viscosity, HYMOVIS must be injected slowly into the affected joint using a suitable sterile needle (18 or 20 G).\u003c\/p\u003e\n\n\u003cp\u003eAll regulations for sterile administration must be strictly observed.\u003c\/p\u003e\n\n\u003cp\u003eJoint effusions must be removed before injecting HYMOVIS.\u003c\/p\u003e\n\n\u003ch3\u003eDosage\u003c\/h3\u003e\n\u003cp\u003eIn case of osteoarthritis, a treatment cycle consists of two injections administered one week apart.\u003c\/p\u003e\n\n\u003cp\u003eIn case of meniscus injury, a treatment cycle consists of two injections administered two weeks apart.\u003c\/p\u003e\n\n\u003ch3\u003eContraindications\u003c\/h3\u003e\n\u003cp\u003eThe product must not be administered to patients with known hypersensitivity to any of the ingredients of the medicinal product or with infections or skin diseases at the injection site.\u003c\/p\u003e\n\n\u003ch3\u003eWarnings and precautions\u003c\/h3\u003e\n\u003cp\u003eTreatment must be discontinued in case of signs of acute inflammation.\u003c\/p\u003e\n\n\u003cp\u003eThe safety and efficacy of HYMOVIS in children and pregnant women have not been established.\u003c\/p\u003e\n\n\u003cp\u003eThe safety and efficacy of using HYMOVIS simultaneously with other intra-articular treatments have not been established.\u003c\/p\u003e\n\n\u003cp\u003eThe syringe is intended for single use; its contents must be injected into only one joint.\u003c\/p\u003e\n\n\u003cp\u003eIn case of reprocessing and\/or reuse, Fidia Farmaceutici cannot guarantee the efficacy, functionality, material structure, purity, or sterility of the medicine. Reuse may lead to illness, infections, and\/or serious injury to the patient or user.\u003c\/p\u003e\n\n\u003cp\u003eHYMOVIS must not be used after the expiration date indicated on the packaging. The expiration date refers to the product properly stored in the original packaging.\u003c\/p\u003e\n\n\u003cp\u003eHYMOVIS must not be used if the packaging is opened or damaged.\u003c\/p\u003e\n\n\u003cp\u003eKeep medicines out of reach of children.\u003c\/p\u003e\n\n\u003ch3\u003eSide effects\u003c\/h3\u003e\n\u003cp\u003eLocalized side effects such as pain, swelling\/effusion, warmth, and redness may occur at the injection site. Such symptoms are usually mild and temporary.\u003c\/p\u003e\n\n\u003cp\u003eMore pronounced inflammatory reactions have been reported in connection with intraarticular injections of hyaluronate.\u003c\/p\u003e\n\n\u003cp\u003eAs with any intraarticular treatment, septic arthritis may rarely occur if general sterility precautions for the injection are not observed.\u003c\/p\u003e\n\n\u003ch3\u003eInteractions\u003c\/h3\u003e\n\u003cp\u003eThe product must not be used together with disinfectants containing quaternary ammonium salts, as sodium hyaluronate hexadecylamide may precipitate in their presence.\u003c\/p\u003e\n\n\u003cp\u003eTo avoid potential interactions, HYMOVIS should not be used simultaneously with other products administered intraarticularly.\u003c\/p\u003e\n\n\u003ch3\u003eStorage\u003c\/h3\u003e\n\u003cp\u003eStore in the original packaging. Do not store above 25 °C. Do not freeze.\u003c\/p\u003e\n\n\u003ch3\u003eType and content of the container\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003ePackage with 1 Luer Lock prefilled syringe\u003c\/li\u003e\n  \u003cli\u003ePackage with 2 Luer Lock prefilled syringes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEach syringe has a backstop and is sealed in an ethylene oxide-sterilized blister pack.\u003c\/p\u003e\n\n\u003cp\u003eEach syringe contains 3 ml of hydrogel and is steam sterilized. The instruction manual is included in every package.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturer:\u003c\/h3\u003e\n\u003cp\u003eFidia Farmaceutici S.p.A.\u003cbr\u003e\nVia Ponte della Fabbrica 3\/A\u003cbr\u003e\n35031 Abano Terme (Padua), Italy\u003c\/p\u003e\n\n\u003ch3\u003eDistribution:\u003c\/h3\u003e\n\u003cp\u003eFidia Pharma GmbH\u003cbr\u003e\nOpladener Straße 149\u003cbr\u003e\n40789 Monheim am Rhein, Germany\u003c\/p\u003e\n\n\u003cp\u003ePhone: +49 2173 8954 200\u003cbr\u003e\nFax: +49 2173 8954 100\u003cbr\u003e\nEmail: medical@fidiapharma.de\u003c\/p\u003e\n\n\u003ch3\u003eInformation status:\u003c\/h3\u003e\n\u003cp\u003eThis instruction manual was last revised in December 2015.\u003c\/p\u003e","brand":"Fidia Pharma GmbH","offers":[{"title":"Default Title","offer_id":47355879752020,"sku":"121-1","price":362.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hymovis-2x-30-ml-fidia-pharma-gmbh-stakonmed-4284658.jpg?v=1772274012"},{"product_id":"cingal-1-x-4-ml","title":"Cingal 1x 4.0 ml","description":"","brand":"Plasmaconcept AG","offers":[{"title":"Default Title","offer_id":47355879784788,"sku":"108","price":159.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/cingal-plasmaconcept-ag-gelenkspritzen-stakonmed-534019.jpg?v=1772214296"},{"product_id":"monovisc-1-x-4-ml","title":"Monovisc 1x 4.0 ml","description":"","brand":"Plasmaconcept AG","offers":[{"title":"Default Title","offer_id":47355879817556,"sku":"122","price":139.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/monovisc-plasmaconcept-ag-gelenkspritzen-stakonmed-183397.jpg?v=1772214915"},{"product_id":"orthovisc-mini-1-x-1-ml","title":"Orthovisc mini 1x 1.0 ml","description":"","brand":"Plasmaconcept AG","offers":[{"title":"Default Title","offer_id":47355879850324,"sku":"123","price":31.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/orthovisc-mini-1x-10-ml-plasmaconcept-ag-gelenkspritzen-stakonmed-6877324.jpg?v=1772274074"},{"product_id":"orthovisc-1-x-2-ml","title":"Orthovisc 1x 2.0 ml","description":"","brand":"Plasmaconcept AG","offers":[{"title":"Default Title","offer_id":47355879883092,"sku":"124","price":37.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/orthovisc-plasmaconcept-ag-gelenkspritzen-stakonmed-479783.jpg?v=1772214984"},{"product_id":"orthovisc-t-1-x-2-ml","title":"Orthovisc T 1x 2.0 ml","description":"","brand":"Plasmaconcept AG","offers":[{"title":"Default Title","offer_id":47355879915860,"sku":"125","price":49.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/orthovisc-t-1x-20-ml-plasmaconcept-ag-gelenkspritzen-stakonmed-3522519.jpg?v=1772274012"},{"product_id":"ostenil-mini-1-x-1-ml","title":"Ostenil mini 1x 1.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/ostenil\" title=\"Ostenil | Joint Injections | StakonMed\"\u003e\u003cspan\u003eOSTENIL\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate 1.0%. Viscous-elastic solution for injection into small joints to improve mobility and relieve pain in osteoarthritis. Transparent solution made from natural, highly purified sodium hyaluronate obtained by fermentation. Free from animal proteins. Sterilized with moist heat. The content and the outer surface of the OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI prefilled syringe are sterile as long as the sterile barrier is intact. For single use only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComposition:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 ml isotonic solution (pH 7) contains 10.0 mg sodium hyaluronate, sodium chloride, disodium phosphate, sodium dihydrogen phosphate, and water for injection purposes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePain and limited mobility due to degenerative and traumatic changes in small synovial joints, e.g., facet joints of the lumbar spine, thumb saddle joint, proximal joint of the big toe, and temporomandibular joint.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI must not be administered to patients with known hypersensitivity to any of the components of the product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTreatment with OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI is not recommended for children, pregnant or breastfeeding women, or patients with inflammatory joint diseases such as rheumatoid arthritis or ankylosing spondylitis. If a joint effusion is present, it should be reduced first. National guidelines for intra-articular injections must be followed, including thorough disinfection of the injection site and other measures to prevent joint infections. OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI should, if necessary under imaging guidance, be injected precisely into the joint space. Avoid injections into blood vessels or surrounding tissue. Do not use if the prefilled syringe or sterile packaging is damaged. Any solution not used immediately after opening must be discarded. Otherwise, sterility cannot be guaranteed, which may increase the risk of infection. Do not resterilize, as this may damage the product. There is currently no information on interference with diagnostic procedures such as MRI, clinical assessments, or therapeutic treatments by OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions:\u003c\/span\u003e \u003cspan\u003eThere is currently no information on incompatibility of OSTENIL® MINI with other medical devices and drugs for intra-articular use or with oral analgesics or anti-inflammatory drugs.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSide effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn very rare cases (less than 1 in 10,000 patients), local reactions such as pain, warmth, redness, swelling\/joint effusion, and tachycardia (rapid heartbeat) may occur during or after injection of OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI. As with all invasive joint treatments, infection may occur in very rare cases. Patients should be informed about contraindications and side effects before injection of OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eReporting side effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAny serious incident related to the medical device must be reported to the manufacturer TRB CHEMEDICA AG and the responsible local authority of the user.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage and administration:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInject OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI 1 to 3 times at weekly intervals into the affected joint. Multiple joints can be treated simultaneously. Depending on the severity of the joint disease, the positive effect of a treatment cycle of three intra-articular injections can last at least six months. Sodium hyaluronate itself is broken down within a few days. If necessary, the treatment cycle can be repeated. Remove the prefilled syringe from the sterile packaging, remove the Luer Lock cap from the syringe, attach a suitable needle with Luer connection (e.g., 18 to 25 G), and lock it by slight rotation. Remove any air bubbles from the syringe before injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDisposal:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDispose of the syringe immediately after use in an appropriate safety container. Do not dispose of the OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI prefilled syringe in household waste. Follow local regulations for proper disposal of the safety container.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynovial fluid, which behaves viscoelastically due to the presence of hyaluronic acid, is found in all synovial joints, where it ensures normal, pain-free movement due to its lubricating and cushioning properties. In degenerative joint diseases such as osteoarthritis, the viscoelasticity of synovial fluid is significantly reduced, impairing its lubricating and cushioning functions. This increases mechanical stress on the joint and cartilage destruction, ultimately leading to pain and restricted mobility of the affected joint. Supplementing this synovial fluid by intra-articular injections with highly purified hyaluronic acid can improve the viscoelastic properties of the synovial fluid. Lubricating and cushioning properties are enhanced, and mechanical overload of the joint is reduced. Clinical studies have shown pain relief and improved joint mobility for up to six months.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStorage:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore in a dry, light-protected place at 2°C to 25°C! Do not use after the expiration date indicated on the packaging. Keep out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 prefilled syringe containing 10 mg\/1.0 ml OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI in sterile packaging.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs long as the EUDAMED database is not fully operational, the Safety and Clinical Performance Report (SSCP) is available to the public on the company website www.trbchemedica.de.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMINI is a medical device. It may only be used by a physician experienced and trained in intra-articular injections.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDate of last revision: 2022-04\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"TRB Chemedica AG","offers":[{"title":"Default Title","offer_id":47355879948628,"sku":"126","price":19.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/ostenil-mini-1x-10-ml-mhd-30042026-trb-chemedica-ag-gelenkspritzen-stakonmed-7803995.jpg?v=1777230014"},{"product_id":"ostenil-1-x-2-ml","title":"Ostenil 1x 2.0 ml","description":"\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/ostenil\" title=\"Ostenil | Joint Injections | StakonMed\"\u003e\u003cspan\u003eOSTENIL\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e®\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate 1.0%. Viscous-elastic solution for injection into the joint space to improve mobility and relieve pain in osteoarthritis. Transparent solution made from natural, highly purified sodium hyaluronate obtained by fermentation. Free of animal proteins. Sterilized with moist heat. The contents and the outer surface of the OSTENIL\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e prefilled syringe are sterile as long as the sterile barrier is intact. For single use only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComposition:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 ml isotonic solution (pH 7) contains 10.0 mg sodium hyaluronate, sodium chloride, disodium phosphate, sodium dihydrogen phosphate, and water for injection purposes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePain and limited mobility of the knee and other large synovial joints such as hip and shoulder.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003emust not be administered to patients with known hypersensitivity to any of the components of the product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions: \u003c\/span\u003e\u003cspan\u003e®\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eTreatment with OSTENIL is not recommended for children, pregnant or breastfeeding women, or in inflammatory joint diseases such as rheumatoid arthritis or ankylosing spondylitis. If a joint effusion is present, it should be reduced first. National guidelines for intra-articular injections must be followed, including thorough disinfection of the injection site and other measures to prevent joint infections. OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eshould be injected precisely into the joint space, if necessary under imaging guidance. Avoid injections into blood vessels or surrounding tissue. Do not use if the prefilled syringe or sterile packaging is damaged. Any solution not used immediately after opening must be discarded. Otherwise, sterility cannot be guaranteed, which may pose an infection risk. Do not resterilize as this may damage the product. There is currently no information on interference with diagnostic procedures such as MRI, clinical assessments, or therapeutic treatments by OSTENIL\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions: \u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eThere is currently no information on incompatibility of OSTENIL with other medical devices and drugs for intra-articular use or with oral analgesics or anti-inflammatory drugs.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSide effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn very rare cases (less than 1 in 10,000 patients), local reactions such as pain, warmth, redness, swelling\/joint effusion, itching, and other local intolerance reactions may occur during or after injection of OSTENIL\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e. As with all invasive joint treatments, infection may occur in very rare cases. It cannot be completely excluded that in very rare cases the intra-articular injection itself causes systemic side effects such as tachycardia, hypotension, hypertension, palpitations, nausea, and shortness of breath. These reactions may occur independently of the solution administered. Patients should be informed about contraindications and side effects before injection of OSTENIL\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eReporting of side effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAny serious incident related to the medical device must be reported to the manufacturer TRB Chemedica AG and the responsible local authority of the user.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage and administration:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInject OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003e3–5 times at weekly intervals into the affected joint. Multiple joints can be treated simultaneously. Depending on the severity of the joint disease, the positive effect of a treatment cycle of five intra-articular injections can last at least six months. If necessary, the treatment cycle can be repeated. Remove the prefilled syringe from the sterile packaging, remove the Luer Lock cap from the syringe, attach a suitable needle with Luer connection (e.g., 18 to 25 G) and lock it by slight rotation. Remove any air bubbles from the syringe before injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDisposal:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDispose of the syringe immediately after use in an appropriate safety container. Do not dispose of the OSTENIL\u003c\/span\u003e\u003cspan\u003e®\u003c\/span\u003e\u003cspan\u003e prefilled syringe in household waste. Follow local regulations for proper disposal of the safety container.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynovial fluid, which behaves viscoelastically due to the presence of hyaluronic acid, is found in all synovial joints where it ensures normal, pain-free movement because of its lubricating and cushioning properties. In degenerative joint diseases such as osteoarthritis, the viscoelasticity of synovial fluid is significantly reduced, impairing its lubricating and cushioning functions. This increases mechanical stress on the joint and cartilage destruction, ultimately leading to pain and restricted mobility of the affected joint. Supplementing this synovial fluid by intra-articular injections with highly purified hyaluronic acid can improve the viscoelastic properties of the synovial fluid. Lubricating and cushioning properties are enhanced, and mechanical overload of the joint is reduced. Clinical studies have shown pain relief and improved joint mobility for up to six months.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStorage:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore in a dry, light-protected place at 2°C to 25°C! Do not use after the expiration date indicated on the packaging. Keep out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1, 3, 5, 100 prefilled syringes of 20 mg\/2.0 ml, each syringe individually sterile packed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs long as the EUDAMED database is not fully operational, the report on safety and clinical performance (SSCP) is available to the public on the company website www.trbchemedica.de.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eis a medical device. It may only be used by a physician experienced and trained in intra-articular injections.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDate of last revision: 2022-01\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"TRB Chemedica AG","offers":[{"title":"Default Title","offer_id":47355879981396,"sku":"127","price":20.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/ostenil-1x-20-ml-trb-chemedica-ag-gelenkspritzen-stakonmed-2970669.jpg?v=1777230014"},{"product_id":"ostenil-plus-1-x-2-ml","title":"Ostenil Plus 1x 2.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/ostenil\" title=\"Ostenil | Joint Injections | StakonMed\"\u003eOSTENIL\u003c\/a\u003e® PLUS\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate 2.0%. A viscoelastic solution for injection into the joint space to improve mobility and relieve pain in osteoarthritis. Transparent solution made from natural, highly purified sodium hyaluronate obtained by fermentation. Free from animal proteins. Sterilized with moist heat. The contents and the outer surface of the OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS prefilled syringe are sterile as long as the sterile barrier is intact. For single use only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComposition:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 ml isotonic solution (pH 7) contains 20.0 mg sodium hyaluronate, sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol, and water for injection purposes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePain and restricted mobility of the knee and other large synovial joints such as hip and shoulder.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS must not be administered to patients with known hypersensitivity to any of the components of the product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTreatment with OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS is not recommended for children, pregnant or breastfeeding women, or in inflammatory joint diseases such as rheumatoid arthritis or ankylosing spondylitis. If a joint effusion is present, it should be reduced first. National guidelines for intra-articular injections must be followed, including thorough disinfection of the injection site and other measures to prevent joint infections. OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS should be injected precisely into the joint space, if necessary under imaging guidance. Avoid injections into blood vessels or surrounding tissue. Do not use if the prefilled syringe or sterile packaging is damaged. Any solution not used immediately after opening must be discarded. Otherwise, sterility cannot be guaranteed, which may pose an infection risk. Do not resterilize, as this may damage the product. There is currently no information on impairment of diagnostic procedures such as MRI, clinical assessments, or therapeutic treatments by OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions: \u003c\/span\u003e\u003cspan\u003eThere is currently no information on incompatibility of OSTENIL® PLUS with other medical devices and drugs for intra-articular use or with oral analgesics or anti-inflammatory drugs.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSide effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn very rare cases (less than 1 in 10,000 patients), local reactions such as pain, warmth, redness, swelling\/joint effusion, itching, and other local intolerance reactions may occur during or after injection of OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS. As with all invasive joint treatments, infection may occur in very rare cases. It cannot be completely excluded that in very rare cases the intra-articular injection itself causes systemic side effects such as tachycardia, hypotension, hypertension, palpitations, nausea, and shortness of breath. These reactions may occur independently of the applied solution. Patients should be informed about contraindications and side effects before injection of OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eReporting of side effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAny serious incident related to the medical device must be reported to the manufacturer TRB Chemedica AG and the responsible local authority of the user.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage and administration:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInject OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS a total of 1 to 3 times at weekly intervals into the affected joint. Multiple joints can be treated simultaneously. Depending on the severity of the joint disease, the positive effect can last at least six months. If necessary, the treatment cycle can be repeated. Remove the prefilled syringe from the sterile packaging, remove the Luer Lock cap from the syringe, attach a suitable needle with Luer connection (e.g., 18 to 25 G) and lock it by slight rotation. Remove any air bubbles from the syringe before injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDisposal:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDispose of the syringe immediately after use in an appropriate safety container. Do not dispose of the OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS prefilled syringe in household waste. Follow local regulations for proper disposal of the safety container.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSynovial fluid, which behaves viscoelastically due to the presence of hyaluronic acid, is found in all synovial joints, where it ensures normal, pain-free movement due to its lubricating and cushioning properties. In degenerative joint diseases such as osteoarthritis, the viscoelasticity of synovial fluid is significantly reduced, impairing its lubricating and cushioning properties. This increases mechanical stress on the joint and cartilage destruction, ultimately leading to pain and restricted mobility of the affected joint. Supplementing this synovial fluid by intra-articular injections with highly purified hyaluronic acid can improve the viscoelastic properties of the synovial fluid. Lubricating and cushioning properties are enhanced, and mechanical overload of the joint is reduced. Clinical studies have shown pain relief and improved joint mobility for up to six months.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS additionally contains mannitol, a radical scavenger that helps stabilize the sodium hyaluronate chains.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStorage:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore in a dry, light-protected place at 2°C to 25°C! Do not use after the expiration date indicated on the packaging. Keep out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 prefilled syringe containing 40 mg\/2.0 ml OSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS in sterile packaging.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs long as the EUDAMED database is not fully operational, the report on safety and clinical performance (SSCP) is available to the public on the company website www.trbchemedica.de.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003ePLUS is a medical device. It may only be used by a physician experienced and trained in intra-articular injections.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDate of last revision: 2022-01\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"TRB Chemedica AG","offers":[{"title":"Default Title","offer_id":47355880014164,"sku":"128","price":57.85,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/260622-01_046.jpg?v=1782293663"},{"product_id":"ostenil-tendon-1-x-2-ml","title":"Ostenil Tendon 1x 2.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/ostenil\" title=\"Ostenil | Joint Injections | StakonMed\"\u003eOSTENIL\u003c\/a\u003e® TENDON\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate 2.0%. Viscoelastic solution for peritendinous injection or injection into the tendon sheath to improve mobility and relieve pain in tendon disorders. Transparent solution made from natural, highly purified sodium hyaluronate obtained by fermentation. Free of animal proteins. Sterilized with moist heat. The content and the outer surface of the OSTENIL® TENDON prefilled syringe are sterile as long as the sterile barrier is intact. For single use only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComposition:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 ml isotonic solution (pH 7) contains 20.0 mg sodium hyaluronate, sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol, and water for injection purposes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor the treatment of pain and restricted mobility of tendons with or without involvement of the tendon sheath such as Achilles tendon, tendon at the humeral epicondyle, supraspinatus, patella, peroneal, biceps tendon, as well as iliotibial band.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL® TENDON must not be administered to patients with known hypersensitivity to any of the components of the product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe use of OSTENIL® TENDON in children, pregnant and breastfeeding women, as well as in acute injuries, is not recommended. The general precautions for peritendinous injections and injections into the tendon sheath, including thorough disinfection of the injection site and other measures to prevent infections, must be observed. OSTENIL® TENDON must be correctly injected into the tendon sheath or correctly injected around the affected tendon, if necessary under imaging guidance. Avoid nerve injuries and injections into blood vessels. Do not use if the prefilled syringe or sterile packaging is damaged. Any solution not used immediately after opening must be discarded. Otherwise, sterility can no longer be guaranteed, which may be associated with a risk of infection. Do not resterilize as this may damage the product. There is currently no information on impairment of diagnostic examinations such as magnetic resonance imaging, clinical assessments, or therapeutic treatments by OSTENIL® TENDON.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThere is currently no information available on incompatibility of OSTENIL® TENDON with other medical devices and drugs applied to the tendon.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSide effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn very rare cases (in fewer than 1 in 10,000 patients), local side effects such as discomfort, pain, warmth, itching, bruising, redness, and swelling may occur after the use of OSTENIL® TENDON. As with all invasive treatments, infection may occur in very rare cases. Patients should be informed about contraindications and side effects before injection of OSTENIL® TENDON.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eReporting of side effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAny serious incident related to the medical device must be reported to the manufacturer TRB CHEMEDICA AG and the responsible local authority of the user.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage and method of administration:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInject OSTENIL® TENDON twice in total at weekly intervals around the affected tendon or into the affected tendon sheath. Multiple tendons can be treated simultaneously. Clinical studies showed a reduction in pain and improvement in mobility for up to twelve months. Sodium hyaluronate itself is broken down within a few days. Repeat treatment cycles are possible if needed. Remove the prefilled syringe from the sterile packaging, remove the Luer-Lock cap from the syringe, attach a suitable needle with Luer connection (e.g., 25 to 27 G) and lock it by slight rotation. Remove any air bubbles from the syringe before injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDisposal:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDispose of the syringe immediately after use in an appropriate safety container. Do not dispose of the OSTENIL® TENDON prefilled syringe in household waste. Follow local regulations for proper disposal of the safety container.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA tendon is a robust structure made of fibrous connective tissue designed to transmit forces from muscles to bones and withstand tension during muscle contraction. Tendons can be surrounded by different structures: fibrous ligaments, synovial sheaths, tendon sheaths, bursae. Overuse or incorrect loading can cause inflammation and\/or degenerative changes in the tendon, leading to pain and loss of function. Making the tendon more glidable could reduce pain, improve tendon function, and decrease the possibility of adhesions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDue to its lubricating and viscoelastic properties, hyaluronic acid can support the gliding ability of tendons as well as the physiological regeneration process. Additionally, hyaluronic acid reduces the free passage of inflammation-promoting cells and molecules due to its macromolecular network structure. Clinical studies showed pain relief and improved mobility for up to twelve months.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL® TENDON is a clear solution of natural, highly pure sodium hyaluronate obtained by fermentation and free of animal proteins. OSTENIL® TENDON also contains mannitol, a free radical scavenger that helps stabilize the sodium hyaluronate chains.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStorage:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore in a dry, light-protected place at 2 °C to 25 °C! Do not use after the expiration date indicated on the packaging. Keep out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOne prefilled syringe 40 mg\/2.0 ml OSTENIL® TENDON in sterile packaging.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs long as the EUDAMED database is not fully operational, the summary report on safety and clinical performance (SSCP) is available to the public on the company website www.trbchemedica.de.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOSTENIL® TENDON is a medical device. It may only be used by a physician experienced and trained in peritendinous injections and injections into the tendon sheath.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDate of last revision: 2022-11\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"TRB Chemedica AG","offers":[{"title":"Default Title","offer_id":47355880046932,"sku":"129","price":56.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/ostenil-tendon-trb-chemedica-ag-gelenkspritzen-stakonmed-774631.jpg?v=1772215089"},{"product_id":"viscoseal-syringe-1-x-2-ml","title":"Viscoseal Syringe 1x 10.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eINFORMATION FOR USE \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/viscoseal\" title=\"Viscoseal Syringe | Joint Injections | StakonMed\"\u003e\u003cspan\u003eVISCOSEAL\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate from fermentation 0.5%. For substitution of joint lubricant. Pre-filled syringe with 10 ml solution (in sterile packaging) for single use. Sterile by moist heat.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eComposition:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 ml isotonic solution contains 5.0 mg sodium hyaluronate from fermentation as well as sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, and water for injection purposes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor pain relief, improved joint mobility, and faster restoration of joint function after arthroscopy or joint lavage in the shoulder or knee joint by removing the rinse fluid and substituting the joint lubricant.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eKnown hypersensitivity to any of the ingredients.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInteractions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDo not bring VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE into contact with objects disinfected with solutions of quaternary ammonium salts.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSide effects:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNo adverse effects are expected when VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE is used according to the indication and prescribed dosage guidelines. There have been no reports of infections or allergic reactions causally related to the use of VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE so far. However, both risks cannot be completely excluded. Contraindications must be observed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage instructions and method of application:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs long as the sterile packaging is unopened, the contents and surface of the pre-filled syringe are sterile. VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE should be used after completion of arthroscopy and normal joint lavage. Remove the pre-filled syringe from the sterile packaging and remove the cap. Attach a suitable cannula and lock it with a slight twist, or connect the pre-filled syringe to an access already in the joint. Before use, any air bubble present in the pre-filled syringe should be removed. Inject VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE into the joint space. This promotes the removal of remaining rinse fluid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eObserve general precautions for arthroscopic procedures. VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE should be correctly instilled into the joint space. Since there is insufficient experience with the use of sodium hyaluronate in children as well as in pregnant and breastfeeding women, the use of VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE is not recommended in these cases. Any solution not used immediately after opening must be discarded. Otherwise, sterility is no longer guaranteed, which can lead to an infection risk. Do not use if the pre-filled syringe or sterile packaging is damaged. Store between 2 °C and 25 °C! Observe expiration date. Keep out of reach of children!\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eArthroscopy is a common procedure for visualization, diagnosis, and treatment of joint problems. To create clear visibility and to remove cartilage debris, the joint is rinsed during arthroscopy with solutions such as physiological saline or Ringer's lactate solution. There is evidence that the rinse fluid remaining in the joint can impair cartilage metabolism. Furthermore, during the procedure, the synovial fluid, which has special viscoelastic and protective properties due to its hyaluronic acid content, is rinsed out of the joint. Therefore, patients who experience long-term improvement in joint function through the procedure may have complaints such as pain, swelling, and impaired joint mobility immediately after the procedure. VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE was developed to relieve such complaints and to enable faster recovery of joint function. VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE contains a highly pure specific fraction of hyaluronic acid produced by a fermentation process and contains no animal proteins. Instillation of VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE into the joint space helps remove remaining rinse fluid and efficiently coats all surfaces within the joint. The VISCOSEAL\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eSYRINGE remaining in the joint acts as a lubricant and shock absorber, and its network of macromolecules prevents free passage of inflammatory cells and molecules through the joint space.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePackage size:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1 pre-filled syringe of 50 mg\/10 ml (in sterile packaging) for single use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor use by a physician only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInformation status: 2019-10\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"TRB Chemedica AG","offers":[{"title":"Default Title","offer_id":47355880505684,"sku":"147","price":56.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/viscoseal-syringe-trb-chemedica-ag-gelenkspritzen-stakonmed-610574.jpg?v=1772216199"},{"product_id":"recosyn-m-d-n-1-x-1-ml","title":"Recosyn m.d.N  1x 1.0 ml","description":"\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/recosyn\" title=\"Recosyn | Gelenkspritzen | StakonMed\"\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003em.d. N\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made from highly purified sodium hyaluronate obtained by bacterial fermentation without genetic modifications, with high molecular weight, used to improve viscosity in intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains 1 ml aqueous, physiological phosphate buffer solution with 10 mg sodium \u003c\/span\u003e\u003cspan\u003ehyaluronate. The sodium hyaluronate hydrogel is in a weak, sterile \u003c\/span\u003e\u003cspan\u003elen, isotonic and apyrogenic phosphate-buffered saline solution with a pH of 7.2 (6.8 – 7.4) in sufficient volume for injection. The fill volume of a prefilled syringe is 1 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe chemical components are listed in the table on the right (weight per volume as mg substance per 1 ml hydrogel).\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eEssential component of healthy synovial fluid is the widespread glycosami\u003c\/span\u003e\u003cspan\u003enoglycan hyaluronic acid. This natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003em.d. N \u003c\/span\u003e\u003cspan\u003econtained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used in patients\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with known hypersensitivity to any of the ingredients\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eor when using anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered precisely into the joint cavity; injections into blood vessels and surrounding tissue must be avoided.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDo not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single treatment session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. Local reactions such as pain, redness, warmth, and swelling may occur in the treated joint. These symptoms can be reduced by cooling the treated area with an ice pack for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. If severe pain or inflammation occurs, treatment should be discontinued. Management of adverse reactions should only be carried out under the supervision of the treating physician. Immediately after the injection, strenuous physical activity should be avoided, and other instructions from the doctor should be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMedical professionals should inform the patient\u003cbr\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must inform a doctor of any adverse event or complication.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds such as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products containing these compounds, or with solutions rinsed with quaternary ammonium compounds used as biocidal preservatives.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRemove the prefilled syringe from its packaging. Remove the protective cap from the Luer-Lock thread. Screw a suitable sterile injection needle onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended to first reduce the effusion by aspiration before injecting the gel and to examine it for bacterial etiology. The hydrogel can be injected intra-articularly 1 to 5 times at intervals determined by the physician. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUnused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eOne box with a prefilled syringe of 1 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eShelf life\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the syringe blister and on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, observe the warning symbols on the packaging.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003eIntended exclusively for use by physicians.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging. Syringe contents are non-toxic and non-flammable.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing it on other patients or the same patient at a different time, the intended properties and sterility are not guaranteed. Otherwise possible \u003c\/span\u003e\u003cspan\u003eTransmission of material contamination and pathogens from the environment, the clinical \u003c\/span\u003e\u003cspan\u003eUse on another area or (other) patients could lead to health complications. Resealing or resterilization does not constitute an allowed or guaranteed restoration of the usable condition.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInformation status 06\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003cspan style=\"font-size: 0.875rem;\"\u003eIntended exclusively for use by physicians.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Recordati Pharma GmbH","offers":[{"title":"Default Title","offer_id":47355880538452,"sku":"130","price":21.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/recosyn-md-n-recordati-pharma-gmbh-gelenkspritzen-stakonmed-883596.jpg?v=1772215360"},{"product_id":"recosyn-20-1-x-2-ml","title":"Recosyn 20 1x 2.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/recosyn\" title=\"Recosyn | Joint Injections | StakonMed\"\u003e\u003cspan\u003eRECOSYN\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e®\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1. Intended Use\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis product is a medical device for use in humans and is injected intra-articularly into the knee joint. The medical device is intended to reduce functional limitations, relieve pain, and consequently improve quality of life.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e2. Indications\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndicated for patients with symptomatic femorotibial knee osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e3. Description\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product consists of a sterile, isotonic, viscoelastic solution for intra-articular use and is supplied in a prefilled syringe. Each prefilled syringe contains 2 ml of the viscoelastic solution. 1 ml of the product contains: 10 mg (1%) sodium hyaluronate as well as sodium chloride, sodium monohydrogen phosphate, citric acid, and water for injection purposes. The product is supplied sterile and is intended for single use only. The product is steam sterilized in its blister packaging. No ingredients or raw materials of animal origin are used in the manufacture of the product. The product contains no medicinal active substances.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e4. Method of Administration and Dosage\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRemove the prefilled syringe from the blister and carefully unscrew the rubber cap from the Luer-Lock connector. For intra-articular injections, a 21G cannula is recommended. Attach the cannula to the Luer-Lock connector and lock it with a slight twist. Hold the syringe during administration as shown in Figure 1. It is recommended to administer three injections of 2 ml of the product per knee at weekly intervals. Both knee joints can be treated simultaneously, and treatment cycles of up to 3 injections can be repeated. To avoid intra-articular infections, the injection must be performed under strict aseptic conditions. It is recommended to apply an ice pack to the treated joint for 5–10 minutes after application to prevent pain, swelling, and bleeding.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e5. Properties and Mode of Action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn patients with degenerative joint disease (osteoarthritis), the viscoelasticity of the synovial fluid is significantly impaired. Mechanical \u003c\/span\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003estress on the joint leads to the breakdown of joint cartilage, which in turn causes restricted joint mobility and pain. The lubricating properties of this product contribute to pain reduction and improved joint mobility. The effect of the product lasts up to 6 months after a treatment cycle of 3 intra-articular injections.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e6. Contraindications and Possible Interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used in the following patients:\u003cbr\u003ePatients with hemochromatosis, ochronosis, or hemophilia \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003ePatients with Paget's disease of bone, chondromatosis, or pigmented villonodular synovitis \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003ePatients with inflammatory, infectious, or metabolic arthritis (rheumatoid arthritis, ankylosing spondylitis, soft tissue rheumatism...) \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003ePatients with a history of coagulation disorders or on anticoagulant therapy \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003ePatients with known allergy to the product or any of its components \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003ePatients requiring permanent or intermittent steroid therapy \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003ePatients with immunodeficiency or with severe or progressive disease (cardiac, pulmonary, hepatic, renal, hematological, neoplastic, or infectious disease) \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003ePatients with venous stasis or lymphostasis in the target limb \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003ePatients with skin diseases or infections at the injection site \u003c\/span\u003e\u003cspan\u003e| \u003c\/span\u003e\u003cspan\u003ePatients with a severe acute or chronic illness for which the use of the product is contraindicated or poses an additional risk according to the physician's assessment\u003cbr\u003eCurrently, no information is available on undesirable interactions with other intra-articularly administered therapies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e7. Side Effects and Adverse Events\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe physician must inform the patient about potential side effects and\/or incompatibilities related to the use of this product, which may occur immediately or some time after the injection. After application, local symptoms may occur in the treated joint (pain, warmth, redness, and swelling). In connection with comparable products, the following adverse events have been reported: mild to moderate joint pain, rarely skin rash, pseudo-septic joint effusions, pruritus, and muscle cramps. In very rare cases, the following adverse events have also been observed: allergic reactions, anaphylactic shock, hemarthrosis, phlebitis, severe acute inflammatory reactions (SAIR), nasopharyngitis, joint stiffness, tendinitis, bursitis, fever, myalgia, and septic arthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe physician must advise the patient to seek medical advice promptly in the event of such an adverse event. Such side effects must be treated appropriately. Adverse reactions related to the injection of the product must be reported to the marketing authorization holder and\/or the manufacturer.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e8. Warnings\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product must only be administered by physicians trained in intra-articular injection techniques. They should also be familiar with all immunological and other risks that may be associated with the use of biological materials. The product must not be used in pregnant or breastfeeding women or in patients under 18 years of age, as no clinical data are available for these groups.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eKeep the product out of sight and reach of children. The product is intended for single use only; the syringe must never be resterilized. Reuse of the product carries a potential infection risk for patients and users. Do not use if the blister packaging is opened and\/or damaged. Do not use any syringe whose protective cap in the blister pack is opened or displaced. Do not use after the expiration date. Patients should be advised to rest the treated joints for 24 hours after each injection (but not immobilize completely) to avoid overuse. Dispose of the syringe, product residues, and cannula after use in a designated container. A 21G cannula is recommended for injection of the product. Compatibility of other needles\/cannulas with the product and syringe has not been tested.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e9. Storage\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore the product at room temperature (2–25 °C\/36–77 °F) and protect from frost and moisture.\u003cbr\u003eAvailable pack sizes: 1 or 5 prefilled syringes\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003e10. Last Revision\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e2020-01 Version number: Z07\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Recordati Pharma GmbH","offers":[{"title":"Default Title","offer_id":47355880571220,"sku":"131","price":22.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/recosyn-20-recordati-pharma-gmbh-gelenkspritzen-stakonmed-263726.jpg?v=1772215288"},{"product_id":"recosyn-forte-n-44-1-x-2-ml","title":"Recosyn forte N 44 1x 2.0 ml","description":"\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/recosyn\" title=\"Recosyn | Gelenkspritzen | StakonMed\"\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eforte N\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made from highly purified sodium hyaluronate obtained by bacterial fermentation without genetic modification, with high molecular weight, used to improve viscosity in intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains 1 ml aqueous, physiological phosphate buffer solution with 22 mg sodium\u003c\/span\u003e\u003cspan\u003ehyaluronate. The sodium hyaluronate hydrogel is in a weak, sterile\u003c\/span\u003e\u003cspan\u003elen, isotonic and apyrogenic phosphate-buffered saline solution with a pH of 7.2 (6.8 – 7.4) in sufficient volume for injection. The fill volume of a prefilled syringe is 2 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe chemical components are listed in the table on the right (weight per volume as mg substance per 1 ml hydrogel).\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eAn essential component of healthy synovial fluid is the widespread glycosami\u003c\/span\u003e\u003cspan\u003enoglycan hyaluronic acid. This natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eforte N \u003c\/span\u003e\u003cspan\u003econtained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used in patients\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with known hypersensitivity to any of the components\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eor when using anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of the treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered precisely into the joint cavity; injections into blood vessels and surrounding tissue must be avoided.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDo not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single application session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. Local reactions such as pain, redness, warmth, and swelling may occur in the treated joint. These symptoms can be reduced by cooling the treated area with an ice pack for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. Treatment should be discontinued in case of severe pain or inflammation. Management of adverse reactions should only be carried out under the supervision of the treating physician. Immediately after the injection, strenuous physical activity should be avoided, and other instructions from the doctor should be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMedical professionals should inform the patient\u003cbr\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must inform a doctor of any adverse event or complication.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds such as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products containing these compounds, or with solutions rinsed with quaternary ammonium compounds as biocidal preservatives.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRemove the prefilled syringe from its packaging. Remove the protective cap from the Luer-Lock thread. Screw a suitable sterile injection needle onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended to first reduce the effusion by aspiration before injecting the gel and to examine it for bacterial etiology. The hydrogel can be injected intraarticularly 1 to 5 times (usually 3) at intervals determined by the physician. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUnused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDosage, method, and duration of application\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eA box containing one prefilled syringe of 2 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eShelf life\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the syringe blister and on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, warning symbols on the packaging must be observed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv title=\"Page 1\" class=\"page\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging. Syringe contents are non-toxic and non-flammable.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing it on other patients or the same patient at a different time, the intended properties and sterility are not guaranteed. Otherwise possible \u003c\/span\u003e\u003cspan\u003eTransmission of material contamination and pathogens from the environment, the clini- \u003c\/span\u003e\u003cspan\u003ein the patient area or (other) patients could lead to health complications. Resealing or resterilization does not constitute an allowed or guaranteed restoration of usability.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStatus of information 06\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Recordati Pharma GmbH","offers":[{"title":"Default Title","offer_id":47355880603988,"sku":"132","price":48.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/recosyn-forte-n-44-recordati-pharma-gmbh-gelenkspritzen-stakonmed-710157.jpg?v=1772215311"},{"product_id":"recosyn-uno-ultra-1-x-4-8-ml","title":"Recosyn Uno Ultra 1x 4.8 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/recosyn\" title=\"Recosyn | Gelenkspritzen | StakonMed\"\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eUno ultra\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains a prefilled syringe with hydrogel made from highly purified sodium hyaluronate obtained by bacterial fermentation without genetic modification, with high molecular weight, used to improve viscosity in intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product contains 1 ml aqueous, physiological phosphate buffer solution with 25 mg Na\u003c\/span\u003e\u003cspan\u003etriumhyaluronate. The sodium hyaluronate hydrogel is in a weak, \u003c\/span\u003e\u003cspan\u003esterile, isotonic, and apyrogenic phosphate-buffered saline solution with a pH of 7.2 (6.8 – 7.4) in sufficient volume for injection. The fill volume of a prefilled syringe is 4.8 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe chemical components are listed in the table on the right (weight per volume as mg substance per 1 ml hydrogel).\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eAn essential component of healthy synovial fluid is the widespread glycosami\u003c\/span\u003e\u003cspan\u003enoglycan hyaluronic acid. This natural biopolymer provides viscoelasticity and, thanks to its lubricating and shock-absorbing properties, enables pain-free physiological movements; it also supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eUno ultra \u003c\/span\u003e\u003cspan\u003eThe contained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used in patients\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with known hypersensitivity to any of the components\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint\u003cbr\u003e- with septic arthritis\u003cbr\u003e- with skin infections or skin diseases in the injection area\u003cbr\u003e- in cases of natural or medication-induced coagulation disorders such as hemophilia\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eor when using anticoagulants such as Marcumar (phenprocoumon) or Coumadin (warfarin)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of the treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered precisely into the joint cavity; injections into blood vessels and surrounding tissue must be avoided.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDo not use if the prefilled syringe or sterile packaging is damaged.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single treatment session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNo adverse effects were observed in biocompatibility tests with the product. Local reactions such as pain, redness, warmth, and swelling may occur in the treated joint. These symptoms can be reduced by applying an ice pack to the treated area for 5 to 10 minutes after injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. Treatment should be discontinued in case of severe pain or inflammation. Management of adverse reactions should only be carried out under the supervision of the treating physician. Immediately after the injection, strenuous physical activity should be avoided and other instructions from the physician should be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMedical professionals should inform the patient\u003cbr\u003e- about possible adverse events related to the product.\u003cbr\u003e- that the patient must report any adverse event or complication to a doctor.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds such as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products containing these compounds or rinsed with solutions containing quaternary ammonium compounds as biocidal preservatives.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eRemove the prefilled syringe from its packaging. Remove the protective cap from the Luer-lock thread. Screw a suitable sterile injection needle onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended to first reduce the effusion by aspiration before injecting the gel and to examine it for bacterial etiology. The hydrogel can be injected intra-articularly once. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUnused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eA box with one prefilled syringe of 4.8 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDurability\u003c\/span\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the syringe blister and on the carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C and protected from light and impact in the original packaging. Accordingly, warning symbols on the packaging must be observed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eFor single use only. Do not resterilize. Do not use syringes, needles, or hydrogel from open or damaged packaging or attempt to reseal packaging. Syringe contents are non-toxic and non-flammable.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eWhen using a product from damaged packaging or reusing it on other patients or the same patient at a different time, the intended properties and sterility are not guaranteed. Otherwise possible \u003c\/span\u003e\u003cspan\u003eTransmission of material contamination and pathogens from the environment, the clinical\u003c\/span\u003e\u003cspan\u003ein the area or (other) patients could lead to health complications. Resealing or resterilization does not constitute an allowed or guaranteed restoration of the usable condition.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInformation status 06\/2021\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Recordati Pharma GmbH","offers":[{"title":"Default Title","offer_id":47355880964436,"sku":"133","price":134.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/recosyn-uno-ultra-recordati-pharma-gmbh-gelenkspritzen-stakonmed-680224.jpg?v=1772215382"},{"product_id":"recosyn-max-forte-n-1-x-2-ml","title":"Recosyn Max forte N 1x 2.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/recosyn\" title=\"Recosyn | Gelenkspritzen | StakonMed\"\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMax forte N\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate intra-articular plus niacinamide\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDescription\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe prefilled syringe contains a hydrogel made of high-molecular and highly purified sodium hyaluronate from bacterial fermentation. The product serves to improve viscosity in the intra-articular connective tissue. It has undergone steam sterilization for injectable products and is non-pyrogenic.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMax forte N \u003c\/span\u003e\u003cspan\u003econtains 2 ml aqueous, physiological phosphate buffer solution with \u003c\/span\u003e\u003cspan\u003e44 mg sodium hyaluronate. The sodium hyaluronate hydrogel is contained in \u003c\/span\u003e\u003cspan\u003ea weak, sterile, isotonic, and apyrogenic phosphate-buffered saline solution with a pH of 7.2 (6.8 – 7.4) in sufficient volume for injection. The fill volume is 2 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe chemical components are listed in the table (weight per volume as mg substance per 1 ml hydrogel):\u003cbr\u003e(a) Sodium hyaluronate, (b) Sodium chloride, (c) Disodium hydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO,\u003cbr\u003e(d) Sodium dihydrogen phosphate 2 H\u003c\/span\u003e\u003cspan\u003e2\u003c\/span\u003e\u003cspan\u003eO, (e) Water for injection, (f) Niacinamide\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eProperties and mode of action\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eHyaluronic acid, a widespread glycosaminoglycan, is an essential component \u003c\/span\u003e\u003cspan\u003ehealthy synovial fluid. This natural biopolymer provides viscoelasticity and\u003c\/span\u003e\u003cspan\u003eenables pain-free physiological movements thanks to its lubricating, shock-absorbing properties. Additionally, it supplies nutrients to the cartilage. The \u003c\/span\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMax forte N \u003c\/span\u003e\u003cspan\u003econtained sodium hyaluronate is a salt of hyaluronic acid.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eIndications\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints, including osteoarthritis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used in patients\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with known hypersensitivity to any of the components.\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003e- with inflammation in the joint.\u003cbr\u003e- with septic arthritis.\u003cbr\u003e- with skin infections or skin diseases in the injection area.\u003cbr\u003e- with natural or medication-induced coagulation disorders such as hemophilia or when using anticoagulants like Marcumar (phenprocoumon) or Coumadin (warfarin).\u003cbr\u003eSince there are no clinical data on the use of hyaluronic acid in children, pregnant or breastfeeding women, use in these patients is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePrecautions\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSince septic arthritis can be a serious complication of the treatment, please observe all precautions usually necessary for surgical procedures. Injections of the hydrogel must be administered directly into the joint cavity; injections into blood vessels and surrounding tissue must be avoided.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDo not use if the prefilled syringe or sterile packaging is damaged.\u003cbr\u003eThe opened product must not be resterilized, resealed, or reused. It is intended for use by a single patient at a single application session.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePossible side effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eNo adverse side effects were observed in biocompatibility tests with the product. Local reactions such as pain, redness, warmth, and swelling may occur at the treated joint. These reactions can be reduced by cooling the treated area with an ice pack for 5 to 10 minutes after the injection. During the first days of treatment, the simultaneous oral intake of pain and anti-inflammatory medications (NSAIDs) may be beneficial. Treatment should be discontinued in case of severe pain or inflammation. Management of adverse reactions should only be carried out under the supervision of the treating physician. Immediately after the injection, strenuous physical activity should be avoided and other instructions from the doctor followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eMedical personnel inform the patient about possible adverse events related to the product and advise that any side effect or complication must be reported to a doctor immediately.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003ePharmacological and chemical interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSo far, there are no data on the incompatibility of the product with other solutions for intra-articular use.\u003cbr\u003eThere is a chemical incompatibility between sodium hyaluronate and quaternary ammonium compounds such as benzalkonium chloride, which can lead to crystalline precipitation. Therefore, this product must never come into contact with surgical instruments or other products that contain these or have been rinsed with solutions containing quaternary ammonium compounds as biocidal preservatives.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDosage, type, and duration of use\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe prefilled syringe is to be removed from its packaging. The protective cap is to be removed from the Luer-Lock thread and a suitable sterile injection needle screwed onto the syringe. The use of a single-use needle is recommended. Air should be evacuated from the needle before injection. The skin area intended for injection must be cleaned with an appropriate topical antiseptic. In the case of joint effusion, it is recommended before the injection of \u003c\/span\u003e\u003cspan\u003eRecosyn\u003c\/span\u003e\u003cspan\u003e® \u003c\/span\u003e\u003cspan\u003eMax forte N \u003c\/span\u003e\u003cspan\u003efirst reduce the effusion by aspiration and examine it for bacterial etiology. The hydrogel can be injected intraarticularly 1 to 5 times at intervals determined by the physician. The beneficial effects of a treatment last at least 6 months. Treatment cycles can be repeated if necessary.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDepending on the fill volume, multiple joints of a patient can be treated simultaneously. Unused product must be disposed of.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eDosage form\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eA box containing one prefilled syringe of 2 ml.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eShelf life\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used after the expiration date. The expiration date (month\/year) is printed on the syringe blister and on the box.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eStorage instructions\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe product should be stored dry between 2° and 25°C, protected from light and impact, in the original packaging. Accordingly, observe the warning symbols on the packaging.\u003cbr\u003eKeep the product out of reach of children.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRecommended user group\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for use by physicians.\u003cbr\u003eFor single use only. Do not resterilize. Do not use or attempt to reseal syringes, needles, and hydrogel from open or damaged packaging.\u003cbr\u003eSyringe contents are non-toxic and non-flammable.\u003cbr\u003eUsing a product from damaged packaging or reusing it on other patients or the same patient at a different time does not guarantee the intended properties and sterility. Otherwise, it can\u003c\/span\u003e\u003cspan\u003ea possible transmission of material contamination and pathogens from the \u003c\/span\u003e\u003cspan\u003eEnvironment, the clinical area, or (other) patients may suffer health complications. Resealing or resterilizing does not constitute an allowed or guaranteed restoration of the usable condition.\u003cbr\u003eUnused syringes and their contents are not infectious and can be disposed of before or after the expiration date, observing national and local regulations. Used syringes and needles must be treated as epidemiologically hazardous waste, and national and local regulations for safe use and disposal must be followed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003erev. 03\/2022-V02 rec\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Recordati Pharma GmbH","offers":[{"title":"Default Title","offer_id":47355880997204,"sku":"134","price":94.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/recosyn-max-forte-n-recordati-pharma-gmbh-gelenkspritzen-stakonmed-544861.jpg?v=1772215337"},{"product_id":"sportvis-1-x-1-2-ml","title":"SportVis 1x 1.2 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/stakonmed.de\/collections\/sportvis\" title=\"SportVis | Gelenkspritzen | StakonMed\"\u003e\u003cspan\u003eSportVisTM\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor pain relief and optimization of ankle recovery after first or second degree sprains.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor the relief of chronic pain and movement restrictions of the elbow in lateral epicondylalgia.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor the relief of pain in patients with symptomatic rotator cuff tendinopathy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSportVis\u003c\/span\u003e\u003cspan\u003eTM \u003c\/span\u003e\u003cspan\u003eis a clear, sterile solution of 1% sodium hyaluronate in phosphate-buffered saline in a prefilled syringe for\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ea series of two periarticular injections into the soft tissue of the ankle: a periarticular injection preferably within 48 hours after the injury and a second periarticular injection 2 to 3 days after the first injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ea periarticular injection in the area of the humeral epicondyle, if necessary, followed by a second injection one week after the first injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ea periarticular injection of SportVis\u003c\/span\u003e\u003cspan\u003eTM \u003c\/span\u003e\u003cspan\u003einto the subacromial space of the shoulder directly above the tendon, followed by a second periarticular injection 14 days after the first injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSodium hyaluronate is a long-chain polysaccharide made of \u003c\/span\u003e\u003cspan\u003econsists of repeating disaccharide units and naturally occurs in the body.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe pH value and osmolality of SportVis\u003c\/span\u003e\u003cspan\u003eTM \u003c\/span\u003e\u003cspan\u003eare biocompatible with soft tissue.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1.2 ml SportVis\u003c\/span\u003e\u003cspan\u003eTM\u003c\/span\u003e\u003cspan\u003e, sterilized by filtration, are contained in a ready-to-use single-use glass syringe. The syringe is packaged in a blister pack and an outer carton.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage and administration:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe periarticular injection of SportVisTM should only be performed by a medical professional experienced in this technique.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDosage:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ea periarticular injection preferably within 48 hours after a first or second degree ankle sprain and a second injection 2 to 3 days after the first injection. A 27 gauge injection needle is recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ea periarticular injection in the area of the lateral epicondyle of the humerus, followed by a second injection at the same site one week after the first injection. A 27 gauge injection needle is recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003ea periarticular injection of SportVis\u003c\/span\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003eTM \u003c\/span\u003e\u003cspan style=\"font-size: 0.875rem;\"\u003einto the subacromial space of the shoulder directly above the tendon, followed by a second periarticular injection 14 days after the first injection. A 22 gauge injection needle is recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eThe syringe content is sterile and should be injected with a needle of a size suitable for the injection site.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe area to be treated should be disinfected before the injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAnkle sprains:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePeriarticular injections should be applied using a single puncture along the anterior talofibular ligament using clinical landmarks. The injection is administered along 3 planes: anteroposterior, medial, and lateral to the proximal landmark on the ligament.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e1.2 ml of SportVisTM is preferably injected within 48 hours after the injury, and a second injection of 1.2 ml is given 2 to 3 days after the first injection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eLateral epicondylalgia:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCarefully palpate to locate the most painful point in the epicondyle area.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePosition the needle at a 45-degree angle to the point of maximum pain in the area of the lateral epicondyle.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAfter piercing the skin, align the needle parallel to the skin and insert it towards the point of maximum pain at the lateral epicondyle. Inject half of the content while withdrawing the needle back towards the skin (but not out of the skin).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRotate the needle 180 degrees (opposite direction) and insert the needle parallel to the skin towards the point of maximum pain at the lateral epicondyle. Inject the remaining content while withdrawing the needle outward.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWithdraw the needle from the skin.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBend and straighten the elbow five times, then rotate it inward and outward five times.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRotator cuff tendinopathy:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHave the patient sit upright, arm relaxed at the side and rotated outward. For guiding the injection, it is recommended to use an ultrasound probe positioned laterally on the shoulder, directed towards the plane of the supraspinatus tendon. Locate the acromion, greater tubercle, humeral head, and subacromial space. Insert the needle 1 cm posterior and 2 cm distal to the anterolateral acromial edge into the space. Advance the needle horizontally and slightly medially under the acromial process. If no resistance is felt on the plunger, inject SportVisTM over the humeral head into the subacromial space. Carefully avoid injecting into the tendon.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDispose of syringe and needle after single use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eApplication:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSportVisTM is intended for pain relief and optimization of regeneration of tendons and ligaments damaged by acute or chronic injuries.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 2\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eSportVisTM sodium hyaluronate increases the naturally occurring sodium hyaluronate present in the soft tissue of damaged tendons and ligaments and supports lubrication and hydration of the affected area. This creates an ideal environment for healing the damaged tissue. SportVisTM has been shown to relieve ankle pain and optimize recovery after first or second-degree injuries and sprains. It relieved chronic pain and disabilities of the elbow with lateral epicondylalgia and the pain of patients with symptomatic rotator cuff tendinopathy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePatients with known hypersensitivity to sodium hyaluronate.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWarnings and precautions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSportVisTM should only be injected by a medical professional trained in this technique.\u003cbr\u003eThe prefilled SportVisTM syringes are intended for single use only. The contents of the syringe should be used for one injection only. Any remaining sodium hyaluronate must be disposed of. If a syringe is stored for a later injection, there is a risk of contamination that may lead to patient infection and\/or foreign body reaction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSportVisTM should not be resterilized, as this may impair device performance and cause serious harm to the patient's health and safety.\u003cbr\u003eSportVisTM must not be injected into blood vessels, as sodium hyaluronate may clog the vessels, potentially leading to embolism or infarction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDirect injection into ligaments and tendons should be avoided as this can cause a rupture. Using an ultrasound probe to guide the injection minimizes this risk.\u003cbr\u003eDo not inject into the soft tissue of patients if there is inflammation, infection, or signs of acute or chronic skin disease at the injection site. Sodium hyaluronate is produced by fermentation of \u003c\/span\u003e\u003cspan\u003eStreptococcus equi \u003c\/span\u003e\u003cspan\u003eManufactured and carefully purified. Nevertheless, the medical professional should consider the immunological and other potential risks associated with the injection of any biological material.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs with any periarticular intervention, there is a risk of infection at the injection site.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThere is no evidence of the safety of SportVisTM during pregnancy and breastfeeding in humans.\u003cbr\u003eThe safety and efficacy of SportVisTM in children under 18 years have not been studied.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSportVisTM must not be injected into a hematoma. Dispose of syringe and needle after single use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNational or local guidelines regarding the safe use and disposal of injection needles must be followed. In case of injury, consult a medical professional immediately.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDo not use if the packaging is damaged. Do not use after the expiration date.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eAdverse reactions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMild erythema that fades over time. Temporary pain, swelling, inflammation, pustules, and discoloration may occur with periarticular injections. Rarely, fever, headache, nausea, edema, effusions, and skin itching may occur, which may or may not be associated with SportVisTM.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIncompatibilities:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe compatibility of SportVisTM with other substances for periarticular injection has not been tested. Therefore, mixing or simultaneous administration with other substances for periarticular injection is not recommended.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStorage:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore at a temperature between 2 °C and 25 °C.\u003cbr\u003eDo not freeze. Protect from light.\u003cbr\u003eDo not use if the sterile packaging is damaged. Do not use after the expiration date.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv class=\"page\" title=\"Page 2\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003e\u003cspan\u003eVersion code:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eZ07\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDate:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMarch 2020\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Recordati Pharma GmbH","offers":[{"title":"Default Title","offer_id":47355881029972,"sku":"140","price":49.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/sportvis-recordati-pharma-gmbh-gelenkspritzen-stakonmed-720046.jpg?v=1772215833"},{"product_id":"suplasyn-1-x-2-ml","title":"Suplasyn 1x 2.0 ml","description":"\u003ch2\u003eSUPLASYN® \/ SUPLASYN® 1-Shot\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eSterile Sodium Hyaluronate Solution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHyaluronic acid is a common component of synovial fluid and plays a central role in maintaining the physiological environment of the joint.\u003c\/p\u003e\n\u003ch3\u003eComposition\u003c\/h3\u003e\n\u003cp\u003eViscoelastic solution of purified hyaluronic acid with a defined molecular weight, produced by fermentation.\u003c\/p\u003e\n\u003cp\u003eOne prefilled syringe contains:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003e\u003c\/th\u003e\n\u003cth\u003eSUPLASYN\u003c\/th\u003e\n\u003cth\u003eSUPLASYN 1-Shot\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSodium hyaluronate\u003c\/td\u003e\n\u003ctd\u003e20 mg\u003c\/td\u003e\n\u003ctd\u003e60 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsotonic, buffered aqueous solution\u003c\/td\u003e\n\u003ctd\u003e2 ml\u003c\/td\u003e\n\u003ctd\u003e6 ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eProperties\u003c\/h3\u003e\n\u003cp\u003eHyaluronic acid is the prototype of a large group of polysaccharides (glycosaminoglycans) that are important components of all extracellular tissue structures, including cartilage and synovial fluid. The active ingredient of SUPLASYN is a hyaluronic acid of defined molecular chain length with a high degree of purity. Injection of SUPLASYN into the joint space helps normalize joint function after joint puncture.\u003c\/p\u003e\n\u003ch3\u003eIndications\u003c\/h3\u003e\n\u003cp\u003eSUPLASYN and SUPLASYN 1-Shot are indicated for the symptomatic treatment of osteoarthritis. SUPLASYN has a therapeutic effect in treating pain and improving joint function in osteoarthritis. Multiple joints can be treated simultaneously.\u003c\/p\u003e\n\u003ch3\u003eDosage and Method of Administration\u003c\/h3\u003e\n\u003cp\u003eDepending on the size of the joint, up to 6 ml is injected intra-articularly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSUPLASYN:\u003c\/strong\u003e The usual treatment with SUPLASYN in 2 ml syringes consists of 3 injections at weekly intervals; up to 6 injections can be administered depending on the severity of the condition.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSUPLASYN 1-Shot:\u003c\/strong\u003e For single use only.\u003c\/p\u003e\n\u003cp\u003eAseptic conditions must be strictly observed. Any remaining hyaluronic acid in the prefilled syringes must be discarded. To use the prefilled syringe, remove the “Luer-lock cap,” attach a suitable needle (21-25 G recommended depending on the size of the joint), and secure it by gently twisting. \u003cstrong\u003eThe graduations on the syringe label are for orientation purposes only.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eContraindications\/Precautions\u003c\/h3\u003e\n\u003cp\u003eDo not use in patients with known hypersensitivity to the ingredients of SUPLASYN. General precautions and contraindications for intra-articular injections must be observed. Do not inject intravascularly. SUPLASYN should only be used in joints free of inflammation\/irritation, as adverse reactions are more common in patients with existing joint inflammation\/irritation.\u003c\/p\u003e\n\u003cp\u003eThere are no clinical data on the use of hyaluronic acid in children, pregnant, or breastfeeding women. Therefore, SUPLASYN should not be used in these patient groups.\u003c\/p\u003e\n\u003cp\u003eAfter injection of SUPLASYN, the treated joint should be rested for 24-48 hours. Physically strenuous activities should be avoided throughout the treatment period with SUPLASYN.\u003c\/p\u003e\n\u003cp\u003eTemporary, short-lasting pain may occur after joint injection as a result of the injection itself. Mild local reactions such as pain, warmth, overheating, redness, effusion, irritation, and swelling\/inflammation may occur in the area of the affected joint. If such symptoms occur, it is recommended to rest the affected joint and apply ice. In most patients, these symptoms resolve within a few days.\u003c\/p\u003e\n\u003cp\u003eIn rare cases, as a sign of hypersensitivity, mild local reactions such as pain, irritation, swelling\/joint inflammation, and effusion may be more pronounced and severe. In these cases, therapeutic intervention such as joint puncture may be necessary. Local adverse reactions may be accompanied by systemic reactions such as fever, chills, or circulatory reactions, and in rare cases, anaphylactic reactions may occur.\u003c\/p\u003e\n\u003cp\u003eIn extremely rare cases, rash\/itching, hives (urticaria), inflammation of the joint lining (synovitis), and a drop in blood pressure have been observed after injection of SUPLASYN. Administration should be discontinued if adverse reactions occur. Do not use SUPLASYN with instruments sterilized in quaternary ammonium salt solutions.\u003c\/p\u003e\n\u003ch3\u003eWarnings\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eKeep out of reach of children. Do not use if the blister packaging is damaged. For use by physicians only. For single use only. Any remaining contents in the syringe must be discarded. Reuse carries the risk of contamination and\/or infection or cross-infection of patients.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003ePackage Sizes\u003c\/h3\u003e\n\u003cp\u003ePackage containing 1 prefilled syringe of 2 ml or 6 ml.\u003c\/p\u003e\n\u003ch3\u003eStorage Instructions\u003c\/h3\u003e\n\u003cp\u003eStore packages between 4 °C and 25 °C. \u003cstrong\u003eProtect from frost.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWarm to room temperature before injection.\u003c\/p\u003e\n\u003ch3\u003eDate of Information Preparation\u003c\/h3\u003e\n\u003cp\u003eFebruary 2010\u003c\/p\u003e\n\u003ch3\u003eInformation Status\u003c\/h3\u003e\n\u003cp\u003eFirst edition\u003c\/p\u003e\n\u003ch3\u003eManufacturer\u003c\/h3\u003e\n\u003cp\u003eBioniche Teo.\u003cbr\u003eInverin, Co. Galway, Ireland.\u003c\/p\u003e\n\u003cp\u003e© Bioniche Pharma Group Limited, Ireland\u003cbr\u003e+49 (0)9306 904463\u003c\/p\u003e\n\u003cp\u003eCE 0473\u003c\/p\u003e","brand":"Mylan Teoranta","offers":[{"title":"Default Title","offer_id":47355881062740,"sku":"141","price":24.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/suplasyn-mylan-teoranta-gelenkspritzen-stakonmed-708382.jpg?v=1772215985"},{"product_id":"synocrom-1-x-2-ml","title":"Synocrom 1x 2.0 ml","description":"\u003cdiv class=\"page\" title=\"Page 1\"\u003e\n\u003cdiv class=\"section\"\u003e\n\u003cdiv class=\"layoutArea\"\u003e\n\u003cdiv class=\"column\"\u003e\n\u003cp\u003eInstructions for use of \u003ca href=\"https:\/\/stakonmed.de\/collections\/synocrom\" title=\"Synocrom | Joint Injections | StakonMed\"\u003eSynocrom\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c\/span\u003e\u003cspan\u003e1. Purpose and Indications\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis product is a medical device intended for use in humans and is injected into synovial joints (knee, hip, ankle, and shoulder) to restore the natural viscoelastic properties of the synovial fluid (viscosupplementation). It is indicated for the treatment of pain and restricted mobility due to degenerative or traumatic changes in synovial joints (osteoarthritis).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e2. Description\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product consists of a sterile, isotonic, viscoelastic solution for intra-articular use and is supplied in a prefilled syringe. Each prefilled syringe contains 2 ml of the viscoelastic solution. 1 ml of the product contains: 10 mg (1%) sodium hyaluronate as well as sodium chloride, sodium monohydrogen phosphate, citric acid, and water for injection purposes. The product is delivered sterile and is intended for single use only. The product is steam sterilized in its blister packaging (sterile barrier). No ingredients or raw materials of animal origin are used in the manufacture of the product. The product contains no medicinal active substances.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e3. Method of Administration and Dosage\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRemove the prefilled syringe from the sterile container, carefully unscrew the rubber cap from the Luer-Lock connector, attach a suitable needle, and secure it with a slight twist. Hold the syringe during administration as shown in Figure 1. Depending on the size of the joint, up to 2 ml can be administered intra-articularly. For knee application, 3 to 5 injections of the product at weekly intervals are recommended. For hip, ankle, and shoulder, 1 to 5 injections may be required; clinical experience and patient improvement should guide the number of applications. Multiple joints can be treated simultaneously, and treatment cycles can be repeated. To avoid intra-articular infections, the injection must be performed under strict aseptic conditions. It is recommended to apply an ice pack to the treated joint for 5–10 minutes after administration to prevent pain and swelling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e4. Properties and Mode of Action\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn patients with degenerative joint disease (osteoarthritis), the viscoelasticity of the synovial fluid is significantly impaired. This leads to mechanical stress on the joint and degradation of the articular cartilage, which in turn causes restricted joint mobility and pain. The lubricating and shock-absorbing properties of this product contribute to pain relief and improved joint mobility. After a treatment cycle of three to five intra-articular injections, this effect can last for several months.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e5. Contraindications and Possible Interactions\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product must not be used in patients with known hypersensitivity to any of the ingredients. Since this product is injected intra-articularly, patients with bacterial arthritis should be excluded from treatment to avoid possible complications. Currently, there is no information on undesirable interactions with other intra-articularly administered therapies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e6. Side Effects and Adverse Events\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eLocal symptoms in the treated joint (pain, warmth, redness, and swelling) may occur after administration. With comparable products, the following adverse events have been reported: mild to moderate joint pain, rarely rash, aseptic joint effusions, pruritus, and muscle cramps. In very rare cases, the following adverse events have also been observed: allergic reactions, anaphylactic shock, hemarthrosis, phlebitis, pseudosepsis, severe acute inflammatory reactions (SAIR), nasopharyngitis, joint stiffness, tendinitis, bursitis, fever, and myalgia.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e7. Warnings\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product should only be administered by physicians trained in intra-articular injections. They should also be familiar with all immunological and other risks associated with the use of biological materials. The product has not been studied in pregnant women or in children\/adolescents under 18 years of age. Keep the product out of sight and reach of children. The product is for single use only; the syringe must not be resterilized after use. Reuse of the product carries a potential infection risk for patients and users. Do not use if the sterile barrier (blister pack) is opened and\/or damaged. Do not use any syringe whose protective cap in the sterile packaging (blister pack) is opened or displaced. Do not use after the expiration date. Patients should be advised to rest the treated joints for 24 hours after each injection (but not immobilize completely) to avoid overuse.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e8. Storage\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStore the product at room temperature (2–25 °C) and protect from frost and moisture. Package sizes: 1, 3, 5, or 50 prefilled syringes\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e9. Information Date\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e05\/2015\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Croma-Pharma GmbH","offers":[{"title":"Default Title","offer_id":47355881095508,"sku":"143","price":19.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/260622-01_040.jpg?v=1782293136"},{"product_id":"curavisc","title":"Curavisc 1x 2.0 ml","description":"\u003ch3\u003eCuravisc®\u003c\/h3\u003e\n\u003cp\u003eSodium hyaluronate E.P.\u003cbr\u003e1.0% viscoelastic solution\u003cbr\u003eSterile solution for intra-articular injection\u003c\/p\u003e\n\u003ch3\u003eComposition:\u003c\/h3\u003e\n\u003cp\u003e1 prefilled syringe with 2 ml (Curavisc®) injection solution contains: 20 mg (Curavisc®) sodium hyaluronate (obtained by fermentation) as well as sodium chloride, sodium monohydrogen phosphate, sodium dihydrogen phosphate, and water for injection.\u003c\/p\u003e\n\u003ch3\u003eIndications:\u003c\/h3\u003e\n\u003cp\u003ePain and functional impairment in degenerative and traumatic damage of synovial joints.\u003c\/p\u003e\n\u003cp\u003eCuravisc® can be used in large joints such as knee, hip, and shoulder joints, as well as in small joints such as facet joints of the spine, thumb saddle joint, interphalangeal joints of fingers and toes, big toe metatarsophalangeal joint, and temporomandibular joint.\u003c\/p\u003e\n\u003ch3\u003eContraindications and precautions:\u003c\/h3\u003e\n\u003cp\u003ePatients with confirmed hypersensitivity to components of the injection solution must not be given the product.\u003c\/p\u003e\n\u003cp\u003eSpecial caution is required in patients with confirmed hypersensitivity to medications.\u003c\/p\u003e\n\u003cp\u003eCuravisc® contains as an active ingredient highly pure sodium hyaluronate obtained by fermentation. In rare individual cases, allergic reactions to neutral protein fractions cannot be excluded.\u003c\/p\u003e\n\u003cp\u003eThe general precautions for intra-articular injections must be observed. Curavisc® must be injected precisely into the joint cavity. Injections into blood vessels and surrounding tissue must be avoided.\u003c\/p\u003e\n\u003cp\u003eSince no clinical experience is available for the use of hyaluronate in children, during pregnancy and breastfeeding, or in inflammatory joint diseases such as rheumatoid arthritis or ankylosing spondylitis, treatment with Curavisc® is not recommended in these cases.\u003c\/p\u003e\n\u003cp\u003eIf joint effusion is present, it is recommended to reduce it by aspiration, rest, and application of an ice pack. Corticosteroid injections may also be considered if necessary. Treatment with Curavisc® can be started two to three days later.\u003c\/p\u003e\n\u003ch3\u003eSide effects:\u003c\/h3\u003e\n\u003cp\u003eLocal symptoms such as pain, warmth, skin redness (flush), and swelling may occur in a joint treated with Curavisc®. Applying an ice pack to the treated joint for five to ten minutes reduces the occurrence of these symptoms.\u003c\/p\u003e\n\u003ch3\u003eInteractions with other products:\u003c\/h3\u003e\n\u003cp\u003eCurrently, there is no information on interactions and incompatibilities of Curavisc® with other solutions for intra-articular use.\u003c\/p\u003e\n\u003cp\u003eConcomitant administration of an oral analgesic or anti-inflammatory drug during the first days of treatment may further improve symptoms.\u003c\/p\u003e\n\u003ch3\u003eDosage and administration:\u003c\/h3\u003e\n\u003cp\u003eCuravisc® is injected once weekly into the affected joint, at least three and at most five times. Multiple joints can be treated simultaneously. Depending on the severity of joint damage, the beneficial effect of a treatment cycle of five intra-articular injections can last for months. The efficacy of a single treatment cycle of fewer than three injections has not been proven. Repeat treatments can be administered as needed at intervals of no less than six months.\u003c\/p\u003e\n\u003cp\u003eRemove the prefilled syringe from the blister pack. Remove the cap and immediately attach a needle appropriate for the size of the joint (e.g., 19 or 21 G). Remove any air bubbles from the syringe before injection.\u003c\/p\u003e\n\u003ch3\u003ePlease note:\u003c\/h3\u003e\n\u003cp\u003eThe injection solution in the syringe is sterile. For protection during storage and transport, the prefilled syringe is packed in a blister pack and a carton. The outer surface of the prefilled syringe is clean but not sterile.\u003c\/p\u003e\n\u003cp\u003eIf the prefilled syringe or blister pack is damaged, the syringe must not be used.\u003c\/p\u003e\n\u003cp\u003eAseptic technique must be strictly observed during administration.\u003c\/p\u003e\n\u003ch3\u003eProperties and mode of action:\u003c\/h3\u003e\n\u003cp\u003eThe hyaluronate responsible for the viscoelasticity of joint fluid (synovial fluid) is present in the synovial fluid of all joints, especially in large weight-bearing joints, where the synovial fluid ensures normal pain-free movement through its lubricating and shock-absorbing properties. Additionally, the synovial fluid is responsible for the nutrient supply of the cartilage.\u003c\/p\u003e\n\u003cp\u003eIn degenerative joint disorders, e.g., osteoarthritis, the viscoelasticity of the synovial fluid is significantly reduced, diminishing its lubricating and shock-absorbing functions. Due to increased mechanical stress on the joint, cartilage destruction increases, leading to pain and restricted mobility of the affected joint. Supplementing the synovial fluid by intra-articular administration of Curavisc®, which contains bird protein-free sodium hyaluronate of high purity, can improve the viscoelastic properties of the synovial fluid.\u003c\/p\u003e\n\u003cp\u003eIn this way, the lubricating and shock-absorbing properties of the synovial fluid are improved, and mechanical overload of the joints is reduced. Usually, after a treatment cycle of five intra-articular injections, pain relief and improved mobility lasting up to six months can be achieved.\u003c\/p\u003e\n\u003ch3\u003ePackage size:\u003c\/h3\u003e\n\u003cp\u003e1 prefilled syringe with 2 ml (Curavisc®) sterile injection solution\u003c\/p\u003e\n\u003ch3\u003eStorage instructions:\u003c\/h3\u003e\n\u003cp\u003eStore between +2 °C and +25 °C. Do not use the product after the expiration date!\u003c\/p\u003e\n\u003cp\u003eFor use by a physician only.\u003c\/p\u003e\n\u003cp\u003eKeep out of reach of children!\u003c\/p\u003e\n\u003ch3\u003eManufacturer:\u003c\/h3\u003e\n\u003cp\u003ecurasan AG\u003cbr\u003eLindigstraße 4\u003cbr\u003e63801 Kleinostheim\u003cbr\u003eGermany\u003c\/p\u003e\n\u003ch3\u003eInformation status:\u003c\/h3\u003e\n\u003cp\u003e01\/2021\u003c\/p\u003e","brand":"Curasan AG","offers":[{"title":"Default Title","offer_id":51849339273556,"sku":"109","price":15.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/curavisc-1x-20-ml-curasan-ag-gelenkspritzen-stakonmed-9774421.jpg?v=1772274023"},{"product_id":"hyalone","title":"HyalOne 1x 4.0 ml","description":"\u003ch2\u003eHyaluronic Acid Sodium Salt Solution for Intraarticular Injection\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePre-filled syringe 60 mg\/4 ml\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eProduct Description\u003c\/h3\u003e\n\u003cp\u003eHYALONE® is a sterile, pyrogen-free, viscoelastic hyaluronic acid sodium salt solution obtained by bacterial fermentation from a high molecular weight fraction. Hyaluronic acid, a polysaccharide of the glycosaminoglycan family, is found in many human tissues, such as cartilage or joint fluid (synovial fluid); it is continuously released into the joint space and constitutes a main component of synovial fluid, giving it its characteristic viscosity and elasticity. These properties are essential for the lubricating and shock-absorbing functions that synovial fluid performs in a healthy joint to protect cartilage and soft tissues from mechanical injury. In traumatic and degenerative joint damage, there is an insufficient supply of hyaluronic acid to the synovial fluid and a loss of viscosity. This leads to impaired joint function and painful symptoms. Extensive data in the literature show that the viscoelastic properties of synovial fluid can be restored by intraarticular administration of hyaluronic acid, resulting in pain relief and improved joint mobility.\u003c\/p\u003e\n\n\u003ch3\u003eComposition\u003c\/h3\u003e\n\u003cp\u003eMain ingredient: Sodium salt of hyaluronic acid 1.5%. Other ingredients: Sodium chloride, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, water for injection.\u003c\/p\u003e\n\n\u003ch3\u003eIndications\u003c\/h3\u003e\n\u003cp\u003eHYALONE® is a temporary synovial fluid substitute for patients with degenerative or mechanical arthropathy of the hip or knee joint, causing a functional alteration of the synovial fluid without acute synovitis.\u003c\/p\u003e\n\n\u003ch3\u003eDosage Instructions and Method of Administration\u003c\/h3\u003e\n\u003cp\u003eApplication must only be performed by qualified physicians.\u003c\/p\u003e\n\n\u003cp\u003eAll rules regarding asepsis and injection technique must be followed.\u003c\/p\u003e\n\n\u003cp\u003eIf necessary, remove exudate before injecting HYALONE®.\u003c\/p\u003e\n\n\u003cp\u003eAfter the first application, further treatments may be necessary to maintain the treatment effect. This depends on the individual patient. Inject HYALONE® with a suitable sterile needle (e.g., 18 – 20 G).\u003c\/p\u003e\n\n\u003cp\u003eFor hip joint application, ultrasound-guided injection is recommended. This is not necessary when HYALONE® is used in the knee joint.\u003c\/p\u003e\n\n\u003cp\u003eThe outer surface of the syringe is sterile, making the product suitable for use in operating rooms.\u003c\/p\u003e\n\n\u003ch3\u003eContraindications\u003c\/h3\u003e\n\u003cp\u003eHYALONE® must not be administered to patients with known individual hypersensitivity to any components of the preparation or in cases of infections or skin diseases at the injection site.\u003c\/p\u003e\n\n\u003cp\u003eThere is no evidence of contraindications for repeated treatment.\u003c\/p\u003e\n\n\u003ch3\u003eWarnings and Precautions\u003c\/h3\u003e\n\u003cp\u003ePreclinical studies in laboratory animals show that the product has no potential reproductive or developmental toxicity. HYALONE® has not been tested in pregnant women. Do not use if the packaging is damaged.\u003c\/p\u003e\n\n\u003cp\u003eDo not use the product after the expiration date indicated on the packaging.\u003c\/p\u003e\n\n\u003cp\u003eThe expiration date refers to storage of the product in the original packaging at a temperature not exceeding 25°C.\u003c\/p\u003e\n\n\u003cp\u003eHYALONE® is intended for single use only; after use, the syringe must be disposed of according to the regulations applicable in the respective country.\u003c\/p\u003e\n\n\u003cp\u003eThis product is a single-use syringe, meaning the syringe should only be used on the same patient. The pre-filled syringe must be disposed of immediately after use, even if the injection solution has not been completely used up.\u003c\/p\u003e\n\n\u003cp\u003eIf the product is reprocessed and\/or reused, Fidia Farmaceutici cannot guarantee the efficacy, function, material structure, purity, or sterility of the product. Reuse may lead to illness, infection, and\/or serious injury to the patient. Disposal of the pre-filled syringe after use must comply with national guidelines.\u003c\/p\u003e\n\n\u003cp\u003eKeep out of reach of children.\u003c\/p\u003e\n\n\u003ch3\u003eAdverse Reactions\u003c\/h3\u003e\n\u003cp\u003eOccasionally, local pain, swelling, warmth, and redness may occur at the injection site. Such symptoms are generally mild and temporary.\u003c\/p\u003e\n\n\u003cp\u003eMore pronounced inflammatory reactions, as sometimes seen with sodium pyrophosphate crystals, have occasionally been reported in connection with intraarticular injections of hyaluronate.\u003c\/p\u003e\n\n\u003cp\u003eAs with any intraarticular treatment, septic arthritis may rarely occur if general precautions for injections are not observed or if the injection site is not aseptic.\u003c\/p\u003e\n\n\u003ch3\u003eInteractions\u003c\/h3\u003e\n\u003cp\u003eDo not use HYALONE® together with disinfectants containing quaternary ammonium salts, as hyaluronic acid may precipitate in their presence. To avoid possible interactions, HYALONE® must not be administered simultaneously with other agents intended for intraarticular use.\u003c\/p\u003e\n\n\u003ch3\u003eStorage\u003c\/h3\u003e\n\u003cp\u003eStore at a temperature not exceeding 25°C.\u003c\/p\u003e\n\n\u003ch3\u003ePackage Size\u003c\/h3\u003e\n\u003cp\u003eEach syringe is packaged in a blister and sterilized with ethylene oxide. One syringe contains 60 mg hyaluronic acid sodium salt in 4 ml solution, steam sterilized.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturer\u003c\/h3\u003e\n\u003cp\u003eFidia Farmaceutici S.p.A. - Via Ponte della Fabbrica 3\/A - 35031 Abano Terme (Padua) Italy\u003c\/p\u003e\n\n\u003cp\u003eFor further information, please contact Fidia Pharma GmbH, Germany:\u003c\/p\u003e\n\n\u003cp\u003ePhone: +49 2173 8954 200 - Fax: +49 2173 8954 100 - Email: medical@fidiapharma.de\u003c\/p\u003e\n\n\u003ch3\u003eInformation Date:\u003c\/h3\u003e\n\u003cp\u003eApril 2012\u003c\/p\u003e","brand":"Fidia Pharma GmbH","offers":[{"title":"Default Title","offer_id":51849352380756,"sku":"121","price":121.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/hyalone-1x-40-ml-fidia-pharma-gmbh-gelenkspritzen-stakonmed-9117331.jpg?v=1772274014"},{"product_id":"sinogel","title":"Sinogel 1x 3.0 ml      (EXP 31.07.2026)","description":"\u003ch2\u003eSINOGEL® 3 ml – Instructions for use\u003c\/h2\u003e\n\u003ch3\u003eDescription\u003c\/h3\u003e\n\u003cp\u003eOsteoarthritis (OA) is a chronic degenerative disease characterized by progressive damage to the articular cartilage, narrowing of the joint space, remodeling of the subchondral bone, formation of marginal joint osteophytes, and synovitis. Optimal OA therapy consists of an intra-articular injection of exogenous hyaluronic acid, which can relieve symptoms by restoring the viscoelastic properties of synovial fluid.\u003c\/p\u003e\n\u003cp\u003eHyaluronic acid sodium salt is formed from repetitive chains of disaccharide units of N-acetylglucosamine and sodium glucuronate and is an essential component of synovial fluid, where it acts as a joint lubricant under shear stress and as a shock absorber under compressive load.\u003c\/p\u003e\n\u003cp\u003eSINOGEL® 3 ml consists of a buffered saline solution of highly purified hyaluronic acid with high molecular weight and sodium chondroitin of biotechnological origin. The hyaluronic acid used in the medical device is obtained by fermentation and has not been chemically modified. This results in excellent tolerability.\u003c\/p\u003e\n\u003ch3\u003ePurpose\u003c\/h3\u003e\n\u003cp\u003eSINOGEL® 3 ml, with its special formula and high glycosaminoglycan concentration (GAG), belongs to the latest generation of intra-articular treatments and was specifically developed for viscosupplementation of large joints, where a large volume of solution with a high concentration of hyaluronic acid without high viscosity is recommended. Thanks to a special and patented treatment of the solution, the hyaluronic acid and sodium chondroitin chains present in the product interact with each other, giving the solution rheological properties so that the viscosity values are lower than those of pure hyaluronic acid at the same concentration.\u003c\/p\u003e\n\u003ch3\u003eIndications\u003c\/h3\u003e\n\u003cp\u003eSINOGEL® 3 ml is indicated for pain or movement restrictions due to degenerative diseases, post-traumatic disorders, or joint changes.\u003c\/p\u003e\n\u003cp\u003eSINOGEL® 3 ml is a medical device designed to restore the physiological and rheological properties of synovial fluid in joints affected by osteoarthritis.\u003c\/p\u003e\n\u003cp\u003eSINOGEL® 3 ml restores the viscoelastic properties of synovial fluid, relieves pain, and promotes the restoration of joint mobility.\u003c\/p\u003e\n\u003ch3\u003eTarget groups and users\u003c\/h3\u003e\n\u003cp\u003eSINOGEL® 3 ml is indicated for adults of both sexes and may only be administered by qualified personnel via intra-articular injection.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSINOGEL® 3 ml is prescription-only.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eComposition\u003c\/h3\u003e\n\u003cp\u003eSINOGEL® 3 ml consists of a pre-filled syringe with 3 ml solution and contains the following ingredients:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eFunctional ingredient\u003c\/th\u003e\n\u003cth\u003eQuantity\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSodium hyaluronate\u003c\/td\u003e\n\u003ctd\u003e72 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSodium chondroitin\u003c\/td\u003e\n\u003ctd\u003e48 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eOther ingredients\u003c\/th\u003e\n\u003cth\u003eQuantity\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSodium chloride\u003c\/td\u003e\n\u003ctd\u003e21.000 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMonosodium phosphate\u003c\/td\u003e\n\u003ctd\u003e0.135 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisodium phosphate\u003c\/td\u003e\n\u003ctd\u003e0.48 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWater for injection purposes\u003c\/td\u003e\n\u003ctd\u003eq.s. 3.0 ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eDosage\u003c\/h3\u003e\n\u003cp\u003eIt is recommended to perform 1 infiltration per treatment cycle. The appropriateness and frequency with which the treatment cycle can be repeated must be individually assessed by the physician, considering the risk-benefit ratio for each patient.\u003c\/p\u003e\n\u003ch3\u003eAvailable packages\u003c\/h3\u003e\n\u003cp\u003eSINOGEL® 3 ml is available in packs containing 1 pre-filled syringe (72.0 mg sodium hyaluronate and 48.0 mg sodium chondroitin in 3 ml sodium chloride buffered saline) and a 21G x 1½” (0.8 x 40 mm) needle.\u003c\/p\u003e\n\u003cp\u003eThe contents of the syringe are sterile and pyrogen-free.\u003c\/p\u003e\n\u003cp\u003ePre-filled syringe steam sterilized.\u003c\/p\u003e\n\u003cp\u003eNeedle sterilized with ethylene oxide.\u003c\/p\u003e\n\u003cp\u003eManufacturer: Terumo Europe N. V. – Interleuvenlaan 40 – 3001 Leuven, Belgium\u003c\/p\u003e\n\u003ch3\u003eInstructions for use\u003c\/h3\u003e\n\u003cp\u003eBefore injecting SINOGEL® 3 ml, joint effusions must be aspirated.\u003c\/p\u003e\n\u003cp\u003eCarefully unscrew the syringe cap, holding the Luer-Lock collar between your fingers and taking special care not to touch the opening.\u003c\/p\u003e\n\u003cp\u003eScrew the 21G needle (included in the package) firmly onto the Luer-Lock collar of the syringe until you feel slight resistance to ensure an airtight seal and prevent fluid leakage during administration.\u003c\/p\u003e\n\u003cp\u003eInject SINOGEL® 3 ml at room temperature and under strictly aseptic conditions. For viscosupplementation of hip osteoarthritis, it is recommended to perform the injection under ultrasound guidance.\u003c\/p\u003e\n\u003cp\u003eInject SINOGEL® 3 ml only into the synovial cavity.\u003c\/p\u003e\n\u003ch3\u003eAfter use\u003c\/h3\u003e\n\u003cp\u003eFill out the implant card and hand it over to the patient.\u003c\/p\u003e\n\u003cp\u003eNote: Fill out one implant card for each prefilled syringe used for treatment (i.e., 1 prefilled syringe = 1 completed implant card).\u003c\/p\u003e\n\u003cp\u003eThe implant card is inside the box; to remove it, proceed as follows:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eOpen the SINOGEL® 3 ml box.\u003c\/li\u003e\n\u003cli\u003eRemove all blister packs with prefilled syringes from the box.\u003c\/li\u003e\n\u003cli\u003eRemove the implant card from the box. Gently press down the blue-bordered area of the outer packaging (back) without breaking it.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch3\u003eInstructions for filling out the implant card\u003c\/h3\u003e\n\u003cp\u003eFill in the fields marked with the following symbols with the specified information:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePatient's name or patient ID\u003c\/li\u003e\n\u003cli\u003eDate of treatment\u003c\/li\u003e\n\u003cli\u003eName and address of the implanting healthcare facility\u003c\/li\u003e\n\u003cli\u003eDoctor's name\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWarnings\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe contents of the prefilled syringe are sterile. The syringe is contained in a sealed blister pack.\u003c\/li\u003e\n\u003cli\u003eThe outer surface of the syringe is not sterile.\u003c\/li\u003e\n\u003cli\u003eDo not use the medical device after the expiration date printed on the package.\u003c\/li\u003e\n\u003cli\u003eDo not use the medical device if the packaging is opened or damaged, as the sterility of the product may be compromised.\u003c\/li\u003e\n\u003cli\u003eThe injection must be performed on healthy skin.\u003c\/li\u003e\n\u003cli\u003eDo not use in pregnant or breastfeeding women.\u003c\/li\u003e\n\u003cli\u003eDo not use in patients with autoimmune diseases.\u003c\/li\u003e\n\u003cli\u003eDo not inject intravascularly. Do not inject outside the joint cavity, into synovial tissue, or the joint capsule.\u003c\/li\u003e\n\u003cli\u003eDo not administer SINOGEL® 3 ml if there is a severe joint effusion.\u003c\/li\u003e\n\u003cli\u003eDo not resterilize. The medical device is intended for single use only.\u003c\/li\u003e\n\u003cli\u003eDo not reuse to avoid contamination risks.\u003c\/li\u003e\n\u003cli\u003eStore at room temperature below 25 °C and away from heat sources. Do not freeze.\u003c\/li\u003e\n\u003cli\u003eOnce opened, the medical device must be used immediately and disposed of after use.\u003c\/li\u003e\n\u003cli\u003eSINOGEL® 3 ml is indicated for adult patients. Keep out of reach of children.\u003c\/li\u003e\n\u003cli\u003eDo not use SINOGEL® 3 ml in case of known hypersensitivity or allergies to any of the product's components.\u003c\/li\u003e\n\u003cli\u003eAfter the injection, instruct the patient to avoid any intense physical activity and to resume normal activities only after a few days.\u003c\/li\u003e\n\u003cli\u003eProtect from sunlight.\u003c\/li\u003e\n\u003cli\u003eExisting air bubbles do not affect the product properties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003ePrecautions for use\u003c\/h3\u003e\n\u003cp\u003eDo not mix the medical device with disinfectants such as quaternary ammonium salts or chlorhexidine, as this may cause the product to precipitate.\u003c\/p\u003e\n\u003ch3\u003eInteractions\u003c\/h3\u003e\n\u003cp\u003eCurrently, no interactions between SINOGEL® 3 ml and drugs\/other treatments are known. However, if you are using medications or other therapeutic measures simultaneously, consult your doctor for more information.\u003c\/p\u003e\n\u003ch3\u003eSide effects\u003c\/h3\u003e\n\u003cp\u003eExtra-articular infiltration of SINOGEL® 3 ml can cause local adverse effects.\u003c\/p\u003e\n\u003cp\u003eDuring the use of SINOGEL® 3 ml, symptoms such as pain, warmth, redness, or swelling at the injection site may occur. These secondary complaints can be relieved by applying ice to the treated joint and usually subside after a short time. Doctors must ensure that patients inform them of any adverse effects that may occur after treatment.\u003c\/p\u003e\n\u003cp\u003eIn case of an adverse event, the manufacturer or the competent authority must be informed.\u003c\/p\u003e\n\u003ch3\u003eOverdose\u003c\/h3\u003e\n\u003cp\u003eAdhere to the specified dosage and contact your doctor or the nearest hospital if you notice side effects related to an overdose.\u003c\/p\u003e\n\u003ch3\u003eContraindications\u003c\/h3\u003e\n\u003cp\u003eSINOGEL® 3 ml must not be injected if there is an infected or severely inflamed joint or if the patient has a skin condition or infection at the injection site.\u003c\/p\u003e\n\u003ch3\u003eShelf life\u003c\/h3\u003e\n\u003cp\u003eShelf life: 36 months.\u003c\/p\u003e\n\u003cp\u003eThe expiration date indicates the maximum shelf life of the medical device.\u003c\/p\u003e\n\u003ch3\u003eDisposal\u003c\/h3\u003e\n\u003cp\u003eDo not dispose of the product in the environment after use. Follow local regulations for product disposal.\u003c\/p\u003e\n\u003ch3\u003eSummary of Safety and Clinical Performance\u003c\/h3\u003e\n\u003cp\u003eYou can download the Summary of Safety and Clinical Performance (SSCP) using the following link:\u003c\/p\u003e\n\u003cp\u003ehttps:\/\/www.ibsa.it\/en\/chi-siamo\/summary-of-safety-and-clinical-performance.html\u003cbr\u003ehttps:\/\/www.ibsa.it\/en\/chi-siamo\/sscp-area-riservata.html\u003c\/p\u003e\n\u003ch3\u003eDate of last revision of the package leaflet\u003c\/h3\u003e\n\u003cp\u003eFebruary 2023\u003c\/p\u003e","brand":"IBSA","offers":[{"title":"Default Title","offer_id":51849374204244,"sku":"136","price":109.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/sinogel-1x-30-ml-ibsa-gelenkspritzen-stakonmed-4474722.jpg?v=1772274022"},{"product_id":"sinovial-hl-64","title":"Sinovial HL 64 1x 2.0 ml","description":"\u003ch2\u003eSINOVIAL® HL 64 2 ml – Instructions for use\u003c\/h2\u003e\n\u003ch3\u003eDescription\u003c\/h3\u003e\n\u003cp\u003eHyaluronic acid sodium salt is formed from repetitive chains of disaccharide units of N-acetylglucosamine and sodium glucuronate and is an essential component of synovial fluid, giving it its special viscoelastic properties.\u003c\/p\u003e\n\u003cp\u003eSINOVIAL® HL 64 2 ml consists of a buffered saline solution with high-molecular-weight (H-HA) and low-molecular-weight (L-HA) hyaluronic acid.\u003c\/p\u003e\n\u003cp\u003eThe high- and low-molecular-weight hyaluronic acid used in the medical device is obtained by fermentation and has not been chemically modified. This results in excellent tolerability.\u003c\/p\u003e\n\u003cp\u003eFurthermore, the HA chains with different molecular weights contained in SINOVIAL® HL 64 2 ml interact with each other thanks to a specific and patented treatment of the solution, giving SINOVIAL® HL 64 2 ml unique rheological properties that allow higher concentrations of hyaluronic acid to be administered at the same solution viscosity.\u003c\/p\u003e\n\u003cp\u003eThe HA chains with different molecular weights offer greater resistance to hyaluronidase, as this enzyme cannot recognize the conformation of these high-molecular complexes. Therefore, SINOVIAL® HL 64 2 ml is better suited for in vivo applications in tissues.\u003c\/p\u003e\n\u003ch3\u003ePurpose of use\u003c\/h3\u003e\n\u003cp\u003eSINOVIAL® HL 64 2 ml with its special formula belongs to the latest generation of intra-articular treatments. SINOVIAL® HL 64 2 ml is a medical device designed to restore the physiological and rheological properties of synovial fluid in joints affected by osteoarthritis. SINOVIAL® HL 64 2 ml reduces joint pain and promotes the restoration of associated joint mobility. Clinical data have shown that SINOVIAL® HL 64 2 ml combined with laser therapy can improve symptoms associated with tendinopathy.\u003c\/p\u003e\n\u003ch3\u003eAreas of application\u003c\/h3\u003e\n\u003cp\u003eSINOVIAL® HL 64 2 ml is indicated for pain or limited mobility due to degenerative diseases (e.g., osteoarthritis), post-traumatic disorders associated with acute and chronic joint complaints in large and small joints.\u003c\/p\u003e\n\u003ch3\u003eTarget groups and users\u003c\/h3\u003e\n\u003cp\u003eSINOVIAL® HL 64 2 ml is indicated for adult men and women and should only be administered by qualified personnel via intra-articular injection.\u003c\/p\u003e\n\u003ch3\u003eComposition\u003c\/h3\u003e\n\u003cp\u003eSINOVIAL® HL consists of a prefilled syringe with 1 or 2 ml solution containing the following ingredients:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eComponent\u003c\/th\u003e\n\u003cth\u003eSyringe volume 1 ml\u003c\/th\u003e\n\u003cth\u003eSyringe volume 2 ml\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSodium hyaluronate\u003c\/td\u003e\n\u003ctd\u003e16 mg (H-HA) + 16 mg (L-HA)\u003c\/td\u003e\n\u003ctd\u003e32 mg (H-HA) + 32 mg (L-HA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSodium chloride\u003c\/td\u003e\n\u003ctd\u003e8.000 mg\u003c\/td\u003e\n\u003ctd\u003e16.000 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSodium phosphate\u003c\/td\u003e\n\u003ctd\u003e0.205 mg\u003c\/td\u003e\n\u003ctd\u003e0.410 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWater for injection purposes\u003c\/td\u003e\n\u003ctd\u003eq.s. 1.0 ml\u003c\/td\u003e\n\u003ctd\u003eq.s. 2.0 ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eDosage\u003c\/h3\u003e\n\u003cp\u003eIt is recommended to perform 1 infiltration per week, with a maximum of 3 infiltrations per treatment cycle. The appropriateness and frequency with which the treatment cycle can be repeated must be individually assessed by the physician considering the risk-benefit ratio for each patient.\u003c\/p\u003e\n\u003ch3\u003eAvailable packages\u003c\/h3\u003e\n\u003cp\u003eSINOVIAL® HL 64 2 ml is available in packages with 1 prefilled syringe in the following volumes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e1 ml prefilled syringe (16 mg (H-HA) + 16 mg (L-HA) hyaluronic acid sodium salt in 1 ml sodium chloride buffered saline) and a 21G x 1½” (0.8 x 40 mm) needle\u003c\/li\u003e\n\u003cli\u003e1 ml prefilled syringe (16 mg (H-HA) + 16 mg (L-HA) hyaluronic acid sodium salt in 1 ml sodium chloride buffered saline) and two needles: 1 needle 22 G x 1½” (0.7 x 40 mm); 1 needle 29 G x ½ TW (0.3 x 12 mm)\u003c\/li\u003e\n\u003cli\u003e2 ml prefilled syringe (32 mg (H-HA) + 32 mg (L-HA) hyaluronic acid sodium salt in 2 ml sodium chloride buffered saline) and a 21G x 1½” (0.8 x 40 mm) needle.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe contents of the syringe are sterile and pyrogen-free.\u003c\/p\u003e\n\u003cp\u003ePrefilled syringe steam sterilized.\u003c\/p\u003e\n\u003cp\u003eNeedles sterilized with ethylene oxide.\u003c\/p\u003e\n\u003cp\u003eManufacturer: Terumo Europe N. V. – Interleuvenlaan 40 – 3001 Leuven, Belgium\u003c\/p\u003e\n\u003ch3\u003eInstructions for use\u003c\/h3\u003e\n\u003cp\u003eJoint effusions must be aspirated before injecting SINOVIAL® HL 64 2 ml.\u003c\/p\u003e\n\u003cp\u003eCarefully unscrew the syringe cap, holding the Luer-Lock collar between your fingers and taking special care not to touch the opening.\u003c\/p\u003e\n\u003cp\u003eScrew the 21G needle (included in the kit) firmly onto the Luer-Lock collar of the syringe until you feel slight resistance to ensure an airtight seal and prevent fluid leakage during administration.\u003c\/p\u003e\n\u003cp\u003eInject SINOVIAL® HL 64 2 ml at room temperature and under strictly aseptic conditions.\u003c\/p\u003e\n\u003cp\u003eInject SINOVIAL® HL 64 2 ml into the synovial cavity of the joint or into the tendon sheath\/peritendinous area according to medical need.\u003c\/p\u003e\n\u003ch3\u003eAfter use\u003c\/h3\u003e\n\u003cp\u003eFill out the implant card and hand it over to the patient.\u003c\/p\u003e\n\u003cp\u003eNote: Fill out one implant card for each prefilled syringe used for treatment (i.e., 1 prefilled syringe = 1 completed implant card).\u003c\/p\u003e\n\u003cp\u003eThe implant card is inside the box; to remove it, proceed as follows:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eOpen the SINOVIAL® HL 64 2 ml box.\u003c\/li\u003e\n\u003cli\u003eRemove all blister packs with prefilled syringes from the box.\u003c\/li\u003e\n\u003cli\u003eRemove the implant card from the box. Gently press down the blue-bordered area of the outer packaging (back side) without breaking it.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch3\u003eInstructions for filling out the implant card\u003c\/h3\u003e\n\u003cp\u003eFill in the fields marked with the following symbols with the specified information:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePatient name or patient ID\u003c\/li\u003e\n\u003cli\u003eDate of treatment\u003c\/li\u003e\n\u003cli\u003eName and address of the implanting healthcare facility\u003c\/li\u003e\n\u003cli\u003eDoctor's name\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWarnings\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe contents of the prefilled syringe are sterile. The syringe and needles are packaged in a sealed blister pack.\u003c\/li\u003e\n\u003cli\u003eThe outer surface of the syringe is not sterile.\u003c\/li\u003e\n\u003cli\u003eDo not use SINOVIAL® HL 64 2 ml after the expiration date printed on the package.\u003c\/li\u003e\n\u003cli\u003eDo not use SINOVIAL® HL 64 2 ml if the packaging is opened or damaged, as the product's sterility may be compromised.\u003c\/li\u003e\n\u003cli\u003eInjection must be performed on healthy skin.\u003c\/li\u003e\n\u003cli\u003eDo not use in pregnant or breastfeeding women.\u003c\/li\u003e\n\u003cli\u003eDo not use in patients with autoimmune diseases.\u003c\/li\u003e\n\u003cli\u003eDo not inject intravascularly. Do not inject outside the joint cavity, into synovial tissue, or the joint capsule.\u003c\/li\u003e\n\u003cli\u003eDo not administer SINOVIAL® HL 64 2 ml if there is a severe joint effusion.\u003c\/li\u003e\n\u003cli\u003eDo not resterilize. The medical device is intended for single use only.\u003c\/li\u003e\n\u003cli\u003eDo not reuse to avoid contamination risks.\u003c\/li\u003e\n\u003cli\u003eStore at room temperature below 25 °C and away from heat sources. Do not freeze.\u003c\/li\u003e\n\u003cli\u003eAfter opening, SINOVIAL® HL 64 2 ml must be used immediately and disposed of after use.\u003c\/li\u003e\n\u003cli\u003eSINOVIAL® HL 64 2 ml is indicated for adult patients.\u003c\/li\u003e\n\u003cli\u003eKeep out of reach of children.\u003c\/li\u003e\n\u003cli\u003eAfter injection, instruct the patient to avoid any intense physical activity and to resume normal activities only after a few days.\u003c\/li\u003e\n\u003cli\u003eExisting air bubbles do not affect the product's properties.\u003c\/li\u003e\n\u003cli\u003eDo not use SINOVIAL® HL 64 2 ml in case of known hypersensitivity or allergies to any of the product's components.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003ePrecautions for use\u003c\/h3\u003e\n\u003cp\u003eDo not mix SINOVIAL® HL 64 2 ml with disinfectants such as quaternary ammonium salts or chlorhexidine, as this may cause the product to precipitate.\u003c\/p\u003e\n\u003ch3\u003eInteractions\u003c\/h3\u003e\n\u003cp\u003eBased on the available in vitro data, no chemical-physical or biological interactions are known between SINOVIAL® HL 64 2 ml and platelet-rich plasma (PRP), which is used for endoarticular infiltrative treatment of osteoarthritis.\u003c\/p\u003e\n\u003cp\u003eCurrently, no interactions between SINOVIAL® HL 64 2 ml and drugs\/other treatments are known. If you are using medications or other therapeutic measures simultaneously, ask your doctor for more information.\u003c\/p\u003e\n\u003ch3\u003eSide effects\u003c\/h3\u003e\n\u003cp\u003eExtra-articular infiltration of SINOVIAL® HL 64 2 ml can cause local adverse effects.\u003c\/p\u003e\n\u003cp\u003eDuring the use of SINOVIAL® HL 64 2 ml, symptoms such as pain, warmth, redness, or swelling at the injection site may occur. These secondary complaints can be relieved by applying ice to the treated area and usually subside. Doctors must ensure that patients are informed about all adverse effects that may occur after treatment.\u003c\/p\u003e\n\u003cp\u003eIn case of an adverse event, the manufacturer or the competent authority must be informed.\u003c\/p\u003e\n\u003ch3\u003eOverdose\u003c\/h3\u003e\n\u003cp\u003eFollow the specified dosage and contact your doctor or the nearest hospital if you notice side effects related to an overdose.\u003c\/p\u003e\n\u003ch3\u003eContraindications\u003c\/h3\u003e\n\u003cp\u003eSINOVIAL® HL 64 2 ml must not be injected if there is an infected or severely inflamed joint or if the patient has a skin condition or infection at the injection site.\u003c\/p\u003e\n\u003ch3\u003eShelf life\u003c\/h3\u003e\n\u003cp\u003eShelf life: 36 months.\u003c\/p\u003e\n\u003cp\u003eThe expiration date indicates the maximum shelf life of the medical device.\u003c\/p\u003e\n\u003ch3\u003eDisposal\u003c\/h3\u003e\n\u003cp\u003eDo not dispose of the product in the environment after use. Follow local regulations for product disposal.\u003c\/p\u003e\n\u003ch3\u003eSummary of Safety and Clinical Performance\u003c\/h3\u003e\n\u003cp\u003eYou can download the Summary of Safety and Clinical Performance (SSCP) using the following link:\u003c\/p\u003e\n\u003cp\u003ehttps:\/\/www.ibsa.it\/en\/chi-siamo\/summary-of-safety-and-clinical-performance.html\u003cbr\u003ehttps:\/\/www.ibsa.it\/en\/chi-siamo\/sscp-area-riservata.html\u003c\/p\u003e\n\u003ch3\u003eDate of last revision of the package leaflet\u003c\/h3\u003e\n\u003cp\u003eFebruary 2023\u003c\/p\u003e","brand":"IBSA","offers":[{"title":"Default Title","offer_id":51849393176916,"sku":"137","price":97.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/sinovial-hl-64-1x-20-ml-ibsa-gelenkspritzen-stakonmed-3381160.jpg?v=1772274014"},{"product_id":"sinovial-16","title":"Sinovial 16 1x 2.0 ml","description":"","brand":"IBSA","offers":[{"title":"Default Title","offer_id":51849410478420,"sku":"138","price":14.85,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/sinovial-16-1x-20-ml-ibsa-gelenkspritzen-stakonmed-3177906.jpg?v=1772274013"},{"product_id":"suplasyn-1-shot-60","title":"Suplasyn 1 Shot 60 1x 6.0 ml","description":"\u003ch2\u003eSUPLASYN® \/ SUPLASYN® 1-Shot\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eSterile Sodium Hyaluronate Solution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHyaluronic acid is a common component of synovial fluid and plays a central role in maintaining the physiological environment of the joint.\u003c\/p\u003e\n\u003ch3\u003eComposition\u003c\/h3\u003e\n\u003cp\u003eViscoelastic solution of purified hyaluronic acid with a defined molecular weight, produced by fermentation.\u003c\/p\u003e\n\u003cp\u003eOne prefilled syringe contains:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003e\u003c\/th\u003e\n\u003cth\u003eSUPLASYN\u003c\/th\u003e\n\u003cth\u003eSUPLASYN 1-Shot\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSodium hyaluronate\u003c\/td\u003e\n\u003ctd\u003e20 mg\u003c\/td\u003e\n\u003ctd\u003e60 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsotonic, buffered aqueous solution\u003c\/td\u003e\n\u003ctd\u003e2 ml\u003c\/td\u003e\n\u003ctd\u003e6 ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eProperties\u003c\/h3\u003e\n\u003cp\u003eHyaluronic acid is the prototype of a large group of polysaccharides (glycosaminoglycans) that are important components of all extracellular tissue structures, including cartilage and synovial fluid. The active ingredient of SUPLASYN is a hyaluronic acid of defined molecular chain length with a high degree of purity. Injection of SUPLASYN into the joint space helps normalize joint function after joint puncture.\u003c\/p\u003e\n\u003ch3\u003eIndications\u003c\/h3\u003e\n\u003cp\u003eSUPLASYN and SUPLASYN 1-Shot are indicated for the symptomatic treatment of osteoarthritis. SUPLASYN has a therapeutic effect in treating pain and improving joint function in osteoarthritis. Multiple joints can be treated simultaneously.\u003c\/p\u003e\n\u003ch3\u003eDosage and Method of Administration\u003c\/h3\u003e\n\u003cp\u003eDepending on the size of the joint, up to 6 ml is injected intra-articularly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSUPLASYN:\u003c\/strong\u003e The usual treatment with SUPLASYN in 2 ml syringes consists of 3 injections at weekly intervals; up to 6 injections can be administered depending on the severity of the condition.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSUPLASYN 1-Shot:\u003c\/strong\u003e For single use only.\u003c\/p\u003e\n\u003cp\u003eAseptic conditions must be strictly observed. Any remaining hyaluronic acid in the prefilled syringes must be discarded. To use the prefilled syringe, remove the “Luer-lock cap,” attach a suitable needle (21-25 G recommended depending on the size of the joint), and secure it by gently twisting. \u003cstrong\u003eThe graduations on the syringe label are for orientation purposes only.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eContraindications\/Precautions\u003c\/h3\u003e\n\u003cp\u003eDo not use in patients with known hypersensitivity to the ingredients of SUPLASYN. General precautions and contraindications for intra-articular injections must be observed. Do not inject intravascularly. SUPLASYN should only be used in joints free of inflammation\/irritation, as adverse reactions are more common in patients with existing joint inflammation\/irritation.\u003c\/p\u003e\n\u003cp\u003eThere are no clinical data on the use of hyaluronic acid in children, pregnant, or breastfeeding women. Therefore, SUPLASYN should not be used in these patient groups.\u003c\/p\u003e\n\u003cp\u003eAfter injection of SUPLASYN, the treated joint should be rested for 24-48 hours. Physically strenuous activities should be avoided throughout the treatment period with SUPLASYN.\u003c\/p\u003e\n\u003cp\u003eTemporary, short-lasting pain may occur after joint injection as a result of the injection itself. Mild local reactions such as pain, warmth, overheating, redness, effusion, irritation, and swelling\/inflammation may occur in the area of the affected joint. If such symptoms occur, it is recommended to rest the affected joint and apply ice. In most patients, these symptoms resolve within a few days.\u003c\/p\u003e\n\u003cp\u003eIn rare cases, as a sign of hypersensitivity, mild local reactions such as pain, irritation, swelling\/joint inflammation, and effusion may be more pronounced and severe. In these cases, therapeutic intervention such as joint puncture may be necessary. Local adverse reactions may be accompanied by systemic reactions such as fever, chills, or circulatory reactions, and in rare cases, anaphylactic reactions may occur.\u003c\/p\u003e\n\u003cp\u003eIn extremely rare cases, rash\/itching, hives (urticaria), inflammation of the joint lining (synovitis), and a drop in blood pressure have been observed after injection of SUPLASYN. Administration should be discontinued if adverse reactions occur. Do not use SUPLASYN with instruments sterilized in quaternary ammonium salt solutions.\u003c\/p\u003e\n\u003ch3\u003eWarnings\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eKeep out of reach of children. Do not use if the blister packaging is damaged. For use by physicians only. For single use only. Any remaining contents in the syringe must be discarded. Reuse carries the risk of contamination and\/or infection or cross-infection of patients.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003ePackage Sizes\u003c\/h3\u003e\n\u003cp\u003ePackage containing 1 prefilled syringe of 2 ml or 6 ml.\u003c\/p\u003e\n\u003ch3\u003eStorage Instructions\u003c\/h3\u003e\n\u003cp\u003eStore packages between 4 °C and 25 °C. \u003cstrong\u003eProtect from frost.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWarm to room temperature before injection.\u003c\/p\u003e\n\u003ch3\u003eDate of Information Preparation\u003c\/h3\u003e\n\u003cp\u003eFebruary 2010\u003c\/p\u003e\n\u003ch3\u003eInformation Status\u003c\/h3\u003e\n\u003cp\u003eFirst edition\u003c\/p\u003e\n\u003ch3\u003eManufacturer\u003c\/h3\u003e\n\u003cp\u003eBioniche Teo.\u003cbr\u003eInverin, Co. Galway, Ireland.\u003c\/p\u003e\n\u003cp\u003e© Bioniche Pharma Group Limited, Ireland\u003cbr\u003e+49 (0)9306 904463\u003c\/p\u003e\n\u003cp\u003eCE 0473\u003c\/p\u003e","brand":"Mylan Teoranta","offers":[{"title":"Default Title","offer_id":51849421750612,"sku":"142","price":117.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/suplasyn-1-shot-60-1x-60-ml-mylan-teoranta-gelenkspritzen-stakonmed-5649656.jpg?v=1772274022"},{"product_id":"synolis-va-40-80","title":"Synolis VA 40\/80 1x 2.0 ml","description":"\u003ch2\u003eInstructions for use SYNOLIS VA\u003c\/h2\u003e\n\n\u003ch3\u003eDescription\u003c\/h3\u003e\n\u003cp\u003eSYNOLIS VA is a viscoelastic, sterile, apyrogenic, isotonic, buffered 2% sodium hyaluronate solution. The sodium hyaluronate used in SYNOLIS VA is obtained by bacterial fermentation and has a high average molecular weight (MW) of 2 MDa. SYNOLIS VA has a neutral pH of 6.8–7.4, similar to synovial fluid.\u003c\/p\u003e\n\n\u003cp\u003eA high concentration and high molecular weight of sodium hyaluronate combined with a polyol (sorbitol), which limits degradation, give this viscoelastic solution the ability to restore joint lubrication and shock absorption properties similar to those of healthy synovial fluid. SYNOLIS VA works by restoring the physiological and viscoelastic properties of synovial fluid, which are progressively lost during the development of osteoarthritis (OA). SYNOLIS VA thus relieves local pain and discomfort caused by symptomatic OA and improves the mobility of synovial joints.\u003c\/p\u003e\n\n\u003ch3\u003eIntroduction\u003c\/h3\u003e\n\u003cp\u003eSYNOLIS VA is available in two package sizes. Each box contains 1 syringe, traceability labels, and instructions for use. Each product includes an implant card for the patient to be completed by the physician.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth\u003eSYNOLIS VA 40\/80\u003c\/th\u003e\n      \u003cth\u003eSYNOLIS VA 80\/160\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003ePrefilled glass syringe with 2 ml viscous pain-relieving gel.\u003c\/td\u003e\n      \u003ctd\u003ePrefilled glass syringe with 4 ml viscous pain-relieving gel.\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eComposition\u003c\/h3\u003e\n\u003cp\u003ePer 1 ml:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eSodium Hyaluronate\u003c\/td\u003e\n      \u003ctd\u003e20 mg\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eSorbitol\u003c\/td\u003e\n      \u003ctd\u003e40 mg\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eBuffered saline q.s.p.\u003c\/td\u003e\n      \u003ctd\u003e1 ml\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSterilization method: Moist heat.\u003c\/p\u003e\n\n\u003ch3\u003eIndications\u003c\/h3\u003e\n\u003cp\u003eSYNOLIS VA is indicated for the treatment of symptomatic osteoarthritis (OA) to relieve pain and improve mobility after degenerative changes in synovial joints:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth\u003eSYNOLIS VA 40\/80\u003c\/th\u003e\n      \u003cth\u003eSYNOLIS VA 80\/160\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eKnee joint\u003c\/td\u003e\n      \u003ctd\u003eKnee and hip joint\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis treatment is intended for patients who have not responded to conservative, non-pharmacological therapy and simple analgesics and\/or NSAIDs, or who have intolerance to simple analgesics and\/or NSAIDs.\u003c\/p\u003e\n\n\u003ch3\u003eDosage, type, and duration of use\u003c\/h3\u003e\n\u003cp\u003eTreatment must be adjusted according to the patient's radiological and physical condition (Kellgren-Lawrence score, pain, and mobility). Existing clinical data have demonstrated efficacy for different injection schedules depending on the severity of osteoarthritis:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth\u003eInjection schedule \/ Severity of the disease\u003c\/th\u003e\n      \u003cth\u003eMild to moderate\u003c\/th\u003e\n      \u003cth\u003eModerate to severe\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e1 injection of SYNOLIS VA 40\/80\u003c\/td\u003e\n      \u003ctd\u003e✓\u003c\/td\u003e\n      \u003ctd\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e1 injection of SYNOLIS VA 80\/160\u003c\/td\u003e\n      \u003ctd\u003e✓\u003c\/td\u003e\n      \u003ctd\u003e✓\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e3 injections of SYNOLIS VA 40\/80 at intervals of 1 week each\u003c\/td\u003e\n      \u003ctd\u003e\u003c\/td\u003e\n      \u003ctd\u003e✓\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAn additional injection of SYNOLIS VA can be given if OA symptoms reoccur or to maintain local pain treatment and joint function. However, in patients who respond to the treatment, the benefit is expected to last at least six months.\u003c\/p\u003e\n\n\u003cp\u003eThe interval before repeating the treatment regimen also depends on the physician's experience and\/or the severity of the disease.\u003c\/p\u003e\n\n\u003cp\u003eSYNOLIS VA should be injected into the synovial cavity by a physician trained in intra-articular (i.a.) injections. Several measures must be taken before injecting SYNOLIS VA:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eSYNOLIS VA should be at room temperature at the time of intra-articular injection.\u003c\/li\u003e\n  \u003cli\u003eThe injection site must be carefully disinfected.\u003c\/li\u003e\n  \u003cli\u003eThe physician is responsible for selecting an appropriate needle size (recommended size for knee joint injections: 18 to 21 G).\u003c\/li\u003e\n  \u003cli\u003eThe needle must be firmly attached to the Luer-lock connection of the syringe.\u003c\/li\u003e\n  \u003cli\u003eInject precisely only into the joint cavity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eContraindications\u003c\/h3\u003e\n\u003cp\u003eSYNOLIS VA must not:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eshould not be injected into patients with known hypersensitivity or allergy to sodium hyaluronate and\/or sorbitol preparations;\u003c\/li\u003e\n  \u003cli\u003eshould not be injected into patients with a skin disease or infection at the injection site;\u003c\/li\u003e\n  \u003cli\u003eshould not be injected intravascularly;\u003c\/li\u003e\n  \u003cli\u003eshould not be injected into pregnant or breastfeeding women;\u003c\/li\u003e\n  \u003cli\u003eshould not be injected into adolescents under 18 years of age.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eSpecial precautions for use\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eBefore treatment, the patient must be informed about the product, its contraindications, and possible side effects.\u003c\/li\u003e\n  \u003cli\u003eUse SYNOLIS VA only for symptomatic osteoarthritis (OA).\u003c\/li\u003e\n  \u003cli\u003eDue to the lack of available clinical data on the tolerability and efficacy of SYNOLIS VA in patients with a history of autoimmune disease, active autoimmune disease, or abnormal physiological conditions, the physician must decide on a case-by-case basis, depending on the type of disease and associated treatments, whether SYNOLIS VA can be injected. It is recommended to advise these patients to undergo a preliminary test and to avoid injection if the disease is active. Careful monitoring of these patients after injection is also recommended.\u003c\/li\u003e\n  \u003cli\u003eBefore use, check the integrity of the inner packaging and the expiration date. Do not use the product if the expiration date has passed or if the packaging has been opened or damaged.\u003c\/li\u003e\n  \u003cli\u003eDo not transfer SYNOLIS VA to another container or add any other components to the product.\u003c\/li\u003e\n  \u003cli\u003eExercise caution when performing the intra-articular injection to avoid injecting outside the intra-articular joint cavity or into the synovial membrane. Viscosupplementation gels injected into the perisynovial area can be painful due to compression of the surrounding tissues.\u003c\/li\u003e\n  \u003cli\u003eInjection into an arm or leg joint with significant venous or lymphatic stasis is not recommended.\u003c\/li\u003e\n  \u003cli\u003eInjection into an infected or severely inflamed joint is not recommended.\u003c\/li\u003e\n  \u003cli\u003eIn cases of severe joint effusions, the doctor must decide on a case-by-case basis whether SYNOLIS VA can be injected. The effusion must be aspirated before injecting SYNOLIS VA.\u003c\/li\u003e\n  \u003cli\u003eSynolis VA is a single-use product and must not be used for multiple patients and\/or multiple treatment sessions.\u003c\/li\u003e\n  \u003cli\u003eThe product must not be resterilized.\u003c\/li\u003e\n  \u003cli\u003eReusing single-use products can lead to infections as sterility is compromised. Only the gel is sterile, not the outside of the syringe.\u003c\/li\u003e\n  \u003cli\u003eSynolis VA must be administered under strict aseptic conditions.\u003c\/li\u003e\n  \u003cli\u003ePatients are advised to avoid strenuous physical activity for at least 48 hours after the injection.\u003c\/li\u003e\n  \u003cli\u003eThe product must be stored under the recommended storage conditions.\u003c\/li\u003e\n  \u003cli\u003eDispose of the syringe (and the needle selected by the doctor) according to recognized medical standards and in compliance with applicable national, local, and institutional requirements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eInteractions with other medicinal products\u003c\/h3\u003e\n\u003cp\u003eThere is a known incompatibility between sodium hyaluronate and quaternary ammonium salts such as benzalkonium chloride. Therefore, SYNOLIS VA must never come into contact with such products (e.g., certain disinfectants) or with medical or surgical devices treated with such products. So far, no data are available on the compatibility of SYNOLIS VA with other products for intra-articular use.\u003c\/p\u003e\n\n\u003ch3\u003eSide effects\u003c\/h3\u003e\n\u003cp\u003eSide effects may occur and must be explained to the patient before treatment. Injection may cause slight bleeding, which stops spontaneously once the injection is completed. Occasionally, one or more of the following reactions may occur immediately or with delay. Temporary local pain, swelling, and\/or joint effusions may occur. These reactions usually heal within a few days. If these symptoms last longer than a week or if other side effects occur, the patient must inform the doctor. The doctor may prescribe appropriate treatment for these adverse effects. Other possible typical side effects of visco-supplementation injections include inflammation, redness, swelling, skin irritation, allergic reactions, and tissue reactions.\u003c\/p\u003e\n\n\u003cp\u003eAny serious incident related to the product must be reported to the manufacturer and the competent authority of the member state where the user and\/or patient is established.\u003c\/p\u003e\n\n\u003ch3\u003eStorage\u003c\/h3\u003e\n\u003cp\u003eStore at 2 °C to 25 °C. Protect from light and extreme cold. Do not freeze the product.\u003c\/p\u003e","brand":"Aptissen GmbH","offers":[{"title":"Default Title","offer_id":51849555050836,"sku":"143-1","price":83.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/synolis-va-4080-1x-20-ml-aptissen-gmbh-gelenkspritzen-stakonmed-2877413.jpg?v=1772274020"},{"product_id":"synolis-va-80-160","title":"Synolis VA 80\/160 1x 4.0 ml","description":"\u003ch2\u003eInstructions for use SYNOLIS VA\u003c\/h2\u003e\n\n\u003ch3\u003eDescription\u003c\/h3\u003e\n\u003cp\u003eSYNOLIS VA is a viscoelastic, sterile, apyrogenic, isotonic, buffered 2% sodium hyaluronate solution. The sodium hyaluronate used in SYNOLIS VA is obtained by bacterial fermentation and has a high average molecular weight (MW) of 2 MDa. SYNOLIS VA has a neutral pH of 6.8–7.4, similar to synovial fluid.\u003c\/p\u003e\n\n\u003cp\u003eA high concentration and high molecular weight of sodium hyaluronate combined with a polyol (sorbitol), which limits degradation, give this viscoelastic solution the ability to restore joint lubrication and shock absorption properties similar to those of healthy synovial fluid. SYNOLIS VA works by restoring the physiological and viscoelastic properties of synovial fluid, which are progressively lost during the development of osteoarthritis (OA). SYNOLIS VA thus relieves local pain and discomfort caused by symptomatic OA and improves the mobility of synovial joints.\u003c\/p\u003e\n\n\u003ch3\u003eIntroduction\u003c\/h3\u003e\n\u003cp\u003eSYNOLIS VA is available in two package sizes. Each box contains 1 syringe, traceability labels, and instructions for use. Each product includes an implant card for the patient to be completed by the physician.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth\u003eSYNOLIS VA 40\/80\u003c\/th\u003e\n      \u003cth\u003eSYNOLIS VA 80\/160\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003epre-filled glass syringe with 2 ml viscous pain-relieving gel.\u003c\/td\u003e\n      \u003ctd\u003epre-filled glass syringe with 4 ml viscous pain-relieving gel.\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eComposition\u003c\/h3\u003e\n\u003cp\u003ePer 1 ml:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eSodium Hyaluronate\u003c\/td\u003e\n      \u003ctd\u003e20 mg\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eSorbitol\u003c\/td\u003e\n      \u003ctd\u003e40 mg\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eBuffered saline q.s.p.\u003c\/td\u003e\n      \u003ctd\u003e1 ml\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSterilization method: Moist heat.\u003c\/p\u003e\n\n\u003ch3\u003eIndications\u003c\/h3\u003e\n\u003cp\u003eSYNOLIS VA is indicated for the treatment of symptomatic osteoarthritis (OA) to relieve pain and improve mobility after degenerative changes in synovial joints:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth\u003eSYNOLIS VA 40\/80\u003c\/th\u003e\n      \u003cth\u003eSYNOLIS VA 80\/160\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eKnee joint\u003c\/td\u003e\n      \u003ctd\u003eKnee and hip joint\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis treatment is intended for patients who have not responded to conservative, non-pharmacological therapy and simple analgesics and\/or NSAIDs, or who have intolerance to simple analgesics and\/or NSAIDs.\u003c\/p\u003e\n\n\u003ch3\u003eDosage, type, and duration of use\u003c\/h3\u003e\n\u003cp\u003eTreatment must be adjusted according to the patient's radiological and physical condition (Kellgren-Lawrence score, pain, and mobility). Existing clinical data have demonstrated efficacy for different injection schedules depending on the severity of osteoarthritis:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth\u003eInjection schedule \/ Severity of the disease\u003c\/th\u003e\n      \u003cth\u003eSevere mild to moderate\u003c\/th\u003e\n      \u003cth\u003eSevere moderate to severe\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e1 injection of SYNOLIS VA 40\/80\u003c\/td\u003e\n      \u003ctd\u003e✓\u003c\/td\u003e\n      \u003ctd\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e1 injection of SYNOLIS VA 80\/160\u003c\/td\u003e\n      \u003ctd\u003e✓\u003c\/td\u003e\n      \u003ctd\u003e✓\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e3 injections of SYNOLIS VA 40\/80 at intervals of 1 week each\u003c\/td\u003e\n      \u003ctd\u003e\u003c\/td\u003e\n      \u003ctd\u003e✓\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAn additional injection of SYNOLIS VA can be given if OA symptoms reoccur or to maintain local pain treatment and joint function. However, in patients who respond to the treatment, the benefit is expected to last at least six months.\u003c\/p\u003e\n\n\u003cp\u003eThe interval before repeating the treatment regimen also depends on the physician's experience and\/or the severity of the disease.\u003c\/p\u003e\n\n\u003cp\u003eSYNOLIS VA should be injected into the synovial cavity by a physician trained in intra-articular (i.a.) injections. Several measures must be taken before injecting SYNOLIS VA:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eSYNOLIS VA should be at room temperature at the time of intra-articular injection.\u003c\/li\u003e\n  \u003cli\u003eThe injection site must be carefully disinfected.\u003c\/li\u003e\n  \u003cli\u003eThe physician is responsible for selecting an appropriate needle size (recommended size for knee joint injections: 18 to 21 G).\u003c\/li\u003e\n  \u003cli\u003eThe needle must be firmly attached to the Luer-Lock connection of the syringe.\u003c\/li\u003e\n  \u003cli\u003eInject precisely only into the joint cavity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eContraindications\u003c\/h3\u003e\n\u003cp\u003eSYNOLIS VA must not:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eshould not be injected into patients with known hypersensitivity or allergy to sodium hyaluronate and\/or sorbitol preparations;\u003c\/li\u003e\n  \u003cli\u003eshould not be injected into patients with a skin disease or infection at the injection site;\u003c\/li\u003e\n  \u003cli\u003eshould not be injected intravascularly;\u003c\/li\u003e\n  \u003cli\u003eshould not be injected into pregnant or breastfeeding women;\u003c\/li\u003e\n  \u003cli\u003eshould not be injected into adolescents under 18 years of age.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eSpecial precautions for use\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eBefore treatment, the patient must be informed about the product, its contraindications, and possible side effects.\u003c\/li\u003e\n  \u003cli\u003eUse SYNOLIS VA only for symptomatic osteoarthritis.\u003c\/li\u003e\n  \u003cli\u003eDue to the lack of available clinical data on the tolerability and efficacy of SYNOLIS VA in patients with a history of autoimmune disease, active autoimmune disease, or abnormal physiological conditions, the physician must decide on a case-by-case basis, depending on the type of disease and associated treatments, whether SYNOLIS VA can be injected. It is recommended to advise these patients to undergo a preliminary test and to avoid injection if the disease is active. Careful monitoring of these patients after injection is also recommended.\u003c\/li\u003e\n  \u003cli\u003eBefore use, check the integrity of the inner packaging and the expiration date. Do not use the product if the expiration date has passed or if the packaging has been opened or damaged.\u003c\/li\u003e\n  \u003cli\u003eDo not transfer SYNOLIS VA into another container or add any other components to the product.\u003c\/li\u003e\n  \u003cli\u003eExercise caution when performing the intra-articular injection to avoid injecting outside the intra-articular joint cavity or into the synovial membrane. Viscosupplementation gels injected into the perisynovial area can be painful due to compression of surrounding tissues.\u003c\/li\u003e\n  \u003cli\u003eInjection into an arm or leg joint with significant venous or lymphatic stasis is not recommended.\u003c\/li\u003e\n  \u003cli\u003eInjection into an infected or severely inflamed joint is not recommended.\u003c\/li\u003e\n  \u003cli\u003eIn cases of severe joint effusions, the doctor must decide on a case-by-case basis whether SYNOLIS VA can be injected. The effusion must be aspirated before injecting SYNOLIS VA.\u003c\/li\u003e\n  \u003cli\u003eSynolis VA is a single-use product and must not be used for multiple patients and\/or multiple treatment sessions.\u003c\/li\u003e\n  \u003cli\u003eThe product must not be resterilized.\u003c\/li\u003e\n  \u003cli\u003eReusing single-use products can lead to infections as sterility is compromised. Only the gel is sterile, not the outside of the syringe.\u003c\/li\u003e\n  \u003cli\u003eSynolis VA must be administered under strict aseptic conditions.\u003c\/li\u003e\n  \u003cli\u003ePatients are advised to avoid strenuous physical activity for at least 48 hours after the injection.\u003c\/li\u003e\n  \u003cli\u003eThe product must be stored under the recommended storage conditions.\u003c\/li\u003e\n  \u003cli\u003eDispose of the syringe (and the needle selected by the doctor) according to recognized medical standards and in compliance with applicable national, local, and institutional requirements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eInteractions with other medicinal products\u003c\/h3\u003e\n\u003cp\u003eThere is a known incompatibility between sodium hyaluronate and quaternary ammonium salts such as benzalkonium chloride. Therefore, SYNOLIS VA must never come into contact with such products (e.g., certain disinfectants) or with medical or surgical devices treated with such products. So far, no data are available on the compatibility of SYNOLIS VA with other products for intra-articular use.\u003c\/p\u003e\n\n\u003ch3\u003eSide effects\u003c\/h3\u003e\n\u003cp\u003eSide effects may occur and must be explained to the patient before treatment. Injection may cause slight bleeding, which stops spontaneously once the injection is completed. Occasionally, one or more of the following reactions may occur immediately or with delay. Temporary local pain, swelling, and\/or joint effusions may occur. These reactions usually heal within a few days. If these symptoms last longer than a week or if other side effects occur, the patient must inform the doctor. The doctor may prescribe appropriate treatment for these adverse effects. Other possible typical side effects of visco-supplementation injections include inflammation, redness, swelling, skin irritation, allergic reactions, and tissue reactions.\u003c\/p\u003e\n\n\u003cp\u003eAny serious incident related to the product must be reported to the manufacturer and the competent authority of the member state where the user and\/or patient is established.\u003c\/p\u003e\n\n\u003ch3\u003eStorage\u003c\/h3\u003e\n\u003cp\u003eStore at 2 °C to 25 °C. Protect from light and extreme cold. Do not freeze the product.\u003c\/p\u003e","brand":"Aptissen GmbH","offers":[{"title":"Default Title","offer_id":51849577333076,"sku":"143-2","price":159.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/synolis-va-80160-1x-40-ml-aptissen-gmbh-gelenkspritzen-stakonmed-7125871.jpg?v=1772274014"},{"product_id":"renehavis","title":"RenehaVis 1x 1.4 ml","description":"","brand":"MDT Int‘l s.a.","offers":[{"title":"Default Title","offer_id":53999822733652,"sku":"135","price":195.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/renehavis-1x-14-ml-originalprodukt-mdt-intl-sa-stakonmed-2169910.jpg?v=1774495632"},{"product_id":"kiomedine-one-1x-3-0-ml","title":"KioMedine One 1x 3.0 ml (Best before 31.01.2027)","description":"","brand":"Aptissen GmbH","offers":[{"title":"Default Title","offer_id":55853743538516,"sku":"121-2","price":133.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0786\/8756\/8212\/files\/260622-01_001.jpg?v=1782290789"}],"url":"https:\/\/stakonmed.com\/collections\/bestseller-gelenkspritzen.oembed","provider":"StakonMed","version":"1.0","type":"link"}